fibroblast growth factor receptor inhibitor compounds, their pharmaceutical composition and their us

专利摘要:
Summary Fibroblast Growth Factor Receptor Inhibitors The present document describes gfr inhibitors, pharmaceutical compositions including such compounds and methods of using such compounds and compositions to inhibit tyrosine kinase activity.
公开号:BR112015000653A2
申请号:R112015000653
申请日:2013-07-11
公开日:2019-11-05
发明作者:L Hodous Brian；V Miduturu Chandrasekhar；L Kim Joseph；Brooijmans Natasja；Bifulco Neil Jr；Mark Wenglowsky Steven
申请人:Blueprint Medicines Corp；
IPC主号:

专利说明:

FIBROBLAST GROWTH FACTOR RECEIVER INHIBITING COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITION AND THEIR USES
Priority claim [1] This application claims priority for patent application USSN 61 / 670,379, filed on July 11, 2012 and USSN 61 / 746,666, filed on December 28, 2012, each of which is incorporated herein by reference in its entirety.
Field of the Invention
[2] They are here described compounds, methods preparation in such compounds, pharmaceutical compositions, and methods in use of such compounds and compositions tyrosine kinase activity.Foundations to inhibit The [3] Receiver growth factor fibroblasts 4
(FGFR-4) is a protein that, in humans, is encoded by the FGFR-4 gene. This protein is a member of the fibroblast growth factor receptor family, where the amino acid sequence has been highly conserved among members throughout evolution. Members of the FGFR 1-4 family differ from each other in their binding affinities and tissue distribution. A representative full-length protein consists of an extracellular region composed of three immunoglobulin-like domains, a single segment that crosses the hydrophobic membrane and a cytoplasmic tyrosine kinase domain. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of signals downstream, ultimately influencing mitogenesis and differentiation. The genomic organization of the FGFR-4 gene spans 18 exons. Although alternative splicing has been observed, there is no evidence that the C-terminal fraction of the IglII domain of this protein varies between three alternative forms, as indicated for FGFR 1-3.
[4] Ectopic mineralization, characterized by inadequate calcium-phosphorus deposition in soft tissues, was observed in
Petition 870160032383, dated 06/29/2016, p. 4/159
2/148 rats treated with an FGFR-1 inhibitor (Brown, AP et al. (2005), Toxicol. Pathol., P. 449-455). This suggests that selective inhibition of FGFR-4, without inhibition of other isoforms of FGFR, including FGFR-1, may be desirable in order to avoid certain toxicities. FGFR-4 binds preferentially to fibroblast growth factor 19 (FGF19) and has recently been associated with the progression of certain sarcomas, kidney cell cancer, breast cancer and liver cancer.
Summary of the Invention [5] FGFR-4 inhibitors are described herein. In addition, pharmaceutical formulations that include an FGFR-4 inhibitor are described here.
[6] In one aspect, the present invention features a Formula 1 compound, or a pharmaceutically acceptable compound thereof:
Warhead.
[7] Formula I [8] where Warhead is a fraction that is capable of forming a covalent bond with a nucleophile; ring A is a 3-8 membered aryl, heteroaryl, heterocyclic or alicyclic group; X is CH or N; Y is CH or NR ⁴ where R ⁴ is H or Ci-s aiquil; L is - [C (R ⁵ ) (R ⁶ )] _q -, where each of R ⁵ and R ⁶ is, independently, H or Ci-s aiquil; eq is 0-4; each of R ⁴ -R ³ is independently halo, cyano, optionally substituted C 1 -alkoxy, hydroxy, oxo, amino, starch, akyl urea, optionally substituted C 1 -alkyl, optionally substituted C 1 -heterocyclyl; m is 0-3; n is 0-4; ep is 0-2. In some embodiments, ring A is phenyl, for example, a 1,2-disubstituted phenyl; R ² is halo or methoxy; n is 2 or 4; X is N; R ¹ is methyl; and / or m is 1.
Petition 870160032383, dated 06/29/2016, p. 5/159
3/148 [9] In another aspect, the invention features a compound of Formula II, or a pharmaceutically acceptable salt thereof:
(R ² ) n
Formula II in which Warhead is a fraction that is capable of forming a covalent bond with a nucleophile; W is C or N; Z is CH or N; Y is CH or NR ⁴ where R ⁴ is H or Cg-g alkyl; R ¹ is H or Ch-g alkyl; each of go _f
R and R and, independently, halo, cyano, optionally substituted Cg-g alkoxy, hydroxy, amino, starch, optionally substituted alkyl urea, optionally substituted Cg-g alkyl, optionally substituted C 1-6 heterocyclyl; n is 0-4; ep is 0-2. In some embodiments, R ² is halo or methoxy; n is 2 or 4; Y is NR ⁴ , where R ⁴ is methyl; and / or R ¹ is methyl.
[10] In another aspect, the invention features a compound of Formula III, or a pharmaceutically acceptable salt thereof:
Formula III in which Warhead is a fraction that is capable of forming a covalent bond with a nucleophile; R ¹ is H or optionally substituted go _f
C1-6 alkyl, including dialkylaminoalkyl; each of R and R and, independently, halo, cyano, optionally substituted Cg_g alkoxy, hydroxy, amino, starch, optionally substituted alkyl urea, optionally substituted Cg_ ₆ alkyl, optionally substituted Cg_ ₆ heterocyclyl; n is 0-4; ep is 0-2. In some embodiments, R ² is halo or methoxy; n is 2 or 4. In some
Petition 870160032383, dated 06/29/2016, p. 6/159
4/148 modalities; R ¹ is methyl; in other embodiments, R ¹ is diethylaminobutyl.
[11] In another aspect, the invention features a compound of
Formula IV, or the pharmaceutically acceptable salt thereof:
Formula IV in which Warhead is a fraction that is capable of forming a covalent bond with a nucleophile; R ¹ is H or optionally substituted OQ _f
C1-6 alkyl; each of R and R and, independently, halo, cyan,
Optionally substituted C1-6 alkoxy, hydroxy, amino, starch, optionally substituted alkyl urea, optionally substituted C1-6 alkyl, optionally substituted C1-6 heterocyclyl; n is 0-4; ep is 0-2. In some embodiments, R ² is halo or methoxy; n is 2 or 4; and / or R ¹ is methyl.
[12] In another aspect, the invention features a compound of Formula V, or the pharmaceutically acceptable salt thereof:
Formula V in which Warhead is a fraction that is capable of forming a covalent bond with a nucleophile; each of R ² -R ³ is, independently, halo, cyano, optionally substituted C 1-6 alkoxy, hydroxy, amino, starch, optionally substituted alkyl urea, optionally substituted C 1 -alkyl, optionally substituted C 1-4 heterocyclyl; Ci-e heterocyclyl
Petition 870160032383, dated 06/29/2016, p. 7/159
5/148 optionally substituted; m is 0-3; n is 0-4; and p is 0-2.
[13] In another aspect, the invention features a compound of Formula VI, or the pharmaceutically acceptable salt thereof:
Warhead
--- (R ¹ ) m \
Formula VI in which Warhead is a fraction that is capable of forming a covalent bond with a nucleophile; L is aryl, heteroaryl, or [C (R ⁵ ) (R ⁶ )] _q -, where each of R ⁵ and R ⁶ is, independently, H or Ch-s alkyl; eq is 0-4; each of R ¹ is, independently, halo, cyano, optionally substituted Ch-6 alkoxy, hydroxy, oxo, amino, starch, optionally substituted alkyl urea, optionally substituted Ch-g alkyl, optionally substituted C 1 -heterocyclyl; em is 0-3. In some embodiments, L is alkylene; in other embodiments, L is phenyl. In some embodiments, R ¹ is trifluorethylurea.
[14] In another aspect, the invention features a compound of Formula VII, or the pharmaceutically acceptable salt thereof:
'Warhead
Formula VII where Warhead is a fraction that is capable of forming a _z Ί 2 x covalent bond with a nucleophile; each of R and R and,
Petition 870160032383, dated 06/29/2016, p. 8/159
6/148 independently, optionally substituted halo, cyano, C 1 -alkoxy, hydroxy, oxo, amino, starch, optionally substituted alkylsulfonamido, optionally substituted alkyl urea, optionally substituted C 1 -alkyl, optionally substituted C 1-4 heterocyclyl; m is 0-3; and n is 0-4.
[15] In another aspect, the invention features a compound of Formula VIII, or the pharmaceutically acceptable salt thereof:
Warhead
-j— (R ³ ) _p
H N
Formula VIII in which Warhead is a fraction that is capable of forming a covalent bond with a nucleophile; ring A is a 3-8 membered aryl, heteroaryl, heterocyclic or alicyclic group; W is C or N, each of X and Z is, independently, CH or N; Y is CH or NR ⁴ where R ⁴ is H or C1-6 alkyl; L is - [C (R ⁵ ) (R ⁶ )] _q -, where each of R ⁵ and R ⁶ is, independently, H or C 1 -alkyl; eq is 0-4; each of R ⁴ -R ³ is, independently, halo, cyano, optionally substituted Cl-6 alkoxy, hydroxy, oxo, amino, starch, alkyl urea, optionally substituted Ch-g alkyl, optionally substituted Cl-6 heterocyclyl; m is 0-3; n is 0-4; ep is 0-2. In some embodiments, ring A is phenyl; R ² is halo or methoxy; n is 2 or 4; X is N; R ¹ is methyl; and / or m is 1.
[16] In other respects, the compound is a compound of Formula IX, or a pharmaceutically acceptable salt thereof:
(R ¹ ) m
HN --- Warhead
Petition 870160032383, dated 06/29/2016, p. 9/159
7/148
Formula IX in which Warhead is a fraction that is capable of forming a covalent bond with a nucleophile; each of R and R and, independently, halo, cyano, optionally substituted C 1-6 alkoxy, hydroxy, oxo, amino, starch, optionally substituted alkyl urea, optionally substituted C 1 -alkyl, optionally substituted heterocyclyl; m is 0-3; and n is 0-4.
[17] In other respects, the invention features a compound of Formula X, or the pharmaceutically acceptable salt thereof:
Formula X where R is a warhead fraction; R and C1-6 alkyl, which is optionally substituted with halo, amino, hydroxy, or cyano; each R ³ is, independently, halo, amino, cyano, C1-6 alkyl, or C1-6 alkoxy, and n is 2-5; and R ⁴ is optionally substituted by C1-6 alkyl.
[1] In the compounds disclosed here, a warhead is a fraction that is reactive with a nucleophile, for example, capable of forming a covalent bond with a nucleophile. Examples of warheads include, but are not limited to, alkyl halides, alkyl sulfonates, heteroaryl halides, epoxides, haloacetamides, maleimides, sulfonate esters, unsaturated alpha-beta ketones, installed alphabetical esters, vinyl sulfones, propargyl amides, acrylamides. In some of these cases, for example, acrylamide and propargyl amide, the N of the warhead is the N adjacent to the formulas shown above. Exemplary warhead structures are shown below:
Petition 870160032383, dated 06/29/2016, p. 10/159
8/148
where X is a leaving group such as halo, or an activated hydroxyl moiety (for example, triflate); and each of R ^a , R ^b , and R ^c is, independently, H, substituted or unsubstituted C1-4 alkyl, substituted or unsubstituted C1-4 cycloalkyl, or cyano.
[18] In the formulas shown above, warheads are typically attached to an N atom in the inhibitor. In other embodiments, the warhead can alternatively be connected to the atom in addition to N. Examples of exemplary warheads include, among others,
Petition 870160032383, dated 06/29/2016, p. 11/159
9/148
Other examples of warheads can be found, for example, in WO 2010/028236 and WO 2011/034907.
[19] In certain embodiments, the FGFR-4 inhibitors of the invention inhibit FGFR-4 activity more potently than they inhibit FGFR-1 activity. For example, the FGFR-4 inhibitors of the invention can inhibit FGFR-4 activity at least 10 times, at least 50 times, at least 100 times, at least 200 times, or at least 500 times more potently than they inhibit FGFR-1 activity.
[20] In one aspect, selectivity is measured by comparing the inhibition of FGFR-1 and FGFR-4 caused by the compound of the present invention in the same type of assay. In one embodiment, the assays used to measure the inhibition of FGFR-1 and FGFR-4 are any of the assays described herein. Typically, inhibition is expressed as IC ₅₀ (the concentration of inhibitor at which 50% of the activity of the enzyme is inhibited) and thus multiples of selectivity are measured by the equation: (ΙΟ ₅₀ FGFR-1) / (IC ₅ o FGFR4) . The same measurements and calculations can be used to measure selectivity for FGFR-2 and FGFR-3, as well as.
[21] Any other FGFR activity assays can be used to determine the relative inhibition of FGFR-1 and FGFR4 by the compounds of the present invention, as long as these assays use what a person skilled in the art considers to be the same parameters for measuring activity FGFR.
[22] In another aspect, the invention features a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound described herein.
[23] In another aspect, the invention features a covalent inhibitor of FGFR-4. In some modalities, the inhibitor
Petition 870160032383, dated 06/29/2016, p. 12/159
10/148 covalent FGFR-4 inhibits FGFR-4 activity more potently, when measured in a biochemical assay, which inhibits FGFR-1 activity. The inhibitor may contain a warhead.
[24] In another aspect, the invention features a compound that inhibits FGFR-4 activity more potently, when measured in a biochemical assay, that inhibits FGFR-1 activity, in which the compound has a lower molecular weight 1500 daltons. For example, the compound can inhibit FGFR-4 activity by at least 10, 50, 100, 200, or 500 times more potent, measured in a biochemical assay, which inhibits FGFR-1 activity. In some cases, this compound can form a covalent bond with FGFR-4, for example, with Cys 522 of FGFR-4.
[25] In another aspect, the invention features an FGFR-4 inhibitory protein comprising an inhibitor that has a covalent bond to a FGFR-4 cysteine residue. The covalent bond can be formed between a fraction of a warhead on the inhibitor and a portion of a FGFR-4 cysteine residue, for example, cysteine residue 552 of the protein. The warhead can be [26] In another aspect, the invention features a method for treating a condition mediated by FGFR-4, a condition characterized by overexpression of FGFR-4, a condition characterized by amplification of FGFR4, a condition mediated by FGF19, a condition characterized by amplified FGF-19, or a condition characterized by overexpression of FGF19, any of these methods comprising administering a therapeutically effective amount of a compound described herein to a subject.
[27] In another aspect, the invention features a method of treating any of the following conditions by administering a therapeutically effective amount of a compound described herein to a subject: hepatocellular carcinoma,
Petition 870160032383, dated 06/29/2016, p. 13/159
11/148 breast cancer, ovarian cancer, lung cancer, liver cancer, a sarcoma, or hyperlipidemia.
[28] The invention includes all possible combinations of modalities described above.
Brief Description of the Drawings [29] Fig. 1 is a spectrum showing masses for FGFR4 protein with and without bound inhibitor.
[30] Fig. 2 is a spectrum that shows FGFR4 protein masses with and without bound inhibitors.
[31] Fig. 3 is a graph showing the caspase activity of Compound 25.
[32] Fig. 4 is a drawing of the crystal structure of Compound 52 linked to the FGFR4 protein.
[33] Fig. 5 is a drawing of the crystal structure of Compound 25 linked to the FGFR4 protein.
[34] Fig. 6 is a line graph that illustrates the anti-tumor effect of Compound 25.
[35] Fig. 7 is a bar graph showing the weights of nude mouse tumors containing Hep3B.
[36] Fig. 8 is a graph representing the change in body weight (%) of nude mice containing Hep3B.
Detailed Description [37] Pan-FGFR inhibitors, such as BGJ398 and AZD4547, are known.
BGJ398
AZD4547
Petition 870160032383, dated 06/29/2016, p. 14/159
12/148 [38] These compounds (ie, pan-FGFR inhibitors) have not been reported to be more potent against FGFR4 than against other FGFR isoforms, ie FGFR1, FGFR2, FGFR3 and. In fact, AZD 4547 is less potent against FGFR4 than it is against the other three isoforms.
[39] Unlike BGJ398 and AZD4547, the compounds described below, can form a covalent bond with the FGFR4 protein; for example, the compounds can form a covalent bond with a cysteine residue from FGFR4, for example, the cysteine at residue 552. FGFRsl-3 does not contain this cysteine. The ability to form a covalent bond between the compound and FGFR4 is, therefore, an important factor for the selectivity of the compounds described here for FGFR4.
[40] The details of construction and arrangement of components set out in the following description or illustrated in the drawings are not intended to be limiting. Other different modalities and forms for the practice of the invention are expressly included. In addition, the phraseology and terminology used here are for the purpose of description and should not be considered as limiting. The use of the term including, includes, includes, comprising or having, containing, involving, and variations thereof, is intended to encompass the items listed below and their equivalents, as well as additional articles.
Definitions [41] Aliphatic group, as used herein, refers to a straight chain, branched chain, or cyclic hydrocarbon group and includes saturated and unsaturated groups, such as an alkyl group, an alkenyl group, and an alkynyl group.
[42] Alkenyl, as used herein, refers to an aliphatic group containing at least one double bond.
[43] Alkoxyl or alkoxy, as used herein, refers to an alkyl group having an oxygen radical attached to it. Representative alkoxy groups include methoxy, ethoxy, propyloxy, tertiary
Petition 870160032383, dated 06/29/2016, p. 15/159
13/148 butoxy and the like.
[44] Alkyl, as used herein, refers to the radical of saturated aliphatic groups, including straight chain alkyl groups, branched chain alkyl groups, cloalkyl (alicyclic) groups, cloalkyl groups substituted with alkyl, and alkyl groups substituted with cloalkyl . Alkylene refers to a double radical, that is, an aliphatic group substituted at two ends. In some embodiments, a straight chain or branched alkyl chain has 30 or less carbon atoms in its structure (for example, C1-C30 for linear chains, C3-C30 for branched chains), and in other embodiments it can have 20 or less , or 10 or less. Likewise, certain cloalkyls may contain 3-10 carbon atoms in their ring structure, and in some embodiments they may have 5, 6 or 7 carbons in the ring structure. The term alkenyl, as used herein, refers to an aliphatic group containing at least one double bond; the term alkynyl, as used herein, refers to an aliphatic group containing at least one triple bond.
[45] Alkylthio, as used herein, refers to a hydrocarbyl group having a sulfur radical attached to it. In some embodiments, the alkylthio moiety is represented by a -Salkyl, -S-alkenyl, or -S-alkynyl. Representative alkylthio groups include methylthio, ethylthio, and the like.
[46] Starch, as on here used, refers to The -C (= 0) - N (R ¹ ) (R ² ) or -N (R ¹ ) -C (= 0) - -R ² , where each one of R ¹ and R ² is H or alkyl. [47] Amino, how on here used, refers to The -nh ₂ , - NH (alkyl) , or -N (alkyl) (alkyl). [48] Amplified, how used here means copies
Additional genes or chromosome segments are produced in cancer cells that can confer a growth or survival advantage.
[49] Aralkyl, as used herein, refers to a group
Petition 870160032383, dated 06/29/2016, p. 16/159
14/148 alkyl substituted with an aryl group (for example, an aromatic or heteroaromatic group).
[50] Aryl, as used herein, refers to 5, 6, and 7-membered single ring aromatic groups that may include from zero to four heteroatoms, for example, phenyl, pyrrolyl, furanyl, thiophenyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, pyrazolyl, pyridinyl, pyrazinyl, pyridazinyl and pyrimidinyl, and the like. Those aryl groups having hetero atoms in the ring structure can also be referred to as aryl heterocycles or heteroaromatics. The aromatic ring can be substituted at one or more positions of the ring with said substituents as described above, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, polycyclic, hydroxyl, alkoxy, amino, nitro, sulfhydryl, imino , starch, phosphate, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclic, aromatic or heteroaromatic fractions, -CF ₃ , -CN, or the like. The term aryl also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two contiguous rings (the rings are fused rings) in which at least one of the rings is aromatic, for example, other cyclic rings they may be cycloalkyl, cycloalkenyl, cycloalkynyl, aryl and / or heterocyclyl. Each ring can contain, for example, 5-7 members.
[51] The term carbocycle or cycloalkyl, as used herein, refers to an aromatic or non-aromatic ring in which each atom of the ring is carbon.
[52] Covalent inhibitor, as used herein, means an inhibitor that can form a covalent bond with a protein.
[53] The enantiomeric excess or% enantiomeric excess of a composition can be calculated using the equation below. In the example shown below a composition contains 90% of an enantiomer, for example, the S-enantiomer, and 10% of the other enantiomer, that is, the R-enantiomer.
Petition 870160032383, dated 06/29/2016, p. 17/159
15/148 ee = (90-10) / 100 = 80%.
[54] Thus, a composition containing 90% of one enantiomer and 10% of the other enantiomer is said to have an enantiomeric excess of 80%. Some of the compositions described herein contain an enantiomeric excess of at least 50%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% of Compound 1 (the S enantiomer). In other words, the compositions contain an enantiomeric excess of the S-enantiomer over the R-enantiomer.
[55] FGFR-4 or FGFR-4 protein refers to any form of the FGFR-4 protein, including wild type and all variant forms (including, but not limited to, mutant forms and splicing variants). The FGFR-4 protein is a product of the FGFR-4 gene, and the FGFR-4 protein therefore includes any protein encoded by any form of the FGFR-4 gene, including all aberrations, for example, indelible, point mutations , translocation fusions, and focal amplifications.
[56] Heteroarylalkyl refers to an alkyl group substituted with a heteroaryl group.
[57] Heterocyclyl or heterocyclic group refers to a ring structure, such as a 3- to 7-membered ring structure, whose rings include one or more heteroatoms. Heterocycles can also be polycyclics, with each group having, for example, 3-7 members in the ring. The term heterocyclyl or heterocyclic group includes saturated or partially saturated heteroaryl and heterocyclyl structures. Heteroaryl refers to a 5-8 membered monocyclic aromatic, 8-12 membered bicyclic group, or 11-14 membered tricyclic ring system having one or more heteroatoms, selected from O, N or S. Any atom of ring may be substituted (for example, by one or more substituents). The term saturated or partially saturated heterocyclyl refers to a non-aromatic cyclic structure that includes at least one heteroatom. Heterocyclyl groups include, for example, thiophenyl, thiantrenyl,
Petition 870160032383, dated 06/29/2016, p. 18/159
16/148 furanyl, pyranyl, isobenzofuranyl, chromenyl, xanthenyl, phenoxyamine, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, isoxazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, quinolone, isolindyl, quinolone, isoindol , naphthyridinyl, quinoxalinyl, quinazolinyl, cinolinyl, pteridinyl, carbazolyl, carboline, phenanthridine, acridine, pyrimidine, phenanthroline, phenazine, phenarsazine, phenothiazine, furazan, phenoxazine, pyrrolidine, oxolane, pyridine, pyridine, pyridine, pyridine, pyridine, pyridine, pyridine, pyridine, pyridine, pyridine, pyridine, pyridine, pyridine, pyridine, pyridine, pyridine, oxazole, such as azetidinones and pyrrolidinones, sultamas, sultones and the like. The heterocyclic ring can be substituted at one or more positions with such substituents as described above, for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, starch, phosphate, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, ketone, aldehyde, ester, heterocyclic, an aromatic or heteroaromatic part, -CF3, -CN, or the like.
[58] Heterocyclylalkyl refers to an alkyl group substituted with a heterocycle group.
[59] Inhibitor refers to a compound that inhibits an enzyme, such that a reduction in the activity of the enzyme can be observed, for example, in a biochemical assay. In certain embodiments, an inhibitor has an IC 50 of less than about 1 μΜ, less than about 500 nM, less than about 250 nM, less than about 100 nM, less than about 50 nM, or less than about 10 nM. An FGFR-4 inhibitor refers to a compound that inhibits FGFR-4.
[60] Overexpressed, as used herein, means that there is production of a gene product in a sample that is substantially higher than that observed in the control sample population (for example, normal tissue).
[61] Selective refers to a compound that inhibits
Petition 870160032383, dated 06/29/2016, p. 19/159
17/148 activity of a target protein, for example, FGFR-4, more potently than it inhibits the activity of other proteins. In this example, the isoforms of FGFR-1, FGFR-2, FGFR-3, and FGFR-4 are all considered to be distinct proteins. In some embodiments, a compound can inhibit the activity of the target protein, for
example, the FGFR-4 at least 1.5, at least 2, fur any less 5, fur any less 10, at least 20, fur least 30, at least 40, in fur any less 50, at least 60, fur least 70, at least any less 80, at any less 90, fur minus 100 at least 200, at least any less 500, OR fur any less ; 10 00 times OR more strongly of what inhibits The
activity of a non-target protein.
[62] Substituted refers to groups having substituents replacing a hydrogen atom on one or more carbons in the structure. It must be understood that substitution or substituted with includes the implicit condition that this substitution is in accordance with the allowed valence of the substituted atom and the substituent and that the substitution results in a stable compound, for example, that does not spontaneously undergo transformation, such as rearrange, cyclization, elimination, etc. As used herein, the term substituted is contemplated to include all allowable substituents on organic compounds. In a broader sense, permitted substituents include substituents of acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic organic compounds. The admissible substituents can be one or more and the same or different for appropriate organic compounds. For the purposes of the present invention, heteroatoms such as nitrogen may have hydrogen substituents and / or any permissible substituents for organic compounds described herein that satisfy the heteroatoms' valences. Substituents may include any substituents described herein, for example, a halogen, a hydroxyl, a carbonyl (such as a carboxyl, an alkoxycarbonyl, a formyl or an acyl), a thiocarbonyl (such as a
Petition 870160032383, dated 06/29/2016, p. 20/159
18/148
thioester, one thioacetate, or one thioformate), a alkoxy, one phosphoryl, one phosphate, a phosphonate >, a phosphinate, one amino, one starch, one amidine, an imine, one cyan, a nitro, one azido, one
sulfhydryl, an alkylthio, a sulfate, a sulfonate, a sulfamoyl, a sulfonamido, a sulfonyl, a heterocyclyl, an aralkyl or an aromatic or heteroaromatic part. It will be understood by those skilled in the art that the fractions substituted in the hydrocarbon chain can themselves be replaced, if applicable. For example, substituted alkyl substituents can include substituted and unsubstituted forms of amino, azido, imino, starch, phosphoryl (including phosphonate and phosphinate), sulfonyl (including sulfate, sulfonamido, sulfamoyl and sulfonate) and silyl groups, as well as ethers, alkylthio, carbonyl (including ketones, aldehydes, carboxylates and esters), -CF ₃ , -CN and the like. Exemplary substituted alkyls are described below. Cycloalkyl may be further substituted with alkyl, alkenyl, alkoxy, alkylthio, aminoalkyl, alkyl substituted with carbonyl, -CF ₃ , -CN, and the like. Analogous substitutions can be made to alkenyl and alkynyl groups to produce, for example, aminoalkenyl, aminoalkynyl, amidoalkenyl, amidoalquinyl, iminoalkenyl, iminoalquinyl, thioalkenyl, thioalquinyl, alkenyl or alkynyl substituted with carbonyl.
[63] As used here, the definition of each expression, for example, alkyl, m, n, etc., when it occurs more than once in any structure, is intended to be independent of its definition elsewhere in the same structure.
[64] Warhead fraction or warhead refers to a radical of an inhibitor that participates, reversibly or irreversibly, with the reaction of a donor, for example, a protein, with a substrate. Warheads can, for example, form covalent bonds with the protein, or they can create stable transition states, that is, a reversible or irreversible alkylating agent. For example, the warhead fraction can be a group
Petition 870160032383, dated 06/29/2016, p. 21/159
19/148 functional in an inhibitor that can participate in a bonding reaction, in which a new covalent bond formed between a fraction of the warhead and a donor, for example, an amino acid residue of a protein. In modalities, a warhead is an electrophile and the donor is a nucleophile like the side chain of a cysteine residue. Examples of suitable warheads include, but are not limited to, the groups shown below:

[65] where X is a leaving group such as halo, or an activated hydroxyl radical (for example, triflate); and each of R ^a , R ^b and R ^c is, independently, H, C 1-4 substituted or unsubstituted alkyl, C 1-4 substituted or unsubstituted alkyl cycle, or cyano.
[66] The compounds described herein may contain unnatural proportions of atomic isotopes in one or more of the atoms that constitute such compounds. For example, compounds can be radiolabeled with radioactive isotopes, such as tritium ( ³ H) or carbon-14 ( ¹⁴ C). All isotopic variations of the compounds disclosed herein, whether radioactive or not, are intended to be encompassed within the scope of the present invention. For example, deuterated compounds or compounds containing ¹³ C are intended to be encompassed within the scope of the invention.
[67] Certain compounds can exist in different tautomeric forms, and all possible tautomeric forms of all compounds described herein are intended to be encompassed within the scope of the invention.
[68] Unless otherwise indicated, the structures illustrated here are also intended to include all forms of isomeric structures (eg, enantiomeric,
Petition 870160032383, dated 06/29/2016, p. 22/159
20/148 diastereoisomeric and geometric (or conformational)); for example, the R and S configurations for each asymmetric center, double bond isomers Z and E, and conformational isomers Z and E. Therefore, the individual stereochemicals as well as enantiomeric, diastereoisomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. Unless otherwise indicated, all tautomeric forms of the compounds of the invention are within the scope of the invention.
[69] The compounds described herein can be useful, as the free base or as a salt. Representative salts include hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate salts. , mesylate, glucoheptonate, lactobionate, and lauryl sulfonate and the like.
(See, for example, Berge et al (1977) ‘Pharmaceutical Salts, J. Pharm Sci 66: 1-19)[70] Certain compounds on here described may exist in shapes
unsolvated as well as solvated forms, including hydrated forms. In general, solvated forms are equivalent to unsolvated forms and are included within the scope of the present invention. Certain compounds described herein can exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are understood to be within the scope of the present invention.
[71] Exemplary compounds include the following:
Petition 870160032383, dated 06/29/2016, p. 23/159
21/148
Petition 870160032383, dated 06/29/2016, p. 24/159
22/148
Petition 870160032383, dated 06/29/2016, p. 25/159
23/148
Petition 870160032383, dated 06/29/2016, p. 26/159
24/148

Petition 870160032383, dated 06/29/2016, p. 27/159
25/148
Petition 870160032383, dated 06/29/2016, p. 28/159
26/148
Pharmaceutical Compositions [72] While it is possible for a compound disclosed herein to be administered alone, it is preferred to administer the compound as a pharmaceutical formulation, wherein the compound is combined with pharmaceutically acceptable excipients or carriers. The compounds disclosed herein can be formulated for administration in any form convenient for use in human or veterinary medicine. In certain embodiments, the compound included in the pharmaceutical preparation can be active on its own, or
Petition 870160032383, dated 06/29/2016, p. 29/159
27/148 can be a prodrug, for example, capable of being converted into an active compound in a physiological environment. In certain embodiments, the compounds provided herein include their hydrates.
[73] The phrase pharmaceutically acceptable is used here to refer to those compounds, material forms, compositions, and / or dosage which are, within the scope of the medical criterion, suitable for use in contact with the tissues of humans and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.
[74] Examples of pharmaceutically acceptable salts of a compound described herein include those derived from pharmaceutically acceptable inorganic and organic acids and bases. Examples of suitable acid salts include acetate, adipate, benzoate, benzenesulfonate, butyrate, citrate, digluconate, dodecyl sulfate, formate, fumarate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, ihydrate, lactate, maleate, malonate, methaneside, malonate, methaneside , nicotinate, nitrate, palmoate, phosphate, picrate, pivalate, propionate, salicylate, succinate, sulfate, tartrate, tosylate and undecanoate. Salts derived from appropriate bases include alkali metal (for example, sodium), alkaline earth metals (for example, magnesium), ammonium and N (alkyl) 4 ⁺ salts. This invention also provides for the quaternization of any basic nitrogen-containing groups of the compounds described herein. Products soluble in water or oil or dispersible products can be obtained by this quaternization.
[75] Examples of pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and
Petition 870160032383, dated 06/29/2016, p. 30/159
28/148 suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) Pyrogen-free water; (17) isotonic saline solution; (18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer solutions; (21), cyclodextrins such as Captisol®; targeting binders linked to nanoparticles, such as Accurins ™; and (22) other compatible non-toxic substances, such as polymer-based compositions, used in pharmaceutical formulations.
[76] Examples of pharmaceutically acceptable antioxidants include: (1) water-soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gaiate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like. Solid dosage forms (for example, capsules, tablets, pills, pills, powders, granules and the like) may include one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and / or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and / or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and / or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as
Petition 870160032383, dated 06/29/2016, p. 31/159
29/148 paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, cetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and (10) dyes. Liquid dosage forms can include emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing and emulsifying agents, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, peanut, corn, germ, olive, castor and sesame), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters sorbitan, and mixtures thereof.
[77] The suspensions, in addition to the active compounds, may contain suspending agents such as isostearyl ethoxylated alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar and tragacanth, and their mixtures.
[78] Ointments, pastes, creams and gels may contain, in addition to an active compound, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, acid silica, talc and zinc oxide, or mixtures thereof.
[79] Powders and sprays may contain, in addition to an active compound, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays may additionally contain customary propellants, such as chlorofluorhydrocarbons and unsubstituted hydrocarbons
Petition 870160032383, dated 06/29/2016, p. 32/159
30/148 volatiles, such as butane and propane.
[80] Formulations can conveniently be presented in unit dosage form and can be prepared by any methods well known in the pharmacy art. The amount of active ingredient that can be combined with a carrier material to produce a single dosage form will vary depending on the host to be treated, the particular mode of administration. The amount of active ingredient that can be combined with a carrier material to produce a single dosage form will generally be the amount of the compound that produces a therapeutic effect.
[81] Dosage forms for topical or transdermal administration of a compound of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, adhesives and inhalants. The active compound can be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants that may be required.
[82] When the compounds described herein are administered as pharmaceutical products, for humans and animals, they can be administered per se or as a pharmaceutical composition containing, for example, 0.1 to 99.5% (more preferably, 0 , 5 to 90%) of active ingredient in combination with a pharmaceutically acceptable carrier.
[83] The formulations can be administered topically, orally, transdermally, rectally, vaginally, parenterally, intranasal, intrapulmonary, intraocularly, intravenously, intramuscularly, intraarterially, intrathecally, intracapsularly, intradermally, intraperitoneally, subcutaneously, subcuticular, or by inhalation.
Indications [84] FGFR-4 regulates the proliferation, survival and secretion of alpha-fetoprotelna during progression of hepatocellular carcinoma (HCC); FGFR-4 inhibitors are therefore
Petition 870160032383, dated 06/29/2016, p. 33/159
31/148 potential promising therapeutic agents for this unmet medical need (Ho et al., Journal of Hepatology, 2009, 50: 118-27). HCC afflicts more than 550,000
people in the world every year and have i love of worse fees in survival of 1 year of any kind cancer. [85] Other link evidence in between FGFR-4 and HCC is shown through FGF involvement 19, one member gives family
fibroblast growth factor (FGF), which consists of hormones that regulate glucose, lipids and energy homeostasis. Increased proliferation of hepatocytes and formation of liver tumors have been observed in FGF 19 transgenic mice. FGF 19 activates FGFR-4, its predominant receptor in the liver, and it is believed that FGFR-4 activation is the mechanism through which which FGF 19 can increase the proliferation of hepatocytes and induce the formation of hepatocellular carcinoma (Wu et al., J Biol Chem (2010) 285 (8): 5165-5170). FGF 19 has been identified as a controller gene in HCC by others, as well (Sawey et al, Cancer Cell (2011) 19: 347-358). Therefore, it is believed that the compounds described here, which are potent and selective inhibitors of FGFR-4, can be used to treat hepatocellular carcinoma and other cancers of the liver.
[86] Oncogenome screening has identified an activating fibroblast growth factor receptor 4 (FGFR-4) mutation Y367C in the human breast cancer cell line MDA-MB-453. This mutation has been shown to cause constitutive phosphorylation, leading to an activation of the mitogen-activated protein kinase cascade. Therefore, it has been suggested that FGFR-4 may be a driver of tumor growth in breast cancer (Roidl et al., Oncogene (2010) 29 (10): 1543-1552). Therefore, it is believed that the compounds described herein, which are potent and selective inhibitors of FGFR-4, can be used to treat FGFR-4 modulated breast cancer.
[87] Molecular modifications (eg, translocations) in genes upstream of FGFR-4 can lead to activation / over
Petition 870160032383, dated 06/29/2016, p. 34/159
32/148 expression of FGFR-4. For example, a translocation / fusion of the PAX3-FKHR gene can lead to FGFR-4 overexpression. Overexpression of FGFR-4 due to this mechanism has been associated with rhabdomyosarcoma (RMS) (Cao et al, Cancer Res (2010) 70 (16): 6497-6508). Mutations in FGFR-4 alone (for example, mutations in the kinase domain) can lead to overactivation of the protein; this mechanism has been associated with a subpopulation of RMS (Taylor et al., J Clin Invest (2009) 119: 3395-3407). Therefore, it is believed that the compounds described herein, which are potent and selective inhibitors of FGFR-4, can be used to treat modulated FGFR-4 RMS and other sarcomas.
[88] Other diseases have been associated with alterations in genes upstream of FGFR-4 or with mutations in FGFR-4 alone. For example, mutations in the FGFR-4 kinase domain lead to excess activation, which has been associated with lung adenocarcinoma (Ding et al., Nature (2008) 455 (7216): 1069-1075). Amplification of FGFR-4 has been associated with conditions such as renal cell carcinoma (TCGA, provisional data). In addition, FGFR4 silencing and inhibition of receptor-ligand binding significantly slows the growth of the ovarian tumor, suggesting that FGFR4 inhibitors could be useful in the treatment of ovarian cancer. (Zaid et al., Clin. Cancer Res. (2013) 809).
[89] Pathogenic elevations of bile acid levels have been linked to variations in FGF19 levels (Vergnes et al., Cell Metabolism (2013) 17, 916-28). A decrease in the level of FGF19 can, therefore, be beneficial in promoting bile acid synthesis and, therefore, in the treatment of hyperlipidemia.
Dose levels [90] The actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention can be varied in order to obtain an amount of the active ingredient that is effective in achieving the desired therapeutic response for a patient.
Petition 870160032383, dated 06/29/2016, p. 35/159
33/148 in particular, composition and method of administration, without being toxic to the patient.
[91] The dosage level selected will depend on a variety of factors including the activity of the particular compound employed herein, or the ester, salt or amide, the route of administration, the time of administration, the rate of excretion of the particular compound that being used, duration of treatment, other drugs, compounds and / or materials used in combination with the particular compound used, age, sex, weight, condition, general health and previous medical history of the patient to be treated, and similar factors well known in medical techniques.
[92] A doctor or veterinarian with current knowledge in the art can readily determine and prescribe the effective amount of the required pharmaceutical composition. For example, the doctor or veterinarian could start with doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
[93] In general, an adequate daily dose of a compound of the invention will be the amount of the compound that is the lowest effective dose to produce a therapeutic effect. Such an effective dose will generally depend on the factors described above. Generally, doses of the compounds of the present invention to a patient will vary between about 0.0001 and about 100 mg per kilogram of body weight per day. For example, the dose can be between 0.1 and 10 g per day; between 0.5 and 5 g per day; or 1-2 g per day. If desired, the effective daily dose of the active compound can be administered as one, two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally in unit dosage forms.
Combination and Targeted Therapy [94] Administration of the FGFR-4 inhibitors described herein
Petition 870160032383, dated 06/29/2016, p. 36/159
34/148 can be combined with other cancer treatments. For example, inhibitors can be administered in combination with surgical treatments, radiation, or other therapeutic agents, such as antibodies, other selective kinase inhibitors, or chemotherapeutic agents. Inhibitors can also be administered in combination with RNAi therapy or antisense therapy. The FGFR-4 inhibitors described herein can be combined with one, two, or more other therapeutic agents. In the examples described below, it is understood that the second therapeutic agent also includes more than one therapeutic agent other than the FGFR-4 inhibitor. An FGFR-4 inhibitor described herein can be administered with one, two, or more other therapeutic agents.
[95] The FGFR-4 inhibitors described here and the second therapeutic agent should not be administered in the same pharmaceutical composition, and may, because of the different physical and chemical characteristics, be administered in different ways. For example, the FGFR-4 inhibitor can be administered orally, while the second therapeutic agent is administered intravenously. The determination of the mode of administration and the convenience of administration, when possible, in the same pharmaceutical composition, are well within the knowledge of the specialist physician. Initial administration can be done according to established protocols known in the art, and then, based on the observed effects, the dosage, modes of administration and times of administration can be modified by the specialist physician.
[96] The FGFR-4 inhibitor and the second therapeutic agent can be administered simultaneously (for example, at the same time, essentially, at the same time or within the same treatment protocol) or sequentially (for example, one after the other, with a time interval between optional), depending on the nature of the proliferative disease, the patient's condition, and the actual choice of the second therapeutic agent to be
Petition 870160032383, dated 06/29/2016, p. 37/159
35/148 administered.
[97] In addition, the FGFR-4 inhibitors described herein can be administered as part of an anticorpodrug conjugate, where the FGFR-4 inhibitor is the charge fraction of the conjugate.
[98] Analysis tools and methods for characterizing the compound:
[99] LCMS: Unless otherwise stated, all liquid chromatography-mass spectrometry (LCMS) data (sample analyzed for purity and identity) was obtained with an Agilent 1260 model-LC system using a mass spectrometer model Agilent 6120 using ES-ΑΡΙ ionization equipped with an Agilent Poroshel 120 reverse phase column (EC-C18, 2.7um particle size, 3.0 x 50mm dimensions) at 22.4 degrees Celsius. The mobile phase consisted of a mixture of solvent 0.1% formic acid in water and 0.1% formic acid in acetonitrile. A constant gradient from 95% aqueous / 5% organic to 5% aqueous / 95% organic mobile phase was used over 4 minutes. The flow was constant at Iml / min.
[100] Proton NMR: Unless otherwise stated, all NMR spectra were obtained with a Varian 400 MHz Unity Inova 400 MHz NMR instrument (acquisition time = 3.5 seconds with a 1 second delay; 16 and 64 scans). Where characterized, all protons were reported in DMSO-d ⁶ solvent as parts per million (ppm) in relation to residual DMSO (2.50 ppm).
[101] Preparatory instruments for the purification of compounds: Silica gel chromatography was performed on each Teledyne Isco CombiFlas® RF unit or a Biotag® Isolera Four unit.
[102] Prep LCMS: Preparative HPLC was performed on a preparative Shimadzu Discovery VP® system equipped with a Luna 5u C18 (2) 100A reverse phase column, packaged AXIA, 250 x 21.2 mm at 22.4 degrees Celsius. The mobile phase was
Petition 870160032383, dated 06/29/2016, p. 38/159
36/148 consisting of a mixture of solvent 0.1% formic acid in water and 0.1% formic acid in acetonitrile. A constant gradient of mobile phase from 95% aqueous / 5% organic to 5% aqueous / 95% organic over 25 minutes was used. The flow rate was constant at 20 mL / min. The reactions carried out in a microwave oven were carried out in a Biotage Initiator microwave unit.
[103] Example 1: Synthesis of N- (2 - ((6- (2,6-dichloro-3,5dimethoxyphenyl) -8-methyl-7-oxo-7,8-dihydropyride [2,3-d] pyrimidin2 -yl) amino) -3-methylphenyl) acrylamide COMPOUND 43
CO ₂ Et MeNH ₂ ^emMe0H
Month
Cl
THF, RT
THF, RT
Month
OH MnO ₂
OH MnO ₂
DCM, RT MeS
N
II
Petition 870160032383, dated 06/29/2016, p. 39/159
37/148
(methylthio) pyrimidine-5-carboxylate _N ^ .CO ₂ Et MeNH ₂ ^emMe0H _Ν ^ γΟΟ ₂ Εί
MeS ^ N ^ XI ^THF ' ^RT MeS ^ N ^ N ^ H [105] A mixture of ethyl 4-chloro-2- (methylthio) pyrimidine-5-carboxylate (5.0 g, 21.5 mmol) and 29% methylamine (5.75 g, 53.72 mmol, methanol (MeOH) solution) in tetrahydrofuran (THF) (100 mL) was stirred at room temperature for 2 hours. The reaction mixture was then concentrated, followed by the addition of sodium bicarbonate (NaHCO ₃ ) (aq., 20 ml), and the resulting solution was extracted with ethyl acetate (EtOAc) (3 x 50 ml). The combined organic layers were washed with water and brine, dried over sodium sulfate, filtered, and concentrated to generate ethyl 4- (methylamino) -2 (methylthio) pyrimidine-5-carboxylate (4.68 g, 96%) as a solid
Petition 870160032383, dated 06/29/2016, p. 40/159
38/148 yellowish. MS (ES +) C ₉ H ₁₃ N ₃ O2S requires: 227, found: 228 [M +
H] ⁺ .
[106] Step 2: Synthesis of (4- (methylamino) -2- (methylthio) pyrimidin-5-yl) methanol
[107] To a suspension of lithium aluminum hydride (LiAlH ₄ ) (1,140 g, 30 mmol) in THF (100 mL) was added ethyl 4- (methylamino) -2- (methylthio) pyrimidine-5-carboxylate (4.536 g , 20 mmol), and the reaction mixture was stirred at room temperature for 2 hours. The solution was carefully quenched with H ₂ O (2 ml), sodium hydroxide (NaOH) (aq., 15%, 2 ml) and more H ₂ O (7 ml), and then stirred for 1 hour. The mixture was extracted with EtOAc (2 χ 100 mL), and the combined organic layers were washed with water and brine, dried over sodium sulfate, and concentrated to generate (4- (methylamino) -2- (methylthio) pyrimidin-5 -yl) methanol (3.2 g, 85%) as a yellowish solid. MS (ES +) CvHuLhOS requires: 185, found: 186 [M + H] ⁺ .
[108] Step 3: Synthesis of 4- (methylamino) -2- (methylthio) pyrimidine-5-carbaldehyde
[109] A suspension of (4- (methylamino) -2- (methylthio) pyrimidin-5-yl) methanol (3.1 g, 16.73 mmol) and manganese dioxide (7.27 g, 83, 67 mmol ) in DCM (40 mL) was stirred at room temperature for 12 hours. The resulting precipitate was filtered, and the filtrate was concentrated to generate 4 (methylamino) -2- (methylthio) pyrimidine-5-carbaldehyde (2.8 g, 91%) as a yellowish solid. MS (ES +) C ₇ H ₉ N ₃ OS requires: 183, found: 184 [M + H] ⁺ .
[110] Step 4: Synthesis of methyl 2- (3,5-dimethoxyphenyl) acetate
Petition 870160032383, dated 06/29/2016, p. 41/159
39/148
[111] To a solution of 2- (3,5-dimethoxyphenyl) acetic acid (5) (600 mg, 3.06 mmol) in MeOH (30 mL) was added under thionyl chloride (3 mL) at 0 ° C, and the reaction mixture was stirred at room temperature overnight. The reaction was monitored by liquid chromatography-mass spectrometry (LCMS). The mixture was diluted with saturated sodium bicarbonate (aq., 20 ml) and extracted with EtOAc (3 x 20 ml). The combined organic layers were washed with water and brine, dried over sodium sulfate, filtered and concentrated to generate methyl 2- (3,5-dimethoxyphenyl) acetate (crude, 700 mg) as a yellow oil. MS (ES +) CnH ^ Cg requires: 210, found: 211 [M + H] ⁺ .
[112] Step 5: Synthesis of 6- (3,5-dimethoxyphenyl) -8-methyl-
2- (methylthio) pyrido [2,3-d] pyrimidin-7 (8H) -one

K ₂ CO ₃ , DMF 110 ° C, 3 h
[113] A solution of 2- (3,5-dimethoxyphenyl) acetate (6) (440 mg, 2.40 mmol), 4-amino-2- (methylthio) pyrimidine-5carbaldehyde (4) (605 mg, 2, 88 mmol) and potassium carbonate (662 mg, 4.8 mmol) in DMF (30 mL) was stirred at 110 ° C for 3 hours.
reaction was monitored by LCMS. The reaction mixture was diluted with H ₂ O (30 ml), and extracted with EtOAc (3 χ 40 ml). The combined organic layers were washed with water and brine, dried over sodium sulfate, filtered and concentrated. The residue was purified by column chromatography (silica gel, petroleum ether / EtOAc = 2: 1) to generate 6- (3,5-dimethoxyphenyl) -8-methyl2- (methylthio) pyrido [2,3-d] pyrimidin -7 (8H) -one (7) (683 mg, 83%) as a white solid. MS (ES +) C ₁₇ H ₁₇ N ₃ O ₅ S requires: 343,
Petition 870160032383, dated 06/29/2016, p. 42/159
40/148 found: 344 [Μ + H] ⁺ .
[114] Step 6: Synthesis of 6- (3,5-dimethoxyphenyl) -8-methyl-
2- (methylsulfonyl) pyrido [2,3-d] pyrimidin-7 (8H) -one
[115] To a solution of 6- (3,5-dimethoxyphenyl) -8-methyl-2 (methylthio) pyrido [2,3-d] pyrimidin-7 (8H) -one (1.05 g, 3.1 mmol) in methanol / dichloromethane (MeOH / DCM) (20 mL / 20 mL) was added a solution of Oxone® (potassium peroximonosulfate) (11.3 g, 18.4 mmol) in H ₂ O (20 mL) in room temperature, and the reaction mixture was stirred at 40 ° C for 18 hours. The reaction was monitored by LCMS. The reaction mixture was diluted with H ₂ O / DCM (150 ml / 100 ml), and the aqueous phase was extracted with DCM (100 ml). The combined organic layers were washed with water (200 ml) and brine (200 ml), dried over sodium sulfate, filtered and concentrated. The crude product was again crystallized with EtOAc to generate 6 (3,5-dimethoxyphenyl) -8-methyl1-2- (methylsulfonyl) pyrido [2,3d] pyrimidin-7 (8H) -one (8) (910 mg, yield 78%) as a yellow solid. MS (ES +) C ₁₇ H ₁₇ N ₃ O ₅ S, requires: 375, found: 376 [M + H] ⁺ .
[116] Step 7: Synthesis of 6- (2,6-dichloro-3,5-dimethoxyphenyl) -8-methyl-2- (methylsulfonyl) pyrido [2,3-d] pyrimidin7 (8H) -one

[117] To a solution of 6- (3,5-dimethoxyphenyl) -8-methyl-2-
Petition 870160032383, dated 06/29/2016, p. 43/159
41/148 (methylsulfonyl) pyrido [2,3-d] pyrimidin-7 (8H) -one (8) (938 mg, 2.5 mmol) in acetonitrile (50 mL) a solution of sulfuryl chloride ( 1.34 g, 10.0 mmol) in acetonitrile (25 mL) for a period of 0.5 hour at a temperature ranging from -10 ° C to 0 ° C. The reaction was monitored by thin layer oromatoography (TLC). The reaction mixture was quenched by the addition of H ₂ O (10 ml). The resulting reaction solution was concentrated under reduced pressure, and the residue was crystallized again with EtOAc / petroleum ether = 1: 2 to generate 6- (2,6dichloro-3,5-dimethoxyphenyl) -8-methyl-2- ( methylsulfonyl) pyrido [2,3d] pyrimidin-7 (8H) -one (9) (760 mg, 69% yield) as a yellow solid. MS (ES +) Ο ₁₇ Η ₁₅ Ο12Ν ₃ Ο53 requires: 443, 445, found: 444, 446 [M + H] ⁺ .
[118] Step 8: Synthesis of 6- (2,6-dichloro-3,5-dimethoxyphenyl) -8-methyl1-2- (2-methyl-6-nitrophenylamino) pyrido [2,3
d] pyrimidin-7 (8H) -one
[119] To a mixture of 6- (2,6-dichloro-3,5-dimethoxyphenyl)
-8-methyl-2- (methylsulfonyl) pyrido [2,3-d] pyrimidin-7 (8H) -one (9) (1.0 g, 2.26 mmol) and 2-methyl-6-nitrobenzenamine (684 mg, 4.5 mmol) in DMF (20 mL), potassium tert-butoxide (756 mg, 6.75 mmol) was added at ~ 10 ° C, and the reaction mixture was stirred at room temperature for 5 minutes. The reaction mixture was diluted with EtOAc (150 ml), and the organic phase was separated, washed with water (2 x 150 ml) and then brine (150 ml), dried over sodium sulfate, filtered and concentrated. The residue was again crystallized with EtOAc to generate 2- (2-amino-6methylphenylamino) - 6- (2,6-dichloro-3,5-dimethoxyphenyl) -8methylpyrido [2,3-d] pyrimidin-7 (8H) - (10) (810 mg, yield
70%) as a yellow solid. MS (ES +) C23H ₁₉ CÍNN ₅ O5 requires: 515,
Petition 870160032383, dated 06/29/2016, p. 44/159
42/148
517, found: 516, 518 [Μ + H] ⁺ .
[120]
Step 9: Synthesis of 2- (2-amino-6-methylphenylamino)
6- (2,6-dichloro-3,5-dimethoxyphenyl) -8-methylpyrido [2,3-d] pyrimidin7 (8H) -one
Cl
Cl
N
II
HN N
Cl
SnCI ₂ 2H ₂ O
EtOAc, 60 ° C
HN N N O γ 0 '
Cl [121]
A mixture of
2- (2-nitro-6-methylphenylamino) -6 (2,6-dichloro-3,5-dimethoxyphenyl) -8-methylpyrido [2,3-d] pyrimidin7 (8H) -one (10) (810 mg, 1.57 mmol) and tin (II) chloride hydrate (1.77 g, 7.86 mmol) in EtOAc (50 mL) was stirred at 60 ° C for 2 hours. The reaction was monitored by LCMS. The reaction mixture was basified with saturated aqueous sodium bicarbonate at pH = 8 ~ 9, diluted with H ₂ O (100 ml), and then extracted with EtOAc (3 x 100 ml). The combined organic layers were washed with brine (150 ml), dried over sodium sulfate, filtered and concentrated. The residue was again crystallized with dichloromethane / ethyl acetate / petroleum ether (DCM / EtOAc / PE) = 1/1/2 to generate 2- (2-amino-6-methylphenylamino) -6- (2,6-dichloro3, 5-dimethoxyphenyl) -8-methylpyrido [2,3-d] pyrimidin-7 (8H) -one (11) (640 mg, 83% yield) as a gray solid. (MS (ES +) C23H21CI2N5O3 requires: 485, 487, found: 486, 488 [Μ + H] ⁺ ; ² ΗNMR (500 MHz, CDC1 ₃ ) δ ppm 8.54 (s, 1H), 7.45 (s , 1H), 7.08 (t, J = 7.5 Hz, 1H), 6.71 (dd, J = 3.5, 7.5 Hz, 2H), 6.65 (br s, 1H), 6.62 (s, 1H), 3.94 (s, 6H), 3.88 (br s, 2H), 3.62 (br s, 3H), 2.24 (s, 3H).
[122] Step 10: Synthesis of N- (2- ((6- (2,6-dichloro-3,5dimethoxyphenyl) -8-methyl-7-oxo-7,8-dihydropyride [2,3-d] pyrimidin2 -yl) amino) -3-methylphenyl) acrylamide COMPOUND 43
Petition 870160032383, dated 06/29/2016, p. 45/159
43/148
[123] 2- (2-amino-6-methylphenylamino) -6- (2,6-dichloro-3,5dimethoxyphenyl) -8-methylpyrido [2,3-d] pyrimidin-7 (8H) -one (11) it was taken in DCM (2 ml) and cooled to 0 ° C, followed by addition of acryloyl chloride (0.010 ml, 0.13 mmol). The reaction was allowed to warm to room temperature and stirred overnight. The mixture was loaded directly onto silica gel and purified by flash chromatography using 0-100% EtOAc / Hexanes gradient to generate the product, N- (2 - ((6- (2,6-dichloro-3,5-dimethoxyphenyl) 8 -meti1-7-oxo-7,8-dihydropyrido [2,3-d] pyrimidin-2-yl) amino) -3methylphenyl) acrylamide (Compound E). The product was obtained as an off-white solid (10 mg; 19% yield). MS (ES +) C _{2 6} H ₂₃ C12N5O4, 540 [M + H] ⁺ .
[124] Example 2: Synthesis of N- (2 - ((6- (2,6-dichloro-3,5dimethoxyphenyl) quinazolin-2-yl) amino) -3-methoxyphenyl) acrylamide COMPOUND 30
Petition 870160032383, dated 06/29/2016, p. 46/159
44/148

Step 1: Synthesis of (2-amino-5-bromophenyl) methanol
Br ^r
THE. BH ₃ -THF
L, THF, 0 ° C- RT
Y COOH 1
NH ₂ ^NH 2 [125] To a solution of 2-amino-5-bromobenzoic acid (10.0 g, 46.3 mmol) in THF (150 mL) was added BH3-THF (1 M, 231 mL) at temperature room, and the reaction mixture was stirred overnight. An aliquot of the reaction mixture was analyzed by LCMS and indicated that the reaction occurred until completion. The reaction was quenched with water (150 ml) and extracted with EtOAc (3 x 500 ml). The organic layers were separated, combined, washed with water (200 ml) and brine (200 ml), dried over sodium sulfate, filtered and concentrated to generate the title compound (10 g, crude), which was used directly in the next step without further purification. MS (ES +) C ₇ H ₈ BrNO requires: 201, found: 202, 204 [M + H] ⁺ .
[126] Step 2: Synthesis of 2-amino-5-bromobenzaldehyde
Petition 870160032383, dated 06/29/2016, p. 47/159
45/148
Br Br
NH ₂ nh ₂ [127] A mixture of (2-amino-5-bromophenyl) methanol (10 g, 49.5 mmoi) and MnO ₂ (25.8 g, 296, 6 mmoi) in CH ₂ C1 ₂ (400 ml) was stirred at RT overnight. LCMS showed that the reaction was complete. The solid was filtered, and the filtrate was concentrated to generate the title compound as a light yellow solid (8 g, 81%), which was used directly in the next step without further purification. sMS (ES +) C ₇ H ₆ BrNO requires: 199, found: 200, 202 [M + H] ⁺ .
[128] Step 3: Synthesis of 6-bromoquinazolin-2-ol
[129] A mixture of 2-amino-5-bromobenzaldehyde (29) (6 g, 30.0 mmoi) and urea (30) (27 g, 450.0 mmoi) was heated to 180 ° C and stirred for 5 hours . LCMS showed that the reaction was complete. The reaction mixture was cooled to room temperature, and the resulting precipitate was washed with H ₂ O (3 x 500 mL) and coevaporated with toluene three times until the trapped moisture was completely removed. 6-bromoquinazolin-2-ol (31) (6 g, 89%) was obtained as a yellow solid. MS (ES +) C ₈ H ₅ BrN ₂ O requires: 224, found: 225, 227 [M + H] ⁺ .
[130] Step 4: Synthesis of 6-bromo-2-chloroquinazoline
POCI ₃
110 ° C, 3 h
[131] A solution of 6-bromoquinazolin-2-ol (31) (6.0 g, 26.7 mmol) in POCI3 (80 mL) was refluxed at 110 ° C for 5 hours. An aliquot of the reaction mixture was analyzed by LCMS and indicated that the reaction occurred until completion. Most of the POCI3 was removed under reduced pressure, and the residue was added
Petition 870160032383, dated 06/29/2016, p. 48/159
46/148 under dripping to ice water (500 mL). The resulting precipitate was collected via filtration as a yellow solid (3.5 g, 54%). MS (ES +) CgfhBrCl ^ requires: 242, found: 243, 245 [M + H] ⁺ .
[132] Step 5: Synthesis of 2-chloro-6- (3,5-dimethoxyphenyl) quinazoline
[133] A mixture of 6-bromo-2-chloroquinazoline (32) (5.0 g, 20.5 mmoi), 3,5-dimethoxyphenylboronic acid (33) (3.7 g, 20.5 mmol), CS2CO3 (20.0 g, 61.5 mmoi) and Pd (PPh ₃ ) 2 Cl2 (1.4 g, 2.1 mmoi) in THF (50 ml), dioxane (50 ml) and water (10 ml) was degassed with N ₂ three times, and stirred at 80 ² C for 3 hours. An aliquot of the reaction mixture was analyzed by both TLC and LCMS, which indicated that the reaction occurred until completion. The mixture was cooled to room temperature, and extracted with EtOAc (3 x 200 ml). The combined organic layers were washed with water and brine, dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography on silica gel (petroleum ether / EtOAc = 8: 1) to obtain 2-chloro-6- (3,5-dimethoxyphenyl) quinazoline (34) as a light yellow solid (2.4 g, 38%). MS (ES +) Ο ₁₆ Η ₁₃ Ο1Ν ₂ Ο2 requires: 300, found: 301, 303 [M + H] ⁺ .
[134] Step 6: Synthesis of 2-chloro-6- (2,6-dichloro-3,5dimethoxyphenyl) quinazoline
[135] To a solution of 2-chloro-6- (3.5
Petition 870160032383, dated 06/29/2016, p. 49/159
47/148 dimethoxyphenyl) quinazoline (34) (2.7 g, 8.9 mmol) in dry THF (80 mL) was added under SO2Cl2 drip (3.0 g, 22.3 mmol) at 20 ² C, and the mixture of reaction was stirred for another hour. An aliquot of the reaction mixture was analyzed by both TLC and LCMS, which indicated that the reaction occurred until completion. The reaction mixture was quenched with water (1 ml), and the solvents were removed under reduced pressure. The precipitate was washed with CH ₃ CN and dried to obtain 2-chloro-6- (2,6-dichloro-3,5dimethoxyphenyl) quinazoline (35) (2.6 g, 79%) as a white solid. (MS (ES +) ChsHnCis ^ CU requires: 368, found: 369, 371 [M + H] ⁺ ; ¹ H-NMR (500 MHz, DMSO) δ ppm 9.67 (s, 1H), 8.168 (d, J = 1.5 Hz, 1H), 8.10 (d, J = 8.5 Hz, 1H), 7.56 (dd, J = 2.0, 8.5
Hz, 1H), 7.07 (s, 1H), 4.00 (s, 6H).
[136] Step 7: Synthesis of 6- (2,6-dichloro-3,5-dimethoxyphenyl) -N- (2-methoxy-6-nitrophenyl) quinazolin-2-amine
[137] 2-Chloro-6- (2,6-dichloro-3,5dimethoxyphenyl) quinazoline (35) (100 mg, 0.27mmol), 2-methoxy-6nitroaniline (36) (57 mg, 0.40 mmol) , Cs ₂ CO ₃ (176 mg, 0.54 mmol), Pd ₂ (dba) 3 (25 mg, 0.027 mmol), and 2-Dicyclohexylphosphino-2 ', 4', 6'triisopropylbiphenyl (Xphos) (26 mg, 0.054 mmol) were taken in DMF (3 ml) in a microwave flask and purged with N ₂ for 5 minutes. The flask was capped and heated to 115 ° C in a microwave for 30 minutes. After cooling to room temperature the reaction mixture was diluted with DCM and washed with brine three times. The organic mixture was dried over sodium sulfate and loaded directly onto silica gel and purified using 0100% EtOAc / Hexanes gradient. 6- (2,6-dichloro-3,5-dimethoxyphenyl) N- (2-methoxy-6-nitrophenyl) quinazolin-2-amine (37) was recovered as a yellow solid (100 mg, 73% yield). MS (ES +)
Petition 870160032383, dated 06/29/2016, p. 50/159
48/148
C ₂₃ H ₁₈ C1 ₂ N ₄ O ₅ , 501 [Μ + H] ⁺ .
[138] Step 8: Synthesis of N ¹ - (6- (2,6-dichloro-3,5dimethoxyphenyl) quinazolin-2-yl) -6-methoxybenzene-1,2-diamine
[139] 6- (2,6-Dichloro-3,5-dimethoxyphenyl) -N- (2-methoxy-6-nitrophenyl) quinazolin-2-amine (38) (100 mg, 0.14 mmol) was taken in methanol (10 ml), 10% Pd / C (15 mg) was added. The mixture was stirred under _H2 balloon for 4 hours. The reaction mixture was filtered through celite and the solvent was removed to generate N ¹ - (6- (2,6-dichloro-3,5-dimethoxyphenyl) quinazolin-2-yl) -6methoxybenzene-1,2-diamine (38 ) in quantitative yield. Compound 38 was taken to the next step without further purification. MS (ES +) C ₂₃ H ₂ oC1 ₂ N ₄ 03, 471 [M + H] ⁺ [140] Step 9: Synthesis of N- (2 - ((6- (2,6-dichloro-3,5dimethoxyphenyl)) quinazolin-2-yl) amino) -3-methoxyphenyl) acrylamide
[141] N ¹ - (6- (2,6-dichloro-3,5-dimethoxyphenyl) quinazolin-2-yl) -6-methoxybenzene-1,2-diamine (38) [142] (96 mg, 0, 20 mmol) was taken in DCM (2 ml) and cooled to 0 ° C, followed by addition of acryloyl chloride (0.018 ml, 0.24 mmol) and stirred at 0 ° C for 2 hours. The mixture was loaded directly onto silica gel and purified by flash chromatography using 0-100% EtOAc / Hexanes gradient. N (2 - ((6- (2,6-dichloro-3,5-dimethoxyphenyl) quinazolin-2-yl) amino) -3
Petition 870160032383, dated 06/29/2016, p. 51/159
49/148 methoxyphenyl) acrylamide (39) was recovered as an off-white solid (30 mg, 28% yield). MS (ES +) C26H22Cl2N4O4, 525 [M + H] ⁺ .
[143] Example 3: COMPOSITE Synthesis 25

[144]
Synthesis of 6- (2,6-dichloro-3,5-dimethoxyphenyl) -N- (2methyl-6-nitrophenyl) quinazolin-2-amine
O ₂ N
[145] 2-Chloro-6- (2,6-dichloro-3,5dimethoxyphenyl) quinazoline (35) (5 g, 13.5 mmol), 2-methyl-6-nitroaniline (3.09 g, 20.3 mmol) , CS2CO3 (13.2 g, 40.6 mmol), Pd2 (dba) 3 (1.24 g, 1.35 mmol), and 2-Dicyclohexylphosphino-2 ', 4', 6 'triisopropylbiphenyl (Xphos) (1 , 29 g, 2.71 mmol) were taken in DMA (100 ml) and purged with N ₂ for 5 minutes. The reaction mixture was heated to 110 ° C for 3 hours. After cooling until
Petition 870160032383, dated 06/29/2016, p. 52/159
50/148 at room temperature the reaction mixture was diluted with DCM (500 ml) and washed with 10% HCl three times (3 x 300 ml) and brine three times. The organic mixture was dried over sodium sulfate and loaded directly onto silica gel and purified using 0100% EtOAc / Hexanes gradient. 6- (2,6-dichloro-3,5-dimethoxyphenyl) N- (2-methyl-6-nitrophenyl) quinazolin-2-amine was recovered as a yellow solid (5.5 g, 81% yield). MS (ES +) C ₂ 3H ₁₈ C12N ₄ O4, 485 [M + H] ⁺ .
[146] Synthesis of N ¹ - (6- (2,6-dichloro-3,5dimethoxyphenyl) quinazolin-2-yl) -6-methylbenzene-1,2-diamine
N
HN N
N. /
6- (2,6-dichloro-3,5-dimethoxyphenyl) -N- (2-methyl-6-nitrophenyl) quinazolin-2-amine (5.5 g, 11.33 ml) was taken in methanol (200 ml) and ethyl acetate (100 ml), 10% Pd / C (650 mg) was added. The mixture was stirred under an H ₂ flask overnight. The reaction mixture was filtered through celite and the solvent was removed to generate N ¹ - (6- (2,6-dichloro-3,5dimethoxyphenyl) quinazolin-2-yl) -6-methylbenzene-1,2-diamine in yield quantitative. This was taken to the next step without further purification. MS (ES +) C23H20CI2N4O2, 455 [M + H] ⁺ [148] Synthesis of N- (2 - ((6- (2,6-dichloro-3,5-dimethoxyphenyl) quinazolin-2-yl) amino) - 3-methylphenyl) acrylamide
N lj HN N
Π I
N. /
Petition 870160032383, dated 06/29/2016, p. 53/159
51/148 [149] N ¹ - (6- (2,6-dichloro-3,5-dimethoxyphenyl) quinazolin-2yl) -6-methylbenzene-1,2-diamine (5.16 g, 11.33 mmol) it was turned into DCM (100 ml) and cooled to 0 ° C, followed by the addition of DIEA (1.781 ml, 10.20 mmol) and acryloyl chloride (1.013 ml, 12.47 mmol) and stirred at 0 ° C for 2 hours. The mixture was loaded directly onto silica gel and purified by flash chromatography using 0-100% EtOAc / Hexanes gradient. N- (2- ((6- (2,6dichloro-3,5-dimethoxyphenyl) quinazolin-2-yl) amino) -3-methylphenyl) acrylamide was recovered as an off-white solid (3.5 g, 61% Yield) . MS (ES +) C26H22Cl2N4O3, 509 [M + H] ⁺ . ⁴ H NMR (400 MHz, DMSO-dg) δ 9.53 (s, 1H), 9.23 (s, 1H), 8.68 (s, 1H), 7.82 - 7, 65 (m, 2H ), 7.51 (s, 2H), 7.21 (m, 1H), 7.12 (d, J = 6.8 Hz, 1H), 7.01 (s, 1H), 6.49 (dd , J = 17.0, 10.2 Hz, 1H), 6.28 - 6.15 (m, 1H), 5.68 (dd, J = 10.2, 2.0 Hz, 1H), 3, 97 (s, 6H), 2.19 (s, 3H).
[150] Example 4: Synthesis of COMPOUND 26 and COMPOUND 10
Petition 870160032383, dated 06/29/2016, p. 54/159
52/148

Cisreío ds asrisi!
CT ia ⁱ⁵ c
Synthesis of 6-bromopyride [2,3-d] pyrimidin-2-amine [151]
[152] 5-bromo-2-fluoricotinaldehyde (3.0 g, 14.78 mmol), guanidine hydrochloride (1.69 g, 17.74 mmol) and triethylamine (4.48 g, 44.35 mmol) were dissolved in 1-methyl-2-pyrrolidinone (15 ml), and the reaction mixture was stirred at 180 ² C for 15 min under microwave. The mixture was cooled to RT, quenched with water (200 mL) and extracted with ethyl acetate (2 χ 300 mL). The organic layers were combined, washed with water (3 χ 50 ml) and brine (3 χ 50 ml), dried over sodium sulfate, filtered and concentrated to generate a crude product, which was purified by silica gel column chromatography ( ethyl acetate: ether of
Petition 870160032383, dated 06/29/2016, p. 55/159
53/148 petroleum = 3: 1) to generate 6-bromopyride [2,3-d] pyrimidin-2 amine (2.0 g, 60%) as a yellow solid. MS (ES +) C7H ₅ BrN ₄ requires: 224, 226, found:
225, 227 [M + H] ⁺ .
[153] Synthesis of 6- (3,5-dimethoxyphenyl) pyrido [2,3-
d] pyrimidin-2-amine

[154] A mixture of 6-bromopyride [2,3-d] pyrimidin-2amine (1.0 g, 4.46 mmol), 3,5-dimethoxyphenylboronic acid (1.2 g, 6.70 mmol), PdCÍ2 (dppf) (364 mg, 0.446 mmol) and potassium carbonate (1.8 g, 13.39 mmol) in 1,4-dioxane / water (4 mL / Ι mL) was degassed with nitrogen for min under microwave . The concentrate mixture to generate a silica petroleum column chromatography product = 4: 1) to generate 6 min and stirred at 110 ² C for 30 reaction was cooled to RT, and crude, which was purified by gel (ethyl acetate: ether of
- (3,5-dimethoxyphenyl) pyrido [2,3d] pyrimidin-2-amine as a yellow solid (400 mg, 31%). MS (ES +) Ο ₁₅ Η ₁₄ Ν4θ2 requires: 282, found: 283 [M + H] ⁺ .
[155] Synthesis of 6- (3,5-dimethoxyphenyl) -N- (2-methyl-6-nitrophenyl) pyrido [2,3-d] pyrimidin-2-amine

[156] To a solution of 6- (3,5-dimethoxyphenyl) pyrido [2,3d] pyrimidin-2-amine (400 mg, 1.42 mmol) in THF (20 mL) at 0 ² C was added hydride sodium (102 mg, 4.25 mmol). The solution was stirred for 20 min., Followed by the addition of 2-fluor-1-methyl-3-nitrobenzene (440 mg, 2.84 mmol). The reaction mixture was
Petition 870160032383, dated 06/29/2016, p. 56/159
54/148 stirred at RT overnight, quenched by water (20 mL) and extracted with ethyl acetate (3 χ 30 mL). The organic layers were combined, washed with brine (50 ml), dried over sodium sulfate, filtered and concentrated to generate a crude product, which was purified by silica gel column chromatography (ethyl acetate: petroleum ether = 4: 1) to generate 6- (3,5dimethoxyphenyl) -N- (2-methyl-6-nitrophenyl) pyrido [2,3-d] pyrimidin-2amine (310 mg, 51%) as a brown solid. MS (ES +) C22H19N5O4 requires: 417, found: 418 [M + H] ⁺ .
[157] Synthesis of N ¹ - (6- (3,5-dimethoxyphenyl) pyrido [2,3-
d] pyrimidin-2-yl) -6-methylbenzene-1,2-diamine

Fe, NH4CI [158]
To a solution of 6- (3,5-dimethoxyphenyl) -N- (2-methyl6-nitrophenyl) pyrido [2,3-d] pyrimidin-2-amine (100 mg, 0.24 mmol) in ethanol (5 mL ) and water (5 ml) were added iron powder (110 mg, 1.92 mmol) and ammonium chloride (100 mg, 1.920 mmol). The mixture was stirred at 100 ² C for 1 hour, cooled to RT, filtered and concentrated. The residue was purified by Preparative HPLC to generate N ¹ - (6- (3,5-dimethoxyphenyl) pyrido [2,3d] pyrimidin-2-yl) -6-methylbenzene-1,2-diamine (29.5 mg, 32%) as a yellow solid. MS (ES +) C22H21N5O2 requires: 387, found: 388 [M + H] ⁺ ; A-NMR (500 MHz, DMSO-ch) δ ppm9,30,
9.21 (br, br, 2H), 8.95 (s, 1H), 8.60 (d, 1H, J = 3.0 Hz), 6,966.92 (m, 3H), 6.63 (d , 1H, J = 5.5 Hz), 6.55 (t, 1H, J = 2.0
Hz), 6.50-6.48 (m, 1H), 4.79 (s, 2H), 3.84 (s, 6H), 2.08 (s,
3H).
[159] Synthesis of 6- (2,6-dichloro-3,5-dimethoxyphenyl) -N- (2methyl-6-nitrophenyl) pyrido [2,3-d] pyrimidin-2-amine
Petition 870160032383, dated 06/29/2016, p. 57/159
55/148
[160] To a stirred solution of 6- (3,5-dimethoxyphenyl) -N (2-methyl-6-nitrophenyl) pyrido [2,3-d] pyrimidin-2-amine (100 mg, 0.24 mmol) in THF (10 ml) at 0 ² C a solution of sulfuryl chloride (0.06 ml, 0.72 mmol) in THF (2 ml) was added dropwise. After stirring at 0 ² C for 2 hrs, the reaction was quenched with water (10 mL) and extracted with ethyl acetate (3 χ 20 mL). The organic layers were combined, washed with brine (20 ml), dried over sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (ethyl acetate: petroleum ether = 3: 1) to generate 6- (2,6dichloro-3,5-dimethoxyphenyl) -N- (2-methyl-6-nitrophenyl ) pyrido [2,3-
d] pyrimidin-2-amine (110 mg, 95%) as a yellow solid. MS (ES +) C22H17CI2N5O4 requires: 485, 487 found: 486, 488 [M + H] ⁺ .
[161] Synthesis of N ¹ - (6- (2,6-dichloro-3,5-dimethoxyphenyl) pyrido [2,3-d] pyrimidin-2-yl) -6-methylbenzene-1,2-diamine
[162] To a solution of 6- (2,6-dichloro-3,5-dimethoxyphenyl) -N- (2-methyl-6-nitrophenyl) pyrido [2,3-d] pyrimidin-2amine (80 mg, 0.168 mmol) in ethanol (4 mL) and water (4 mL) was
Petition 870160032383, dated 06/29/2016, p. 58/159
56/148 iron powder (75 mg, 1.344 mmoi) and ammonium chloride (74 mg, 1.344 mmol) were added. The mixture was stirred at 100 ² C for 2 hrs, cooled to RT, filtered and concentrated. The residue was purified by silica gel column chromatography (ethyl acetate: petroleum ether = 4: 1) to generate N ¹ - (6- (2,6-dichloro3, 5-dimethoxyphenyl) pyrido [2,3-d ] pyrimidin-2-yl) -6-methylbenzene1,2-diamine (40 mg, 53%) as a yellow solid. MS (ES +) C22H19CI2N5O2 requires: 455, 457, found: 456, 458 [M + H] ⁺ . ¹ H-NMR (400 MHz, DMSO-dg) <5 ppm 9.33 (br. S., 1H), 9.01 (s, 1H), 9.65 (br. S., 1H), 8, 23 (s, 1H), 7.05 (s, 1H), 6.93 (br. S., 1H), 6, 64-6, 63 (m, 1H), 6.50-6.49 (m , 1H), 4.80 (s, 2H), 3.99 (s, 6H), 2.09 (s, 3H).
[163] Synthesis of N- (2 - ((6- (3,5-dimethoxyphenyl) pyrido [2,3d] pyrimidin-2-yl) amino) -3-methylphenyl) acrylamide
[164] N- (2 - ((6- (3,5-dimethoxyphenyl) pyrido [2,3-
d] pyrimidin-2-yl) amino) -3-methylphenyl) acrylamide was prepared using the procedure similar to COMPOUND 30. The product was purified by flash chromatography using 0-50% EtOAc / DCM gradient to generate the title compound. MS (ES +) C25H23N5O3 requires: 441, found: 442 [165] Synthesis of N- (2- ((6- (2,6-dichloro-3,5-dimethoxyphenyl) pyrido [2,3-d] pyrimidin- 2-yl) amino) -3methylphenyl) acrylamide
Petition 870160032383, dated 06/29/2016, p. 59/159
57/148
[166] N- (2 - ((6- (2,6-dichloro-3,5-dimethoxyphenyl) pyrido [2,3-d] pyrimidin-2-yl) amino) -3methylphenyl) acrylamide was prepared using the procedure similar to COMPOUND 30. The product was purified by flash chromatography using 0-10% MeOH / DCM gradient to generate the title compound. MS (ES +) C25H21CI2N5O3 requires: 510, found: 511 [M + H] ⁺ . ¹ H-NMR (400 MHz, DMSO-d ₆ ) δ 9.53 (s, 1H), 9.35 (s,
1H), 9.06 (s, 1H), 8.70 (s, 1H), 8.27 (d, J = 2.6 Hz, 1H), 7.78 (s, 1H), 7.23 ( d, J = 7.9 Hz, 1H), 7.15 (s, 1H), 7.06 (s, 1H),
6.52 (dd, J = 17.0, 10.1 Hz, 1H), 6.22 (dd, J = 17.0, 2.0 Hz,
1H), 5.69 (d, J = 10.6 Hz, 1H), 3.98 (s, 6H), 2.20 (s, 3H).
[167] Example 4: Synthesis of COMPOUND 45 in MeOH
Petition 870160032383, dated 06/29/2016, p. 60/159
58/148

[168] Synthesis of 2-chloro-N-methyl-5-nitropyrimidin-4 amine
° ^2N ^ n ch ₃ nh ₂ ^emMe0H
CI ^ N ^ CI DIPEA, THF, -78 ° C, 3 h [169] To a solution of 2,4-dichloro-5-nitropyrimidine (5 g, 26 mmol) in THF (50 mL) was added diisopropylethylamine ( 3.36 g, 26 mmol) at -78 ° C, followed by dropping methylamine (13 mL, 2 mol / L in methanol, 26 mmol). After the addition, the mixture was heated to RT and stirred for 3 h. The reaction mixture was then diluted with ethyl acetate and washed with brine (50 ml * 3). The organic layer was dried over sodium sulfate, filtered and concentrated to give the title compound (4.4 g, 100%) as a yellow solid. MS (ES +) C5H5CIN4O2 requires: 188,
190, found: 189, 191 [M + H] ⁺ .
Synthesis of 2-chloro-N ⁴ -methylpyrimidine-4,5-diamine

Petition 870160032383, dated 06/29/2016, p. 61/159
59/148 [171] To a stirred solution of 2-chloro-N-methyl-5-nitropyrimidin-4-amine (1.9 g, 10 mmol) in acetic acid (30 mL) was added iron powder (4 g, 71 mmol), and the suspension mixture was heated to 60 ° C for 16 hours. The solvent was removed under reduced pressure, and the residue was diluted with brine and ethyl acetate. The solid was filtered, and the filtrate was extracted with ethyl acetate (50 ml * 12). The organic layers were separated, combined, dried over sodium sulfate, filtered and concentrated to generate the title compound (1.1 g, 69%). MS (ES +) C5H7CIN4 requires: 159, 161, found:
160, 162 [M + H] ⁺ .
[172] Synthesis of ethyl 2- (3,5-dimethoxyphenyl) -2-oxoacetate
n-BuLi, THF
-78 ° C, 4 h
[173] To a solution of l-bromo-3,5-dimethoxybenzene (2.17 g, 10 mmol) in THF (15 mL) was added under lithium drip (8 mL, 2.5 mol / L in hexane, 20 mmol) at -78 ° C. After stirring for 50 min. at -78 ° C, a solution of diethyl oxalate (4 g, 27 mmol) in THF (10 mL) was added. The mixture was stirred at -78 ° C for an additional 4 h, then quenched with saturated ammonium chloride and extracted with ethyl acetate (50 mL * 3). The organic layers were combined, washed with brine, dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography on silica gel to generate the title compound (1.7 g, 71%). MS (ES +) C ^ H ^ Os requires: 238, found: 239 [M + H] ⁺ .
[174] Synthesis of 2-chloro-6- (3,5-dimethoxyphenyl) -8methylpteridin-7 (8H) -one
Petition 870160032383, dated 06/29/2016, p. 62/159
60/148 '' O

[175] An oxoacetate mixture (1 a, 4.2 mmol ° ethyl 2- (3,5-dimethoxyphenyl) -2e 2-chloro-N ⁴ -methylpyrimidine-4,5 diamine (600 mg, 3.8 mmol) in ethanol (100 ml) and acetic acid (2.5 ml) it was stirred at 80 ° C for 48 h and cooled to RT (5 ° C) .The mixture was diluted with dichloromethane and washed with brine. The organic layer was directly concentrated and purified by chromatography on silica gel to generate the title compound (700 mg, 50%) MS (ES +) Ci ₅ H ₁₃ C1N4O3 requires: 332, 334, found: 333, 335 [M + H] ⁺ .
[176] Synthesis of 2-chloro-6- (2,6-dichloro-3,5 dimethoxyphenyl) -8-methylpteridin-7 (8H) -one
[177] To a solution of 2-chloro-6- (3,5-dimethoxyphenyl) -8methylpteridin-7 (8H) -one (300 mg, 0.9 mmol) in THF (5 mL) was added under dripping chloride sulfuryl (300 mg), and the mixture was stirred at RT for 4 h. Additional sulfuryl chloride (300 mg) was added and stirred at RT for 3 days. The reaction was quenched by 5 drops of water and then stirred for 5 min. The precipitate was collected via filtration and dried to generate the title compound (240 mg, 67%) as a yellow solid. MS (ES +) Ci5HnCl ₃ N4O ₃ requires: 400, 402, found: 400, 403 [M + H] ⁺ .
[178] Synthesis of 6- (2,6-dichloro-3,5-dimethoxyphenyl) -8methyl-2- (2-methyl-6-nitrophenylamino) pteridin-7 (8H) -one
Petition 870160032383, dated 06/29/2016, p. 63/159
61/148
° [179] To a solution of 2-methyl-6-nitrobenzenamine (100 mg, 1 mmol) in N, N-dimethylformamide (5 mL) was added sodium hydride (53 mg, 1.3 mmol), and The mixture was stirred at RT (10 ° C) for 10 min., followed by the addition of 2-chloro-6- (2,6dichloro-3,5-dimethoxyphenyl) -8-methylpteridin-7 (8H) -one (322 mg , 1 mmol). The mixture was stirred at RT (10 ° C) for another 30 min and then quenched with water. The precipitate was collected via filtration, washed with cold water and dried to generate the title compound (180 mg, 75%) as a yellow powder. MS (ES +) C ₂₂ H ₁₈ C1 ₂ N ₆ O ₅ requires: 516, 518, found: 517, 519 [M + H] ⁺ .
[180] Synthesis of 2- (2-amino-6-methylphenylamino) -6- (3,5dimethoxyphenyl) -8-methylpteridin-7 (8H) -one
[181] To a solution of 6- (2,6-dichloro-3,5dimethoxyphenyl) -8-methyl-2- (2-methyl-6-nitrophenylamino) pteridin7 (8H) -one (200 mg, 0.38 mmoi ) in ethanol (50 ml) and water (2 ml), iron powder (210 mg, 3.8 ml) and ammonium chloride (450 mg, 8 mmol) were added. The mixture was refluxed for 2 h. The solvents were evaporated, and the residue was diluted with brine and dichloromethane. The solid was filtered, and the filtrate was extracted with dichloromethane (50 ml * 6). The organic layers were combined, dried over sodium sulfate, filtered and
Petition 870160032383, dated 06/29/2016, p. 64/159
62/148 concentrated to generate the title compound (70 mg, 38%). MS (ES +) C22 H ₂ o Cl ₂ N ₆ O ₃ requires: 486, 488, found: 487, 489 [Μ + H] ⁺ . ² ΗNMR (500 MHz, CDC1 ₃ ) δ ppm 8.83 (s, 1H), 7.09 (t, 1H, J = 8.0 Hz), 6.74-6.71 (m, 2H), 6 , 65 (s, 1H), 3.94 (s, 6H), 3.85 (br. S., 2H), 3.63-3.59 (br, 3H), 2.25 (s, 3H) .
[182] Synthesis of N- (2 - ((6- (2,6-dichloro-3,5 dimethoxyphenyl) -8-methyl-7-oxo-7,8-dihydropteridin-2-yl) amino) -3methylphenyl) acrylamide
[183] N- (2 - ((6- (2,6-dichloro-3,5-dimethoxyphenyl) -8-methyl7-oxo-7,8-dihydropteridin-2-yl) amino) -3-methylphenyl) acrylamide was prepared using the procedure similar to COMPOUND 30. The product was purified by flash chromatography using 0-10% MeOH / DCM gradient to generate the title compound. MS (ES +) C ₂ 5H22C1 ₂ N ₆ O4 requires: 540, found: 541 [M + H] ⁺ .
[184] Example 5: COMPOSITE synthesis 39
Petition 870160032383, dated 06/29/2016, p. 65/159
63/148
Synthesis of ethyl 6-chloro-4- (methylamino) nicotinate
[185]
^{2E t} MeNH ₂ ^saldeHCI
DIPEA, CH ₃ CN, 70 ° C, _C | overnight [186] To a solution of ethyl 4,6-dichloronicotinate (5.0 g, 22.7 mmol) in acetonitrile (50 mL) was added methylamine hydrochloride salt (1.84 g, 27.2 mmol) and diisopropylethylamine (14.6 g, 113.6 mmol) and the reaction mixture was warmed to 70 ² C overnight. LCMS showed that the reaction was complete. The reaction was cooled to RT, quenched with water (50 mL) and extracted with ethyl acetate (3 χ 100 mL). The organic layers were separated, combined, washed with water (50 ml) and brine (100 ml), dried over sodium sulfate, filtered and concentrated to generate the title compound (4.7 g, crude), which was directly used in the next step without further purification. MS (ES +) C9HHCIN2O2 requires: 214, 216, found: 215, 217 [M + H] ⁺ .
[187] Synthesis of (6-chloro-4- (methylamino) pyridin-3 yl) methanol
Petition 870160032383, dated 06/29/2016, p. 66/159
64/148
LiBH ₄ N oh a solution of ethyl 6-chloro-4 (methylamino) nicotinate (4.7 g, 21.9 mmol) in THF (30 mL) and methanol (30 mL) was added lithium borohydride (2.4 g ,
109.8 mmol) and the reaction mixture was warmed to 55 ² C overnight. LCMS showed that the reaction was complete. The reaction was cooled to RT, quenched with water (1 mL) and filtered. The filtrate was concentrated to generate the title compound (4.2 g, crude) as a white solid, which was used directly in the next step without further purification. MS (ES +) C7H9CIN2O requires: 172, 174, found: 173, 175 [M + H] ⁺ .
[189] Synthesis of 6-chloro-4- (methylamino) nicotinaldehyde
[190] A mixture of (6-chloro-4- (methylamino) pyridin-3yl) methanol (4.2 g, 24.7 mmol) and manganese (IV) oxide (active, 25.8 g, 296, 6 mmol) in dichloromethane (50 ml) and THF (50 ml) was stirred at RT overnight. LCMS showed that the reaction was complete. The solid was filtered, and the filtrate was concentrated to generate the title compound (3.7 g, crude) as a light yellow solid, which was used directly in the next step without further purification. MS (ES +) C7H7CIN2O requires: 170, 172, found: 171, 173 [M + H] ⁺ .
[191] Synthesis of 7-chloro-3- (3,5-dimethoxyphenyl) -1-methyl-
1,6-naphthyridin-2 (1H) -one
(methylamino) nicotinaldehyde (3.7 g, 21.7 mmol), methyl 2- (3.5 Petition 870160032383, 06/29/2016, page 67/159
65/148 dimethoxyphenyl) acetate (4.5 g, 21.7 mmol) and potassium carbonate (9.0 g, 65.1 mmol) in N, N-dimethylformamide (30 mL) was heated to 105 ² C for 5 h. LCMS showed that the reaction was complete. The reaction was cooled to RT, quenched with water (200 mL), and filtered. The filter cake was washed with petroleum ether (50 ml) and ethyl acetate (50 ml) to generate the title compound (5.8 g, 77%) as a yellow solid. MS (ES +) Ci8H ₁₉ ClN ₂ O3 requires: 346, 348, found: 347, 349 [M + H] ⁺ .
[193] Synthesis of 7-chloro-3- (2,6-dichloro-3,5dimethoxyphenyl) -1-methyl-1,6-naphthyridin-2 (1H) -one

[194]
To a solution of 7-chloro-3- (3,5-dimethoxyphenyl) -1 methyl-1,6-naphthyridin-2 (1H) -one (5.6 g, 16.9 mmol) in acetonitrile (30 mL) sulfuryl chloride (3.36 mL, 42.2 mmol) was added dropwise at -20 ² C, and the mixture was stirred for another 15 min. LCMS showed that the reaction was complete. The reaction was quenched with water (1 ml), and the solvents were removed under reduced pressure. The precipitate was washed with acetonitrile and dried to generate the title compound (5.01 g, 75%) as a white solid. MS (ES +) Ci7H ₁₃ C13N ₂ O3 requires: 399, 401, found: 400, 402 [M + H] ⁺ ; ⁴ H-NMR (500 MHz, DMSO-dg) δ ppm 8.82 (s, 1H), 8.01 (s, 1H), 7.71 (s, 1H), 7.04 (s, 1H), 3.98 (s, 6H), 3.66 (s, 3H).
[195] Synthesis of 3- (2,6-dichloro-3,5-dimethoxyphenyl) -1 methyl-7 - ((2-methyl-6-nitrophenyl) amino) -1,6-naphthyridin-2 (1H) - ona
Petition 870160032383, dated 06/29/2016, p. 68/159
66/148
[196] 3- (2,6-dichloro-3,5-dimethoxyphenyl) -l-methyl-7 - ((2 methyl-6-nitrophenyl) amino) -1,6-naphthyridin-2 (1H) -one was prepared using the procedure similar to COMPOUND 30.
[197] Synthesis of 7 - ((2-amino-6-methylphenyl) amino) -3- (2,6-dichloro-3,5-dimethoxyphenyl) -1-methyl-1,6-naphthyridin-2 (1H) -one
[198] 7 - ((2-amino-6-methylphenyl) amino) -3- (2,6-dichloro-
3,5-dimethoxyphenyl) -1-methyl-1,6-naphthyridin-2 (1H) -one was prepared using the procedure similar to COMPOUND 30.
[199] Synthesis of 7 - ((2-amino-6-methylphenyl) amino) -3- (2,6-dichloro-3,5-dimethoxyphenyl) -1-methyl-1,6-naphthyridin-2 (1H) -one
Petition 870160032383, dated 06/29/2016, p. 69/159
67/148

[200] 7 - ((2-amino-6-methylphenyl) amino) -3- (2,6-dichloro-
3,5-dimethoxyphenyl) -1-methyl-1,6-naphthyridin-2 (1H) -one was prepared using the procedure similar to COMPOUND 30. The product was purified by flash chromatography using 0-100% EtOAc / DCM gradient to generate the title compound. MS (ES +) C27H24CI2N4O4 requires: 538, found: 539 [M + H] ⁺ . ⁴ H NMR (400 MHz, DMSO-d6) δ 9.47 (s, 1H), 8.43 (d, J = 10.0 Hz, 2H), 7.70 (d, J = 12.6 Hz, 2H), 7.22 (t, J = 7.8 Hz, 1H), 7.14 (d, J = 7.6 Hz, 1H), 6.97 (s, 1H), 6.46 (dd, J = 17.0, 10.2 Hz, 1H), 6.18 (dd, J = 17.0, 2.1 Hz, 1H), 6.09 (s, 1H), 5.65 (dd, J = 10.2, 2.1 Hz, 1H), 3.95 (s, 6H), 3.39 (s, 3H), 2.20 (s, 3H).
[201] Example 6: COMPOSITE Synthesis 48
Petition 870160032383, dated 06/29/2016, p. 70/159
68/148
Synthesis of 5 - ((3,5-dimethoxyphenylamino) methyl) -N-methyl-2 (methylthio) pyrimidin-4-amine
[202] A mixture of 4- (methylamino) -2- (methylthio) pyrimidine-5-carbaldehyde (1.0 g, 5.46 mmol) and 3.5-dimethoxyaniline (840 mg, 5.46 mmol) in methanol (60 mL) was stirred at RT for 3 h, followed by the addition of sodium cyanoborohydride (520 mg, 8.20 mmol) and 1 mL of acetic acid. The reaction mixture was then stirred at RT for an additional 4 h. LCMS showed that the reaction was complete. The reaction was quenched by 30 mL of IN HCI, then stirred for 0.5 h and extracted with ethyl acetate (3 x 50 mL). The organic layers were separated, combined, washed with saturated aqueous sodium bicarbonate solution and brine, dried over sodium sulfate, filtered and concentrated to generate the title compound (crude 1.2 g, 69%) as a solid.
Petition 870160032383, dated 06/29/2016, p. 71/159
69/148 white, which was used directly in the next step without further purification. MS (ES +) C15H20N4O2S requires: 320, found: 321 [M + H] ⁺ .
[203] Synthesis of 3- (3,5-dimethoxyphenyl) -1-methyl-7- (methylthio) -3,4-dihydropyrimido [4,5-d] pyrimidin-2 (1H) -one
4 [204] To a mixture of 5 - ((3,5dimethoxyphenylamino) methyl) -N-methyl-2- (methylthio) pyrimidin-4-amine (1.1 g, 3.43 mmol) and N-ethyl-N -isopropylpropan-2-amine (1.33 g, 10.30 mmol) in 10 mL of THF was added a solution of triphosgene (357 mg, 1.20 mmol) in 5 mL of THF at 0 ° C, and stirred for 1 h. The reaction mixture was then heated to RT and stirred for an additional 5 h. LCMS showed that the reaction was complete. The reaction mixture was quenched by water and extracted with ethyl acetate (3 x 15 mL). The organic layers were separated, combined, washed with a saturated aqueous solution of sodium bicarbonate and brine, dried over sodium sulfate, filtered and concentrated to generate the title compound (crude 1.1 g, 92%) as a white solid, which was used directly in the next step without further purification. MS (ES +) C ₁₆ H ₁₈ N ₄ O ₃ S requires: 346, found: 347 [M + H] ⁺ .
[205] Synthesis of 3- (3,5-dimethoxyphenyl) -1-methyl-7 (methylsulfonyl) -3,4-dihydropyrimido [4,5-d] pyrimidin-2 (1H) -one
Petition 870160032383, dated 06/29/2016, p. 72/159
70/148 [206] To a solution of 3- (3,5-dimethoxyphenyl) -l-methyl-7 (methylthio) -3,4-dihydropyrimido [4,5-d] pyrimidin-2 (Ifi) -one ( 1.0 g, 2.89 mmol) in 20 ml of dichloromethane 3 chlorobenzoperoxoic acid (1.50 g, 8.66 mmol) was added at 0 ° C, and the solution was stirred for 0.5 h at 0 ° C. The mixture was heated to RT and stirred overnight. LCMS showed that the reaction was complete. The reaction mixture was diluted with 30 ml of dichloromethane, washed with saturated aqueous sodium bicarbonate solution and brine, dried over sodium sulfate, filtered and concentrated to give the title compound (800 mg, 73%) as a yellow solid, which was used directly in the next step without further purification. MS (ES +) C ₁₆ H ₁₈ N ₄ O ₅ S requires: 378, found: 379 [M + H] ⁺ .
[207] Synthesis of 3- (2,6-dichloro-3,5-dimethoxyphenyl) -1- methyl-7- (methylsulfonyl) -3,4-dihydropyrimido [4,5-d] pyrimidin2 (1H) -one
[208] To a solution of 3- (3,5-dimethoxyphenyl) -1-methyl-7- (methylsulfonyl) -3,4-dihydropyrimido [4,5-d] pyrimidin-2 (1H) -one (400 mg , 1.06 mmol) in 15 mL of dichloromethane was added sulfuryl chloride (285 mg, 2.12 mmol) at 0 ° C, and then stirred at 0 ² C for 3 h. LCMS showed that the reaction was complete. The reaction mixture was diluted with 20 ml of dichloromethane, washed with water and brine, dried over sodium sulfate, filtered and concentrated to generate the title compound (450 mg, 96%) as a yellow solid, which was used directly in the step without further purification. MS (ES +) Ci ₆ H ₁₆ C12N4O ₅ S requires: 446, 448, found: 447, 449 [M + H] ⁺ .
[209] Synthesis of 3- (2,6-dichloro-3,5-dimethoxyphenyl) -1
Petition 870160032383, dated 06/29/2016, p. 73/159
71/148 methyl-7- (2-methyl-6-nitrophenylamino) -3,4-dihydropyrimido [4,5
d] pyrimidin-2 (Ifl) -one
dimethoxyphenyl) -1-methyl-7- (methylsulfonyl) -3,4 dihydropyrimido [4,5-d] pyrimidin-2 (1H) -one (450 mg, 1.01 mmol) and 2-methyl-6-nitroaniline (230 mg, 1.51 mmol) in 5 mL of N, Ndimethylformamide was added potassium tert-butanolate (339 mg, 3.02 mmol) at RT and stirred for 0.5 h. LCMS showed that the reaction was complete. The mixture was quenched by 80 ml of water, and the precipitate was collected via filtration and dried to generate the title compound (290 mg, 56%) as a yellow solid, which was used directly in the next step without further purification. MS (ES +) C22H2 oC 1 ₂ N ₆ O ₅ requires: 518, 520, found: 519, 521 [M + H] ⁺ .
[211] Synthesis of (7- (2-amino-6-methylphenylamino) -3- (2,6-dichloro-3,5-dimethoxyphenyl) -l-methyl-3,4-dihydropyrimido [4,5— d] pyrimidin- 2 (1H) -one
[212] A mixture of 3- (2,6-dichloro-3,5-dimethoxyphenyl) 1-methyl-7- (2-methyl-6-nitrophenylamino) -3,4-dihydropyrimido [4,5— d] pyrimidin -2 (1H) -one (290 mg, 0.56 ml) in ethanol (10 ml) and water (2 ml) was stirred at 70 ² C for 20 min. before iron powder
Petition 870160032383, dated 06/29/2016, p. 74/159
72/148 (320 mg, 5.60 mmol) and ammonium chloride (250 mg, 2.79 mmol) are added. The reaction mixture was stirred at 70 ² C for another 6h. LCMS showed that the reaction was complete. The solid was filtered, and the filtrate was concentrated. The residue was dissolved in ethyl acetate (30 ml), washed with water and brine, dried over sodium sulfate, filtered and concentrated. The residue was purified by Prep-HPLC to generate the title compound (27 mg, 10%) as a white solid. MS (ES +) C22H22C12N6O3 requires: 488, 490, found: 489, 491 [M + H] ⁺ . ¹ H-NMR (500 MHz, CDC13) δ ppm 7.89 (s, 1H), 7.04 (t, 1H, J = 8.0 Hz), 6.69 (d, 2H, J = 7.5 Hz), 6.60 (s, 1H), 4.53 (s, 2H), 3.94 (s, 6H), 3.34 (s, 3H), 2.24 (s, 3H).
[213] Synthesis of N- (2 - ((6- (2,6-dichloro-3,5-dimethoxyphenyl) -8-methyl-7-oxo-5,6,7,8-tetrahydropyrimido [4,5— d] pyrimidin-2-yl) amino) -3-methylphenyl) acrylamide
[214] N- (2 - ((6- (2,6-dichloro-3,5-dimethoxyphenyl) -8-methyl7-OXO-5,6,7,8-tetrahydropyrimido [4,5-d] pyrimidin- 2-yl) amino) -3methylphenyl) acrylamide was prepared using the procedure similar to COMPOUND 30. The product was purified by flash chromatography using 0-10% MeOH / DCM gradient to generate the title compound. MS (ES +) Ο25Η ₂ 4Ο1 ₂ Ν ₆ Ο4 requires: 542, found: 543 [M + H] ⁺ . ⁴ H-NMR (400 MHz, DMSO-d ₆ ) δ 9.48 (s, 1H), 8.35 (s, 1H), 7.99 (s, 1H), 7.66 (s, 1H), 7.16 (t, J = 7.8 Hz, 1H), 7.10 - 7.06 (m, 1H), 6.99 (s, 1H), 6.53 (dd, J = 17.0, 10.2 Hz, 1H), 6.22 (dd, J = 16.9, 2.1 Hz, 1H), 5.71 (dd, J = 10.2, 2.0 Hz, 1H), 4, 48 (s, 2H), 3.96 (s, 6H), 3.44 (s, 3H), 2.17 (s, 3H).
Petition 870160032383, dated 06/29/2016, p. 75/159
73/148 [215]
Example 7: Synthesis of COMPOUND 24 and COMPOUND 6

[216] Synthesis of 5-bromo-N- (2-methyl-6-nitrophenyl) pyrimidin-2-amine
[217] To a solution of 5-bromo-2-chloropyrimidine (1.5 g,
Petition 870160032383, dated 06/29/2016, p. 76/159
74/148
7.89 mmol) and 2-methyl-6-nitroaniline (800 mg, 5.26 mmol) in N, Ndimethylformamide (10 mL) in a sealed tube potassium tert-butoxide (1.76 g, 15.78 mmol) was added , and the mixture was heated in a microwave at 130 ² C for 2 hrs. LCMS showed that the reaction was complete. The reaction was cooled to RT, quenched with water (20 mL) and extracted with ethyl acetate (3 χ 100 mL). The organic layers were separated, combined, washed with water (50 ml) and brine (100 ml), dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography on silica gel (petroleum ether: ethyl acetate = 10: 1) to generate the title compound as a yellow solid (500 mg, 31%). MS (ES +) CnHgBr ^ Cp requires: 309, 311, found: 310, 312 [M + H] ⁺ .
[218] Synthesis of 5 - ((3,5-dimethoxyphenyl) ethynyl) -N- (2methyl-6-nitrophenyl) pyrimidin-2-amine
[219] A mixture of 5-bromo-N- (2-methyl-6-nitrophenyl) pyrimidin-2-amine (573 mg, 3.0 mmol), 1-ethynyl-3,5-dimethoxybenzene (483 mg, 3.0 mmol) , triphenylphosphine (157 mg, 0.60 mmol), bis (triphenylphosphino) palladium (II) chloride (210 mg, 0.30 mmol), copper (I) iodide (57 mg, 0.30 mmol) and diethylamine (1 , 50 ml, 15.0 mmol) in N, N-dimethylformamide (10 ml) was degassed with nitrogen three times, and then stirred at 80 ² C for 2 hrs. LCMS showed that the reaction was complete. The mixture was cooled to RT, quenched with water (20 ml) and extracted with ethyl acetate (3 x 80 ml). The combined organic layers were separated, washed with water and brine, dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography on silica gel (petroleum ether: ethyl acetate = 4: 1) to generate the title compound as a yellow solid (460
Petition 870160032383, dated 06/29/2016, p. 77/159
75/148 mg, 39%). MS (ES +) C2iH ₁₈ N ₄ O4 requires: 390, found: 391 [Μ + H] ⁺ .
[220] Synthesis of N ¹ - (5 - ((3,5 dimethoxyphenyl) ethinyl) pyrimidin-2-yl) -6-methylbenzene-1,2-diamine
[221] A mixture of 5 - ((3,5-dimethoxyphenyl) ethynyl) -N- (2-methyl-6-nitrophenyl) pyrimidin-2-amine (150 mg, 0.38 mmol), iron (171 mg, 3.04 mmol) and ammonium chloride (246 mg, 4.56 mmol) in ethanol (20 mL) and water (2 mL) was stirred at 85 ² C for 1 h. LCMS showed that the reaction was complete. The reaction was cooled to RT, and the solid was filtered. The filtrate was concentrated, and the residue was purified by Prep-HPLC to generate the title compound as a white solid (55 mg, 44%). MS (ES +) C21H20N4O2 requires: 360, found: 361 [M + H] ⁺ . ¹ H-NMR (500 MHz, DMSO-cÇ) δ ppm 8.76 (s, 1H), 8.50-8.46 (br, 2H), 6.88 (t, 1H, J = 7.0 Hz ), 6.66 (s, 2H), 6.57 (d, 1H, J = 7.5 Hz), 6.54 (s, 1H), 6.44 (d, 1H, J = 6.5 Hz ), 4.74 (s, 2H), 3.76 (s, 6H), 2.01 (s, 3H).
[222] Synthesis of N- (2- ((5- ((3,5-dimethoxyphenyl) ethynyl) pyrimidin-2-yl) amino) -3methylphenyl) acrylamide
[223] N ¹ - (5 - ((3,5-dimethoxyphenyl) ethynyl) pyrimidin-2-yl) -
6-methylbenzene-1,2-diamine was prepared using the procedure similar to COMPOUND 30. The product was purified by
Petition 870160032383, dated 06/29/2016, p. 78/159
76/148 flash chromatography using 0-100% EtOAc / Hexanes gradient to generate the title compound. MS (ES +) C24H22N4O3 requires: 414, found: 415 [M + H] ⁺ . ¹ H-NMR (400 MHz, DMSO-de) δ ppm 9.60 9.38 (m, 1H), 8.79 (s, 1H), 8.51 (s, 2H), 7.69 (d, J = 8.1 Hz,
1H), 7.19 (t, J = 7.8 Hz, 1H), 7.15 - 7.06 (m, 1H), 6.67 (d, J =
2.3 Hz, 2H), 6, 60 - 6.45 (m, 2H), 6.22 (dd, J = 17.0, 2.1 Hz,
1H), 5.71 (dd, J = 10.2, 2.1 Hz, 1H), 3.76 (s, 6H), 2.12 (s,
3H).
[224] Synthesis of 5 - ((2,6-dichloro-3,5-dimethoxyphenyl) ethynyl) -N- (2-methyl-6-nitrophenyl) pyrimidin-2-amine

[225] To a solution of 5 - ((3,5-dimethoxyphenyl) ethynyl) -N (2-methyl-6-nitrophenyl) pyrimidin-2-amine (50 mg, 0.13 mmol) in acetonitrile (5 mL) sulfuryl chloride (44 mg, 0.33 mmol) was added dropwise at -20 ² C, and the mixture was stirred for another 10 min. LCMS showed that the reaction was complete, and the reaction was quenched with water (0 , 5 mL). The solvents were evaporated, and the residue was purified by Prep-HPLC to generate the title compound as a yellow solid (30 mg, 50%). (MS (ES +) 02ΐΗ ₁₆ 01 ₂ Ν404 requires: 459, 461, found: 460, 462 [M + H] ⁺ ;
[226] Synthesis of N ¹ - (5 - ((2,6-dichloro-3,5-dimethoxyphenyl) ethynyl) pyrimidin-2-yl) -6-methylbenzene-1,2-diamine
[227] A mixture of
5 - ((2,6-dichloro-3,5dimethoxyphenyl) ethynyl) -N- (2-methyl-6-nitrophenyl) pyrimidin-2-amine
Petition 870160032383, dated 06/29/2016, p. 79/159
77/148 (150 mg, 0.33 mmol), iron (147 mg, 2.64 mmol) and ammonium chloride (214 mg, 3.96 mmol) in ethanol (20 mL) and water (2 mL) was stirred at 85 ² C for 1 h. LCMS showed that the reaction was complete. The reaction was cooled to RT, and the solid was filtered. The filtrate was concentrated, and the residue was purified by Prep-HPLC to generate the title compound as a white solid (58 mg, 35%). MS (ES +) C2iH18Cl2N4O2 requires: 429, 431, found: 430, 432 [M + H] ⁺ . ¹ H-NMR (400 MHz, DMSO-d6) δ ppm 8.90 (s, 1H), 8.55-8.44 (br, 2H), 6.97 (s, 1H), 6, 89-6 , 86 (m, 1H), 6.57 (d, 1H, J = 7.6 Hz), 6.44 (d, 1H, J = 7.6 Hz), 4.75 (s, 2H), 3 , 94 (s, 6H), 2.01 (s, 3H).
[228] Synthesis of N- (2 - ((5 - ((2,6-dichloro-3,5 dimethoxyphenyl) ethynyl) pyrimidin-2-yl) amino) -3 methylphenyl) acrylamide
[229] N- (2 - ((5 - ((2,6-dichloro-3,5-dimethoxyphenyl) ethinyl) pyrimidin-2-yl) amino) -3methylphenyl) acrylamide was prepared using the procedure similar to COMPOUND 30. The product was purified by flash chromatography using 0-100% EtOAc / Hexanes gradient to generate the title compound. MS (ES +) C24H20CI2N4O3 requires: 482, found: 483 [M + H] ⁺ . ¹ H-NMR (400 MHz, DMSO-dg) δ ppm 9.47 (s, 1H), 8.93 (s, 1H), 8.54 (s, 2H), 7.71 (d, J = 8 , 1 Hz, 1H), 7.19 (t, J = 7.8 Hz, 1H), 7.09 (d, J = 7.4 Hz, 1H), 6.98 (s, 1H),
6.53 (dd, J = 17.0, 10.2 Hz, 1H), 6.22 (dd, J = 17.0, 2.1 Hz,
1H), 5.70 (dd, J = 10.2, 2.1 Hz, 1H), 3.94 (s, 6H), 2.13 (s,
3H).
[230] Example 8: COMPOSITE synthesis 40
Petition 870160032383, dated 06/29/2016, p. 80/159
78/148
[231] Synthesis of diethyl 2-methyl-3-oxopentanedioate
Honey, NaH, THF RT. 48 h ^Et ° ^2C
CO ₂ Et
2 [232] To a solution of diethyl 3-oxopentanedioate (23.2 g, 114.8 mmol) in tetrahydrofuran (100 mL) was added sodium hydride (60%, 4.8 g, 120.5 mmol) at 0 ° C, and the reaction mixture was stirred at RT for 30 min., Followed by the addition of iodomethane (7.15 ml, 114.8 mmol). The reaction mixture was stirred at RT for 48 h, quenched with water (500 mL) and extracted with ethyl acetate (500 mL χ 3). The organic layers were separated, combined, washed with water (200 ml) and brine (200 ml), dried over sodium sulfate, filtered and concentrated. The residue was purified by a silica gel column (petroleum ether: ethyl acetate = 20: 1) to generate the title compound as a colorless oil (9 g, 36%). MS (ES +) CioH ₁₆ 0 ₅ requires: 216, found: 217 [M + H] ⁺ .
[233] Synthesis of ethyl 4-hydroxy-5-methyl-6-oxo-1, 6-
Petition 870160032383, dated 06/29/2016, p. 81/159
79/148

dihydropyridine-3-carboxylate
1) (AcO) ₂ O, (EtO) ₃ CH, 120 ° C, 4 h
2) 30% NH ₄ OH, 0 ° C-RT, 2 h [234] To a solution of diethyl 2-methyl-3-oxopentanedioate (10 g, 46.25 mmol) in 1,1'-trioxidanediyldipropan-1- one (400 mL) was added trietoxymethane (38 mL, 231.25 mmol), and the mixture was heated to 120 ² C for 4 h, followed by the addition of 30% ammonia (600 mL) at 0 ° C. The reaction mixture was stirred at RT for an additional 2 h. LCMS monitored that the reaction was complete. The precipitate was collected via filtration and dissolved in dichloromethane (400 ml). The solid was filtered, and the filtrate was concentrated to generate the title compound (5.5 g, crude) as a yellow solid. MS (ES +) CgHnNCq requires: 197, found: 198 [M + H] ⁺ .
[235] Synthesis of ethyl 4,6-dichloro-5-methylnicotinate
[236] A solution of ethyl 4-hydroxy-5-methyl-6-oxo-6dihidropiridina-3-carboxylate (5.0 g, 21.4 mmol) in phosphoryl trichloride (100 mL) was refluxed at 125 ² C for 12 h. LCMS monitored that the reaction was complete. The majority of phosphoryl trichloride was evaporated, and the residue was added under an ice-water drip (100 ml). The resulting mixture was neutralized with aqueous sodium carbonate (50 ml) and extracted with ethyl acetate (200 ml). The organic layer was separated, combined, washed with water and brine, dried over sodium sulfate, filtered and concentrated. The residue was purified by column on silica gel (petroleum ether: ethyl acetate = 15: 1) to generate the title compound (1.6 g, 32%) as a yellow oil. MS (ES +) C9H9CI2NO2 requires: 232, 234, found: 233, 235 [M + H] ⁺ .
[237] Synthesis of ethyl 6-chloro-5-methyl-4- (methylamino) nicotinate
Petition 870160032383, dated 06/29/2016, p. 82/159
80/148
[239] To a solution of ethyl 4,6-dichloro-5methylnicotinate (2.6 g, 11.1 mmoi) in acetonitrile (60 ml) was added under 40% methylamine in water (689 mg, 22.2 mmoi) drip. , 60 ml), and the mixture was stirred at 50 ² C for 72 h. LCMS monitored that the reaction was complete. The reaction mixture was concentrated and extracted with ethyl acetate (100 ml). The organic layer was separated, combined, washed with water and brine, dried over sodium sulfate, filtered and concentrated. The residue was purified by silica gel column (petroleum ether: ethyl acetate = 2: 1) to generate the title compound (2.05 g, 81%) as a colorless oil. MS (ES +) C ₁₀ H ₁₃ ClN ₂ O2 requires: 228, 230, found:
229, 231 [M + H] ⁺ .
[240] Synthesis of (6-chloro-5-methyl-4- (methylamino) pyridin-
LiAIH ₄ , THF 0 ° C-RT, 1.5 h
[241] To a solution of ethyl 6-chloro-5-methyl-4 (methylamino) nicotinate (2.0 g, 8.8 ml) in tetrahydrofuran (60 ml) was added lithium aluminum hydride at 0 ° ^C , and to The mixture was stirred at RT for 1.5 h. LCMS monitored that the reaction was complete. The reaction was quenched by sodium sulfate decahydrate (1.5 g) and filtered. The filtrate was concentrated to generate the title compound (1.4 g, crude) as a white solid. MS (ES +) C8HHCIN2O requires: 186, 188, found: 187, 189 [M + H] ⁺ .
[242] Synthesis of 6-chloro-5-methyl-4- (methylamino) nicotinaldehyde
Petition 870160032383, dated 06/29/2016, p. 83/159
81/148
JLJx 0H ^Mn ° ² ' ^DCM _r to ⁰ rt, QN
I η I H
7 [243] A mixture of (6-chloro-5-methyl-4- (methylamino) pyridin-3-yl) methanol (1.4 g, 8.0 mmol) and manganese oxide (2.8 g, 32 mmol) in dichloromethane (100 mL) was stirred at RT for 4 h. LCMS monitored that the reaction was complete. The solid was filtered, and the filtrate was concentrated to generate the title compound (1.2 g, crude) as a yellow oil. MS (ES +) C ₈ H ₉ C1N ₂ O requires: 184, 186, found: 185, 187 [M + H] ⁺ .
[244] Synthesis of 7-chloro-3- (3,5-dimethoxyphenyl) -1,8-dimethyl-1,6-naphthyridin-2 (1H) -one

K ₂ CO ₃ , DMF
105 ° C, O.N.
[245] A mixture of 6-chloro-5-methyl-4 (methylamino) nicotinaldehyde (3.11 g, 16.8 mmol), methyl 2- (3,5-dimethoxyphenyl) acetate (4.25 g, 20.2 mmol) ) and potassium carbonate (2.8 g, 20.3 mmol) in N, N-dimethylformamide (100 ml) was stirred at 105 C for ² overnight. LCMS monitored that the reaction was complete. The reaction mixture was cooled to RT and quenched by water. The precipitate was filtered and dried to generate the title compound (5.5 g, crude) as a yellow solid. MS (ES +) C ₁₈ H ₁₇ C1N ₂ O ₃ requires: 344, 346, found: 345, 347 [M + H] ⁺ .
[246] Synthesis of 3- (3,5-dimethoxyphenyl) -1,8-dimethyl-7- (2-nitrophenylamino) -1,6-naphthyridin-2 (1H) -one

Petition 870160032383, dated 06/29/2016, p. 84/159
82/148 [247] A mixture of 7-chloro-3- (3,5-dimethoxyphenyl) -1,8-dimethyl-1,6-naphthyridin-2 (1H) -one (800 mg, 2.32 mmol), 2-nitrobenzenamine (320 mg, 2.32 mmol), Pd2 (dba) s (100 mg), JohnPhos (100 mg) and potassium tert-butanolate (480 mg, 4.64 mmol) in N, N-dimethylformamide (10 mL) was heated in a sealed tube at 100 ² C under microwave for 1 h. LCMS monitored that the reaction was complete. The mixture was concentrated and purified by Prep-HPLC to generate the title compound (150 mg, 15%) as a brown solid. MS (ES +) C24H22N4O5 requires: 446, found: 447 [M + H] ⁺ .
[248] Synthesis of 3- (2,6-dichloro-3,5-dimethoxyphenyl) -1,8-dimethyl-7- (2-nitrophenylamino) -1,6-naphthyridin-2 (1H) -one
[249] To a solution of 3- (3,5-dimethoxyphenyl) -1,8-dimethyl-7- (2-nitrophenylamino) -1,6-naphthyridin-2 (1H) -one (120 mg, 0.27 mmol) in acetonitrile (120 mL) sulfuryl chloride (185 mg, 1.35 mmol) was added at -15 ° C, and the mixture was stirred at -15 ² C for 10 min. LCMS monitored that the reaction was complete . The reaction mixture was quenched with water (1 ml) and concentrated. The precipitate was collected via filtration, washed with acetone / petroleum ether (1: 5) and dried to generate the title compound (100 mg, 72%) as a white solid. MS (ES +) C24H ₂ oC ₁₂ N405 requires: 514,
516, found: 515, 517 [M + H] ⁺ .
[250] Synthesis of 7- (2-aminophenylamino) -3- (2,6-dichloro3,5-dimethoxyphenyl) -1,8-dimethyl-1,6-naphthyridin-2 (1H) -one
Petition 870160032383, dated 06/29/2016, p. 85/159
83/148
dimethoxyphenyl) -1,8-dimethyl-7- (2-nitrophenylamino) -1,6-naphthyridine
2 (1H) -one (100 mg, 0.2 mmol) in ethyl acetate (20 mL) was added stannous chloride (150 mg, 0.8 mmol), and the mixture was stirred at 80 ² C for 1 h. LCMS monitored that the reaction was complete. The solid was filtered, and the filtrate was concentrated. The residue was purified by Prep-HPLC to generate the title compound (38.6 mg, 41%) as a yellow solid. MS (ES +) C24H22CI2N4O3 requires: 484, 486, found: 485, 487 [M + H] ⁺ ; ^ -NMR (500 MHz, DMSO-de) δ ppm 8.24 (s, 1H), 7.76 (s, 1H), 7.67 (s, 1H), 7.03 (d, 1H, J = 7.5 Hz), 6.97 (s, 1H), 6, 92-6, 89 (m, 1H), 6.75-6.73 (m, 1H), 6.57-6.54 (m , 1H), 4.77 (s, 2H), 3.95 (s, 6H), 3.66 (s, 3H), 2.43 (s, 3H).
[252] Synthesis of N- (2 - ((3- (2,6-dichloro-3,5 dimethoxyphenyl) -1,8-dimethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-7il ) amino) phenyl) acrylamide
[253] N- (2 - ((3- (2,6-dichloro-3,5-dimethoxyphenyl) -1,8dimethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-7yl) amino) phenyl) acrylamide was prepared using the procedure
Petition 870160032383, dated 06/29/2016, p. 86/159
84/148 similar to COMPOUND 30. The product was purified by preparative thin layer chromatography using 0-5% MeOH / DCM gradient to generate the title compound. MS (ES +) C27H24CI2N4O4 requires: 538, found: 539 [M + H] ⁺ .

[255] Synthesis of (2-amino-4-methoxyphenyl) methanol
2 [256] To a solution of 2-amino-4-methoxybenzoic acid (15.0 g, 89.8 mmol) in THF (300 mL) was added borohydride in THF (450 mL, 450 mmol) at 0 ° C, and the reaction mixture was stirred at RT overnight. LCMS showed that the reaction was complete. The reaction was quenched with water (150 ml) and extracted with ethyl acetate (500 ml x3). The organic layers were separated, combined, washed with water (200 ml) and brine (200 ml), dried over sodium sulfate, filtered and concentrated to
Petition 870160032383, dated 06/29/2016, p. 87/159
85/148 generate the title compound. MS (ES +) C ₈ HnNO ₂ requires: 153, found: 154 [M + H] ⁺ .
[257] Synthesis of 2-amino-4-methoxybenzaldehyde
3 [258] A mixture of (2-amino-4-methoxyphenyl) methanol (20 g, 131.0 mmol) and manganese oxide (68 g, 786.0 mmol) in dichloromethane (300 mL) was stirred at RT for in the evening. LCMS showed that the reaction was complete. The solid was filtered, and the filtrate was concentrated. The residue was purified by chromatography on silica gel (petroleum ether: ethyl acetate = 6: 1) to generate the title compound (7 g, 35%) as a yellow solid. MS (ES +) C ₈ H ₉ NO ₂ requires: 151, found: 152 [M + H] ⁺ .
[259] Synthesis of 2-amino-5-bromo-4-methoxybenzaldehyde
Br
[260] To a stirred solution of 2-amino-4methoxybenzaldehyde (6 g, 39.7 mmol) in dichloromethane (100 mL) was added N-bromosuccinimide (7 g, 39.7 mmol). LCMS monitored the reaction until the starting material was completely consumed. The reaction mixture was diluted with dichloromethane and water. The separated organic layer was dried over sodium sulfate, filtered and concentrated to give the title compound (5 g, 56%) as a yellow solid. MS (ES +) C ₈ H ₈ BrNO ₂ requires: 229, 231, found: 230, 232 [M + H] ⁺ .
[261] Synthesis of 6-bromo-7-methoxyquinazolin-2-ol
Petition 870160032383, dated 06/29/2016, p. 88/159
86/148
[262] A mixture of 2-amino-5-bromo-4-methoxybenzaldehyde (3 g, 13.1 mmol) and urea (12 g, 196.5 mmol) was stirred at 180 ² C for 2 h. LCMS showed that the reaction was complete. The reaction mixture was cooled to RT and washed with water (3 x 100 ml). The precipitate was collected and dried to generate the title compound (3 g, crude) as a yellow solid. MS (ES +) C8H ₇ BrN ₂ O ₂ requires: 254, 256, found: 255, 257 [M + H] ⁺ .
[263] Synthesis of 6-bromo-2-chloro-7-methoxyquinazoline n ίΓ 1 ^{P0C |} 3]
130 ° C, 5 h
I [264] A solution of 6-bromo-7-methoxyquinazolin-2-ol (3.0 g, 11.8 mmol) in phosphoryl trichloride (30 mL) was refluxed at 130 ² C for 5 h. LCMS showed that the reaction was complete. The reaction was cooled to RT, and most of the phosphoryl trichloride was evaporated. The residue was added under dripping ice water (100 mL), and the resulting precipitate was collected via filtration to generate the title compound as a
yellow solid (2.4 g, 75%). MS (ES +) CgHgBrClISUO requires: 272, 274, found : 273, 275 [M + H] ⁺ . [265] Synthesis in 2- -chlor- -6- (3,5-dimethoxyphenyl) -7-
methoxyquinazoline
[266]
A mixture of 6-bromo-2-chloro-7-methoxyquinazoline (2.4 g, 8.82 mmo 1), 3.5-dimethoxyphenylboronic acid (1.6 g, 8.82
Petition 870160032383, dated 06/29/2016, p. 89/159
87/148 mmol), cerium carbonate (8.6 g, 26.46 mmol) and Pd (PPh ₃ ) 2C12 (1.4 g, 2.1 mmol) in THF (10 mL), dioxane (10 mL) and water (2 mL) was degassed with nitrogen three times and stirred at 85 ² C for 3
H. LCMS monitored that the reaction was complete. The mixture was cooled to RT and extracted with dichloromethane (3 x 50 ml). The organic layers were separated, combined, washed with water and brine, dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography on silica gel (petroleum ether: ethyl acetate = 1: 4) to generate the title compound (1.1 g, 38%) as a white solid. MS (ES +) Ο ₁₇ Η ₁₅ Ο1Ν ₂ Ο3 requires: 330, 332, found: 331, 333 [M + H] ⁺ .
[267] Synthesis of 2-chloro-6- (2,6-dichloro-3,5-dimethoxyphenyl) -7-methoxyquinazoline

[268] To a solution of 2-chloro-6- (3,5-dimethoxyphenyl) -7methoxyquinazoline (200 mg, 0.61 mmol) in acetonitrile (5 mL) was added sulfuryl chloride (205 mg, 1.52 mmol ), and the mixture was stirred at -20 C for 1 ² h. The reaction was quenched with water (1 ml) and concentrated under reduced pressure. The precipitate was washed with acetonitrile and dried to generate the title compound as a white solid (120 mg, 50%). MS (ES +) C17H13C13N2O3 requires: 398, found: 399, 401 [M + H] ⁺ ; ¹ H-NMR (400 MHz, DMS0-d6) δ ppm 9.43 (s, 1H), 8.02 (s, 1H), 7.55 (s, 1H), 7.03 (s, 1H), 3.98 (s, 6H), 3.93 (s, 3H).
[269] Synthesis of 6- (2,6-dichloro-3,5-dimethoxyphenyl) -7 methoxy-N- (2-methyl-6-nitrophenyl) quinazolin-2-amine
Petition 870160032383, dated 06/29/2016, p. 90/159
88/148

[270] 6- (2,6-dichloro-3,5-dimethoxyphenyl) -7-methoxy-N- (2 methyl-6-nitrophenyl) quinazolin-2-amine was prepared using a procedure similar to COMPOUND 30. The product was purified by flash chromatography using 0-100% EtOAc / Hexanes gradient to generate the title compound. MS (ES +) C24H20CI2N4O5 requires: 514, found: 515 [M + H] ⁺ .
[271] Synthesis of Nl- (6- (2,6-dichloro-3,5-dimethoxyphenyl) -
7-methoxyquinazolin-2-yl) -6-methylbenzene-1,2-diamine <: r

[272] Nl- (6- (2,6-dichloro-3,5-dimethoxyphenyl) -7 methoxyquinazolin-2-yl) -6-methylbenzene-1,2-diamine was prepared using the procedure similar to COMPOUND 30. A The reaction was filtered through celite to generate crude product. MS (ES +) C24H22CI2N4O3 requires: 484, found: 485 [M + H] ⁺ .
[273] Synthesis of N- (2 - ((6- (2,6-dichloro-3,5-dimethoxyphenyl) -7-methoxyquinazolin-2-yl) amino) -3methylphenyl) acrylamide
Petition 870160032383, dated 06/29/2016, p. 91/159
89/148 [274] N- (2- ((6- (2,6-dichloro-3,5-dimethoxyphenyl) -7methoxyquinazolin-2-yl) amino) -3-methylphenyl) acrylamide was prepared using the procedure similar to COMPOUND 30. The product was purified by flash chromatography using 0-10% MeOH / DCM gradient to generate the title compound. MS (ES +) C27H24CI2N4O4 requires: 538, found: 539 [M + H] ⁺ .
[275] Example 10: COMPOSITE synthesis 34
at 3 s $
s 8

[277] A solution of 2-amino-3-fluorbenzoic acid (10.85 g, 70 mmol) in dichloromethane (175 mL) was added Nbromosuccinimide (12.46 g, 70 mmol), and the mixture was stirred at RT for 2 h. LCMS showed that the reaction was complete. The precipitate was filtered and washed with dichloromethane (100 ml * 3) to generate the title compound (12.7 g, 78%) as a gray solid,
Petition 870160032383, dated 06/29/2016, p. 92/159
90/148 which was used directly in the next step without further purification. MS (ES +) CvHsBrFNCq requires: 233, 235, found: 232, 234 [M - H] X
Synthesis of (2-amino-5-bromo-3-fluorophenyl) methanol [278]
[279] To a solution of 2-amino-5-bromo-3fluorbenzoic acid (14.5 g, 62.2 mmol) in THF (150 mL) at 0 ² C was added borohydride in THF (1 M, 310 mL) ), and the reaction mixture was stirred at RT overnight. LCMS showed that the reaction was complete. The reaction was quenched with methanol (150 ml), concentrated in vacuo, diluted with aqueous sodium bicarbonate (400 ml) and extracted with ethyl acetate (200 ml * 3). The organic layers were separated, combined, washed with water (200 ml) and brine (200 ml), dried over sodium sulfate, filtered and concentrated to generate the title compound (13.0 g, crude), which was directly used in next step without further purification. MS (ES +) C7H ₇ BrFNO requires: 219, 221, found:
220, 222 [M + H] ⁺ .
[280] Synthesis of 2-amino-5-bromo-3-fluorbenzaldehyde
HO | V MnO ₂ , DCM ^
Η ₂ Ν ^/ ^ γ ^RT ' ^{0 Ν} · Η ^' η ^
F F
4 [281] A mixture of (2-amino-5-bromo-3-fluorophenyl) methanol (13 g, 59.4 mmol) and manganese oxide (31 g, 356.4 mmol) in dichloromethane (400 mL) RT was stirred overnight. TLC showed that the starting material was completely consumed. The solid was filtered, and the filtrate was concentrated to generate the title compound (11 g, 85%) as a light yellow solid, which was used directly in the next step without further purification.
Petition 870160032383, dated 06/29/2016, p. 93/159
91/148 [282] Synthesis of 6-bromo-8-fluorquinazolin-2-ol
[283] A stirred mixture of 2-amino-5-bromo-3fluorbenzaldehyde (2.17 g, 10 mmol) and urea (9 g, 150 mmol) was heated to 180 ² C for 2 h. LCMS showed that the reaction was complete. The reaction mixture was cooled to RT, and the resulting precipitate was filtered and washed with water (500 ml * 3). The trapped moisture was completely removed by coevaporation with toluene three times. The title compound (2 g, 83%) was obtained as a yellow solid. MS (ES +) C ₈ H4BrFN ₂ O requires: 242, 244, found: 243, 245 [M + H] ⁺ .
[284] Synthesis of 6-bromo-2-chloroquinazoline
..- Br í J j Ϊ J T
HO '' Ν 'Ύ' reflux, 5h cr '' 'V'
F F
7 [285] A solution of 6-bromoquinazolin-2-ol (9.72 g, 40 mmol) in phosphorous oxychloride (100 mL) was refluxed for 5 h. LCMS showed that the reaction was complete. The reaction was cooled to RT, and most of the phosphorous oxychloride was removed under reduced pressure. The residue was added under a drip in ice water (500 ml), and the resulting precipitate was collected by filtration to generate the title compound (9 g, 87%) as a yellow solid. MS (ES +) C ₈ H ₃ BrClFN2 requires: 260, 262, found: 261, 263 [M + H] ⁺ .
[286] Synthesis of 2-chloro-6- (3,5-dimethoxyphenyl) -8fluorquinazoline
Petition 870160032383, dated 06/29/2016, p. 94/159
92/148
A mixture of 6-bromo-2-chloro-8-fluoroquinazoline (4.0 g, 15.4 mmol), 3,5-dimethoxyphenylboronic acid (4.47 g, 16.9 mmol), cesium carbonate (10, 0 g, 30.8 mmol) and Pd (PPh ₃ ) 2 Cl2 (236 mg, 0.77 mmol) in THF (200 mL) and water (10 mL) was degassed with nitrogen three times, and stirred at 80 ² C for 3 h. Both TLC and LCMS showed that the reaction was complete. The reaction mixture was cooled to RT and directly concentrated. The residue was purified by chromatography on silica gel (petroleum ether: dichloromethane = 2: 1 to 1: 1) to generate the title compound (2.5 g, 51%) as a yellow solid. MS (ES +) Ο ₁₆ Η ₁₂ Ο1ΕΝ ₂ Ο2 requires: 318/320, found: 319/321 [M + H] ⁺ .
[287] Summary of
2-chloro-6- (2,6-dichloro-3,5dimethoxyphenyl) -8-fluoroquinazoline
[288] To a solution of 2-chloro-6- (3,5-dimethoxyphenyl) -8 fluorquinazoline (1.5 g, 4.7 mmoi) added under drip chloride mmol) at 0 ° C, and the mixture was stirred showed that the reaction was complete, water (1 mL), and the solvents reduced. The residue was washed to generate the title compound (700 mg, (ES +) C ₁₆ H ₁₀ C13FN2O2 requires: 386, in dry THF (40 mL) was sulfuryl (1.59 g, 1.75 for 1 h. Both TLC and LCMS The reaction was quenched with were removed under pressure with acetonitrile and dried to 38%) as a white solid. (MS 388, found: 387, 389 [M + δ ppm 9.74 (d, 1H J = 1.0 Hz),
4.00 (s, 6H).
H] ⁺ ; ¹ H-NMR (400 MHz, DMS0-d ₆ )
8.03-7, 99 (m, 2H), 7.08 (s, 1H),
Petition 870160032383, dated 06/29/2016, p. 95/159
93/148 [289] Synthesis of 6- (2,6-dichloro-3,5-dimethoxyphenyl) -8-fluor-N- (2-methyl-6-nitrophenyl) quinazolin-2-amine
[290] 6- (2,6-dichloro-3,5-dimethoxyphenyl) -8-fluor-N- (2methyl-6-nitrophenyl) quinazoiin-2-amine [291] was prepared using the procedure similar to
COMPOUND 30. The product was purified by flash chromatography using 0-100% EtOAc / Hexanes gradient to generate the title compound. MS (ES +) C ₂ 3H ₁₇ C1 ₂ FN4O4 requires: 502, found: 503 [M + H] ⁺ .
[292] Synthesis of Nl- (6- (2,6-dichloro-3,5-dimethoxyphenyl) 8-fluorquinazolin-2-yl) -6-methylbenzene-1,2-diamine
[293] Nl- (6- (2,6-dichloro-3,5-dimethoxyphenyl) -8-fluorquinazolin-2-yl) -6-methylbenzene-1,2-diamine was prepared using the procedure similar to COMPOUND 30. The reaction was filtered through celite to generate crude product. MS (ES +)
Ο23Η ₁₉ Ο1 ₂ ΕΝ4Ο2 requires: 472, found: 473 [M + H] ⁺ .
[294] Synthesis of N- (2 - ((6- (2,6-dichloro-3,5-dimethoxyphenyl) -8-fluorquinazolin-2-yl) amino) -3methylphenyl) acrylamide
Petition 870160032383, dated 06/29/2016, p. 96/159
94/148

[295] N- (2 - ((6- (2,6-dichloro-3,5-dimethoxyphenyl) -8-fluorquinazolin-2-yl) amino) -3-methylphenyl) acrylamide was prepared using the procedure similar to the COMPOUND 30. The product was purified by flash chromatography using 0-10% MeOH / DCM gradient to generate the title compound. MS (ES +) C26H21CI2FN4O3 requires: 526, found: 527 [M + H] ⁺ . ¹ H-NMR (400 MHz, DMSO-ass) δ 9.53 (d, J = 27.9 Hz, 1H), 9.28 (s, 1H), 8.96 (s, 1H), 7.75 (d, J = 29.9 Hz, 1H), 7.59 (d, J = 1.7 Hz, 1H), 7.49 (d, J = 10.8 Hz, 1H), 7.02 (s , 1H), 6.50 (s, 1H), 6.21 (dd, J = 16.9, 2.1 Hz, 1H), 5.75 (s, 1H), 5.68 (dd, J = 10.2, 2.0 Hz, 1H), 3.98 (d, J = 4.6 Hz, 6H), 2.19 (s, 3H).
[296] Example 10: COMPOSITE 50 Synthesis
Petition 870160032383, dated 06/29/2016, p. 97/159
95/148 [297] Synthesis of tert-butyl 4- (2,5-dichloropyrimidin-4-yl) piperazine-1-carboxylate
[298] To a solution of 2,4,5-trichloropyrimidine (0.475 g, 2.6 mmol) in dry DMF (8.5 mL) was added tert-butyl piperazine-1-carboxylate (0.51 g, 2, 7 mmol) followed by DIEA (0.51 mL, 3.1 mmol) at 0 ° C, and the mixture was stirred for 1 h. LCMS showed that the reaction was complete. The reaction was diluted with water (100 ml), and the white solid was filtered. The residue was washed with water and dried to generate the title compound (445 mg, 51%) as a white solid. MS (ES +) C ^ H ^ ClgNrêg requires: 332, found: 333 [M + H] ⁺ [299] Synthesis of tert-butyl (2- ((5-chloro-4- (piperazin-1yl) pyrimidin-2 -yl) amino) phenyl) carbamate
TFÂ dksssnss [300] To a solution of tert-butyl 4- (2,5dichloropyrimidin-4-yl) piperazine-1-carboxylate (0.1 g, 0.3 mmol) in DCM (1.0 mL) was added TFA (1.0 ml) and the mixture was stirred for 1 h. An aliquot of the reaction mixture was analyzed by LCMS, which indicated that the reaction occurred until completion. The solvents were removed and the residue was dried in a high vacuum. The crude product was used for the next step without
Petition 870160032383, dated 06/29/2016, p. 98/159
96/148 another purification.
[301] To a solution of 2,5-dichloro-4- (piperazin-1yl) pyrimidine (0.3 mmol) in Dioxane (4.0 mL) was added TFA (0.060 mL, 0.75 mmol) and tert- butyl (2-aminophenyl) carbamate (0.094 g, 0.45 mmol) and the mixture was stirred at 100 ² C for 24 h. After cooling to room temperature the reaction mixture was diluted with EtOAc and washed with saturated aqueous sodium bicarbonate solution. The organic mixture was dried over sodium sulfate and charged over silica gel and purified using 0-10% MeOH / DCM gradient containing 10% NH ₄ OH to generate the title compound (28 mg, 23%) as a white solid. MS (ES +) Ο ₁₉ Η ₂ 5Ο1Ν ₆ Ο ₂ requires: 404, found: 405 [M + H] ⁺ [302] Synthesis of tert-butyl (2- (((5-chloro-4- (4 - (( 3 (trifluormetii) phenyl) carbamoyl) piperazin-1-yl) pyrimidin-2-yl) amino) phenyl) carbamate
[303] To a solution of tert-butyl (2- ((5-chloro-4 (piperazin-1-yl) pyrimidin-2-yl) amino) phenyl) carbamate (28 mg, 0.068 mmol) in DCM (0, 7 ml) l-isocyanate-3 (trifluormetii) benzene (0.011 ml, 0.082 mmol) and triethylamine (0.015 ml, 0.1 mmol) were added and the mixture was stirred at 23 ² C for 16 h. The crude reaction mixture was loaded onto silica gel and purified using 0-50% EtOAc / Hexanes gradient to generate the title compound (25 mg, 62%). MS (ES +) C ₂ 7H2 ₉ C1F3N ₇ O ₃ requires: 591, found: 592 [M + H] ⁺ [304] Synthesis of 4- (2 - ((2-acrylamidophenyl) amino) -5chloropyrimidin-4-yl ) -N- (3- (trifluormetii) phenyl) piperazine-1carboxamide
Petition 870160032383, dated 06/29/2016, p. 99/159
97/148
[305] To a solution of tert-butyl (2- ((5-chloro-4- (4 - ((3 (trifluormethyl) phenyl) carbamoyl) piperazin-1-yl) pyrimidin-2-yl) amino) phenyl) carbamate (0.025 g, 0.043 mmoi) in DCM (1.0 ml) TFA (1.0 ml) was added and the mixture was stirred for 1 h. An aliquot of the reaction mixture was analyzed by LCMS, which indicated that the reaction occurred until completion. The solvents were removed and the residue was dried in a high vacuum. The crude product was used for the next step without further purification.
[306] To a solution of 4- (2 - ((2-aminophenyl) amino) -5chloropyrimidin-4-yl) -N- (3- (trifluormethyl) phenyl) piperazine-1carboxamide (0.043 mmoi) in DCM (0, 5 ml), acryloyl chloride (0.004 ml, 0.052 mmol) and DIEA (0.018 ml, 0.11 ml) were added and the mixture was stirred at 0 ² C for 1 h. The crude reaction mixture was loaded onto silica gel and purified using 0-7% MeOH / DCM gradient to generate the title compound (10 mg, 43%). MS (ES +) C25H23CIF3N7O2 requires: 545, found: 546 [M + H] ⁺ [307] Example 11: COMPOSITE synthesis 54
Petition 870160032383, dated 06/29/2016, p. 100/159
98/148

[308]
Synthesis of tert-butyl 4- (2-chloro-5-methylpyrimidin4-yl) piperazine-1-carboxylate
Petition 870160032383, dated 06/29/2016, p. 101/159
99/148
Η
Boc [309] To a solution of 2,4-dichloro-5-methylpyrimidine (0.75 g, 4.6 mmol) in dry DMF (15.5 ml) was added tertbutyl piperazine-1-carboxylate (0.9 g , 4.85 mmol) followed by DIEA (0.91 mL, 5.5 mmol) at 0 ° C, and the mixture was stirred to room temperature overnight. LCMS showed that the reaction was complete. The reaction was diluted with water (120 ml), and the solid was filtered. The residue was washed with water and dried to generate the title compound (1.386 g, 96%) as a white solid. MS (ES +) C14H21CIN4O2 requires: 312, found: 313 [M + H] ⁺ [310] 4- ((4- (4- (tert butoxycarbonyl) piperazin-l-yl) -5-methylpyrimidin-2 acid synthesis -yl) amino) -3nitrobenzoic

CS2CO3 BrettPhos-Pd ‘BuOH 90 ° C
[311]
A mixture of tert-butyl 4- (2-chloro-5 methylpyrimidin-4-yl) piperazine-1-carboxylate (0.15 g, 0.48 mmol), 4-amino-3-nitrobenzoic acid (97 mg, 0 , 53 mmol), BrettPhos-Pd mixture (20 mg, 0.015 mmol), and cesium carbonate (470 mg, 1.44 mmol) in ^t BuOH (2.4 mL) was heated in a sealed tube at 100 ² C during the night. The mixture was diluted with EtOAc, filtered through a celite plug, loaded over silica gel and purified using 0-10% MeOH / DCM gradient to generate the title compound (75
Petition 870160032383, dated 06/29/2016, p. 102/159
100/148 mg, 34%). MS (ES +) C2iH ₂ 6N ₆ O ₆ requires: 458, found: 459 [Μ + H] ⁺ [312] Synthesis of tert-butyl 4- (5-methyl-2 - ((4 - ((1metiIpiperidin-4 -yl) carbamoyl) -2-nitrophenyl) amino) pyrimidin-4yl) piperazine-1-carboxyate
^[313] A mixture of 4- ((4- (4- (tertbutoxycarbonyl) piperazin-1-yl) -5-methylpyrimidin-2-yl) amino) -3 nitrobenzoic acid (0.075 g, 0.164 mmol), 1-methylpiperidin -4-amine (37 mg, 0.33 mmol), HATU (140 mg, 0.37 mmol), and DIEA (0.1 mL, 0.6 mmol) in DMF (3.0 mL) was stirred at room temperature environment at night. The reaction mixture was diluted with EtOAc, washed with saturated aqueous sodium bicarbonate solution and saturated brine solution. The crude mixture was loaded onto silica gel and purified using 0-10% MeOH / DCM gradient containing 10% NH ₄ OH to generate the title compound (73 mg, 80%). MS (ES +) C ₂₇ H ₃₈ N ₈ O ₅ requires: 554, found: 555 [M + H] ⁺ [314] Synthesis of N- (4-cyanophenyl) -4- (5-methyl-2 - (( 4 - (((1-methylpiperidin-4-yl) carbamoyl) -2-nitrophenyl) amino) pyrimidin-4yl) piperazine-1-carboxamide
1) TFA, DCM
2) Et ₃ N, DCM NCO
N
[315]
To a solution of tert-butyl 4- (5-methyl-2 - ((4 - ((1Petition 870160032383, 06/29/2016, page 103/159
101/148 methylpiperidin-4-yl) carbamoyl) -2-nitrophenyl) amino) pyrimidin-4yl) piperazine-1-carboxylate (0.073 g, 0.13 mmol) in DCM (1.0 mL) was added TFA (1, 0 ml) and the mixture was stirred for 1 h. An aliquot of the reaction mixture was analyzed by LCMS, which indicated that the reaction occurred until completion. The solvents were removed and the residue was dried in a high vacuum. The crude product was used for the next step without further purification.
[316] To a solution of 4 - ((5-methyl-4- (piperazin-1yl) pyrimidin-2-yl) amino) -N- (1-methylpiperidin-4-yl) -3nitrobenzamide (0.073 mmol) in DCM (1.5 ml) 4 isocyanatobenzonitrile (23 mg, 0.16 mmol) and triethylamine (0.055 ml, 0.39 mmol) were added and the mixture was stirred at 23 ² C for 16 h. The crude reaction mixture was filtered and washed with minimal volume of DCM and then hexanes to generate the title compound (97 mg, 100%). MS (ES +) C30H34N20O4 requires: 598, found: 599 [M + H] ⁺ [317] Synthesis of 4- (2 - ((2-amino-4 - ((1-methylpiperidin-4yl) carbamoyl) phenyl) amino ) -5-methylpyrimidin-4-yl) -N- (4cyanophenyl) piperazine-1-carboxamide

[318] 4- (2 - ((2-amino-4 - (((1-methylpiperidin-4yl) carbamoyl) phenyl) amino) -5-methylpyrimidin-4-yl) -N- (4cyanophenyl) piperazine-1-carboxamide was prepared using the procedure similar to COMPOSITE 30. The reaction was filtered through celite to generate crude product. MS (ES +) C3oH ₃₆ N ₁₀ 02 requires: 568, found: 569 [M + H] ⁺ .
[319] Synthesis of 4- (2 - ((2-acrylamido-4 - (((1 methylpiperidin-4-yl) carbamoyl) phenyl) amino) -5-methylpyrimidin-4Petition 870160032383, 06/29/2016, p. 104/159
102/148 il) -N- (4-cyanophenyl) piperazine-1-carboxamide
[320] 4- (2 - ((2-acrylamido-4 - (((1-methylpiperidin-4-yl) carbamoyl) phenyl) amino) -5-methylpyrimidin-4-yl) -N- (4-cyanophenyl) piperazine-1 -carboxamide was prepared using a procedure similar to COMPOUND 30. The reaction mixture was purified by preparative thin layer chromatography to generate the title product. MS (ES +) C33H ₃₈ N ₁₀ O3 requires: 622, found: 623 [M + H] ⁺ . ⁴ H NMR (400 MHz, DMSO-d6) δ 9.98 (s,
1H), 9.08 (s, 1H), 8.30 (s, 1H), 8.21 - 8.07 (m, 3H), 7.93 (d, J = 10.7 Hz, 2H), 7.67 (m, 4H), 6.50 (dd, J = 16.9, 10.2 Hz, 1H),
6.33 - 6.25 (m, 1H), 5.83 - 5.76 (m, 1H), 3.78 (m, 2H), 3.59 (m, 4H), 3.43 (m, 4H), 2.92 (d, J = 11.4 Hz, 2H), 2.30 (s, 3H), 2.23 (s, 2H), 2.14 (s, 3H), 1.79 ( m, 2H), 1.69 - 1.54 (m, 2H).
[321] Example 12: COMPOSITE 20 Synthesis
Petition 870160032383, dated 06/29/2016, p. 105/159
103/148
HATU
DBA
Synthesis of imidazo [1,2-a] pyridine-8-carbonitrile [322]

^[323] To a solution of 2-aminonicot inonitrile (1.0 g, 8.39 mmol) in EtOH (10 ml) in a sealed 20 ml flask was added 2-chloroacetaldeldo (1.611 ml, 9.23 mmol) o The flask was then sealed and heated to 120 ° C overnight. The reaction was cooled to RT and quenched with 2N Na2CO3, EtOH removed in vacuo and extracted with DCMx3. The organics combined and washed with water then brine2. Dried over sodium sulfate and the solvent removed to generate the title compound as a yellow brown solid (1.2 g, 8.38 mmoi, 100% yield) was verified by MS (ES +) C8H5N3 requires: 143 found: 144 [M + H] ⁺
Petition 870160032383, dated 06/29/2016, p. 106/159
104/148 [324] Synthesis of 3-iodoimidazo [1,2-a] pyridine-8carbonitrile
I [325] To a stirred solution of imidazo [1,2-a] pyridine-8carbonitrile (1.2 g, 8.38 mmol) in dichloromethane (10 ml) was added N-iodosuccinimide (1.89 g, 8, 38 mmol). LCMS monitored the reaction until complete consumption of the starting material. The reaction mixture was diluted with dichloromethane and water. The separated organic layer was dried over sodium sulfate, filtered and concentrated to generate 3-iodoimidazo [1,2-a] pyridine-8carbonitrile (1.8 g, 6.69 mmol, 80% yield) as a brown solid. MS (ES +) C ₈ H ₈ IN3 requires: 269, found: 270 [M + H] ⁺ .
[326] Synthesis of 1- (3- (8-cyanoimidazo [1,2-a] pyridin-3yl) -5-isopropoxyphenyl) -3- (2,2,2-trifluorethyl) urea

[327] To a mixture of 3-iodoimidazo [1,2-a] pyridine-8carbonitrile (100 mg, 373 pmol), 1- (3-isopropoxy-5- (4,4,5,5tetramethyl-1,3, 2-dioxaborolan-2-yl) phenyl) -3- (2,2,2trifluorethyl) urea (90 mg, 224 pmol), PdC12 (dppf) -CH2C12 adduct (30.5 mg, 37.3 pmol) in Dioxane ( 3 ml), 2M Na2CO3 (0.559 ml, 1119 pmol) was added. The flask was degassed for 5 minutes then capped and heated to 110 ° C for 30 minutes in a micro
Petition 870160032383, dated 06/29/2016, p. 107/159
105/148 waves. After cooling to room temperature the reaction was partitioned between EtOAc and brine, separated and the organics washed with brinex2. Combined organics were dried directly on silica and purified via flash chromatography (0100% Hex / EtOAc; 12g column). The title compound was recovered (30 mg, 71.9 pmol, 32.1% yield) as a brown solid. MS (ES +) C20H18F3N5O2 requires: 417, found: 418 [M + H] ⁺ .
[328] Synthesis of 1- (3- (8- (aminomethyl) imidazo [1,2a] pyridin-3-yl) -5-isopropoxyphenyl) -3- (2,2,2-trifluorethyl) urea
[329] 1- (3- (8-cyanoimidazo [1,2-a] pyridin-3-yl) -5-isopropoxyphenyl) -3- (2,2,2-trifluorethyl) urea (0.030 g, 0.072 mmoi) was taken in 7N AMMONIA in methanol (20 mL, 140 ml) and PdC (10 mg, 0.094 ml) added. The reaction was stirred under an H ₂ balloon for 1 hour. The mixture was then filtered through celite and solvent removed. The residue was dried under high vacuum overnight to generate the title compound as a yellow solid (0.026 g, 0.062 ml, 86% yield). MS (ES +) C ₂ oH ₂₂ F3N ₅ 0 ₂ requires: 421, found: 422 [M + H] ⁺ .
[330] Synthesis of N - ((3- (3-isopropoxy-5- (3- (2,2,2trifluorethyl) ureido) phenyl) imidazo [1,2-a] pyridin-8yl) methyl) propioamide
Petition 870160032383, dated 06/29/2016, p. 108/159
106/148


[331] To a solution of 1- (3- (8- (aminomethyl) imidazo [1,2-
a] pyridin-3-yl) -5-isopropoxyphenyl) -3- (2,2,2-trifluorethyl) urea (26 mg, 0.062 mmol) in DCM (3 ml) DIEA (0.075 ml, 0.432 mmol) was added and HATU (35.2 mg, 0.093 mmol) and finally propiolic acid (4.95 μΐ, 0.080 mmol). Reaction was stirred for 30 minutes at room temperature. The reaction was loaded directly onto a silica column and purified by flash chromatography (0-10% CH2 Cl2 / MeOH) to generate the title compound (19 mg, 0.040 mmol, 65.0% yield) as an off-white solid. MS (ES +) C23H22F3N5O3 requires: 473, found: 474 [M + H] ⁺ . NMR (400 MHz, DMSO-d ₆ ) δ 9.34 (s, 1H), 8.92 (s, 1H),
8.47 (d, J = 6.8 Hz, 1H), 7.74 (s, 1H), 7.17 (d, J = 1.9 Hz, 2H), 7.10 (s, 1H), 6.98 (s, 1H), 6.82 (s, 1H), 6.74 (s, 1H),
4.69 - 4.58 (m, 2H), 3.93 (dd, J = 9.7, 6.4 Hz, 2H), 2.72 - 2.64 (m, 1H), 1.30 - 1.19 (m, 6H).
[332] Example 13: COMPOSITE Synthesis 21
Petition 870160032383, dated 06/29/2016, p. 109/159
107/148
Synthesis of 7-chloro-3-iodoimidazo [1,2-a] pyridine [333]
NIS
DMF
[334] 7-chloro-3-iodoimidazo [1,2-a] pyridine was prepared using the procedure described in W02008078091. MS (ES +)
C7H4CIIN2 requires: 278, found: 279 [M + H] ⁺ .
[335] Synthesis of 3- (7-chloroimidazo [1,2-a] pyridin-3 yl) aniline
Petition 870160032383, dated 06/29/2016, p. 110/159
108/148
ΗΟχ _βΧ ΟΗ
CS2CO3
Pd (P'Bu3) ₂
THF / H ₂ O
110 ° C
[336] 3- (7-chloroimidazo [1,2-a] pyridin-3-yl) aniline was prepared using the procedure described in W02008078091. MS (ES +) Ci3H ₁₀ ClN ₃ requires: 243, found: 244 [M + H] ⁺ .
[337] Synthesis of 1- (3- (7-chloroimidazo [1,2-a] pyridin-3yl) phenyl) -3- (2,2,2-trifluorethyl) urea
1) DIEA, THF, 60 ° C
[338] To a solution of 3- (7-chloroimidazo [1,2-a] pyridin-
3-yl) aniline (0.15 mmol) in THF (1.5 mL) 4-nitrophenyl carbon hydrochloride (30 mg, 0.15 mmol) and DIEA (0.036 mL, 0.225 mmol) were added. The mixture was heated to 60 ² C for 6 h. To the crude carbamate was added DIEA (0.036 mL, 0.225 mmol) and 2,2,2-trifluoretan-l-amine (0.014 mL, 0.18 mmol) and the solution was treated at 60 ² C overnight. The reaction mixture was diluted with EtOAc and water. The separated organic layer was dried over sodium sulfate, filtered and concentrated. The crude mixture was purified by flash chromatography (0-6% MeOH / DCM) to generate the title compound (38 mg, 69% yield). MS (ES +)
C16H12CIF3N4O requires: 368, found: 369 [M + H] ⁺ .
[339] Synthesis of 1- (3- (7- (2-aminophenyl) imidazo [1,2-
Petition 870160032383, dated 06/29/2016, p. 111/159
109/148
a] pyridin-3-yl) phenyl) -3- (2,2,2-trifluorethyl) urea

CS2CO3 Pd (P'Bu ₃ ) ₂ THF / H ₂ O 125 ° C
[340]
To a mixture of 1- (3- (7-chloroimidazo [1,2
a] pyridin-3-yl) phenyl) -3- (2,2,2-trifluorethyl) urea (20 mg, 0.052 mmol), 2- (4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl) aniline (15 mg, 0.066 mmol) and cesium carbonate (51 mg, 0.156 mmol) in a mixture of THF / H ₂ O (2/1, 0.75 ml) Pd (P ^t Bu3) was added ) ₂ (3 mg, 0.005 mmol). The flask was degassed for 5 minutes then capped and heated to 125 ° C for 20 minutes in a microwave. After cooling to room temperature, the reaction mixture was filtered through a celite pad and purified via flash chromatography (0-10% MeOH / DCM gradient containing 10% NH4OH) to generate the title compound (20 mg, 90% yield). MS (ES +) C2 ₂ H ₁₈ F3N ₅ O requires: 425, found: 426 [M + H] ⁺ .
[341] Synthesis of N- (2- (3- (3- (3- (2,2,2-trifluorethyl) ureido) phenyl) imidazo [1,2-a] pyridin-7yl) phenyl) acrylamide
Petition 870160032383, dated 06/29/2016, p. 112/159
110/148
[342] N- (2- (3- (3- (3- (2,2,2-trifluorethyl) ureido) phenyl) imidazo [1,2-a] pyridin-7yl) phenyl) acrylamide was prepared using the procedure similar to COMPOUND 30. The product was purified by preparative thin layer chromatography using 0-10% MeOH / DCM gradient to generate the title compound. MS (ES +) C25H20F3N5O2 requires: 479, found: 480 [M + H] ⁺ .
[343] Example 14: Synthesis of COMPOUND 38 [344] Synthesis of N- (2- (3- (3-isopropoxy-5- (3- (2,2,2trifluorethyl) ureido) phenyl) imidazo [l, 2- a] pyridin-7-yl) phenyl) acrylamide
Petition 870160032383, dated 06/29/2016, p. 113/159
111/148 [345] N- (2- (3- (3-isopropoxy-5- (3- (2,2,2-trifluorethyl) ureido) phenyl) imidazo [1,2-a] pyridin-7yl) phenyl ) acrylamide was prepared using the procedure similar to COMPOUND 30. The product was purified by HPLC using 5-70% Acetonitrile / water + 0.1% gradient formic acid to generate the title compound as a formate salt. MS (ES +) C28H26F3N5O3 requires: 537, found: 538 [M + H] ⁺ .
[346] Example 15: COMPOSITE 11 Synthesis

il) piperidin-3-yl) carbamate
Petition 870160032383, dated 06/29/2016, p. 114/159
112/148
[348] tert-butyl (1- (2-chloropyrimidin-4-yl) piperidin-3 yl) carbamate was prepared using the procedure similar to
COMPOUND 54 using 2,4-dichloropyrimidine and tert-butyl piperidin
3-ilcarbamate. MS (ES +) C14H21CIN4O2 requires: 312, found: 313 [M + H] ⁺ [349] Synthesis of tert-butyl (1- (2 - ((2-nitrophenyl) amino) pyrimidin-4-yl) piperidin-3 -yl) carbamate

CS2CO3 BrettPhos-Pd ‘BuOH 90 ° C
[350] tert-butyl (1- (2- ((2-nitrophenyl) amino) pyrimidin-4yl) piperidin-3-yl) carbamate was prepared using the procedure similar to COMPOUND 54 using 2-nitroaniline. MS (ES +) C20H26N6O4 requires: 414, found: 415 [M + H] ⁺ [351] Synthesis of N- (1- (2- ((2-nitrophenyl) amino) pyrimidin4-yl) piperidin-3-yl) propane -l-sulfonamide
1) TFA, DCM
2) Et ₃ N, DCM
[352] To a solution
(1- (2- ((2nitrophenyl) amino) pyrimidin-4-yl) piperidin-3-yl) carbamate (0.14
Petition 870160032383, dated 06/29/2016, p. 115/159
113/148 g, 0.34 mmol) in DCM (2.0 mL) TFA (1.0 mL) was added and the mixture was stirred for 1 h. An aliquot of the reaction mixture was analyzed by LCMS, which indicated that the reaction occurred until completion. The solvents were removed and the residue was dried in a high vacuum. The crude product was used for the next step without further purification.
[353] To a solution of 4- (3-aminopiperidin-1-yl) -N- (2-nitrophenyl) pyrimidin-2-amine (0.34 mmol) in DCM (3.5 mL) at 0 ² C was added propane -1 sulfonyl chloride (0.045 ml, 0.4 ml) and triethylamine (0.12 ml, 0.85 ml) and the mixture was warmed to room temperature overnight. The crude reaction mixture was concentrated and purified by flash chromatography (07.5% MeOH / DCM) to generate the title compound (36 mg, 24% yield). MS (ES +) C ₁₈ H ₂ 4N ₆ O4S requires: 420, found: 421 [M + H] ⁺ .
[354] Synthesis of N- (1- (2 - ((2-aminophenyl) amino) pyrimidin4-yl) piperidin-3-yl) propane-1-sulfonamide

[355] N- (1- (2 - ((2-aminophenyl) amino) pyrimidin-4-yl) piperidin-3-yl) propane-1-sulfonamide was prepared using the procedure similar to COMPOUND 30. The reaction was filtered by celite to generate crude product. MS (ES +) C ₁₈ H ₂ 6N ₆ O ₂ S requires: 390, found: 391 [M + H] ⁺ .
[356] Synthesis of N— (2 - ((4— (3 - (propylsulfonamido) piperidin-1-yl) pyrimidin-2yl) amino) phenyl) acrylamide
Petition 870160032383, dated 06/29/2016, p. 116/159
114/148
[357] N- (2 - ((4- (3- (propylsulfonamide) piperidin-1-yl) pyrimidin-2-yl) amino) phenyl) acrylamide was prepared using a procedure similar to COMPOUND 30. The product was purified by preparative thin layer chromatography using 0-6% MeOH / DCM gradient to generate the title compound. MS (ES +) C21H28N6O3S requires: 444, found: 445 [M + H] ⁺ .
[358] Example 16: COMPOSITE Synthesis 52
[359] The starting material 1- (tert-butyl) -3- (2 - ((4 (diethylamino) butyl) amino) -6- (3,5-dimethoxyphenyl) pyrido [2,3d] pyrimidin-7- il) urea (PD173074) can be purchased from, for example, SelleckChem.com. in a dry vessel, acryloyl chloride (2 equiv.) and diisopropylethylamine (4.3 equiv.) are added to a solution of 1- (tert-butyl) -3- (2 - ((4 (diethylamino) butyl) amino ) -6- (3,5-dimethoxyphenyl) pyrido [2,3d] pyrimidin-7-yl) urea (1 equiv.) In anhydrous dichloromethane at 0 ° C. After stirring at room temperature for 2 hours, the reaction mixture is concentrated, diluted with DMSO and purified by reverse phase HPLC (5-95% water / acetonitrile). After concentration of the fractions, the product N- (7- (3- (tert-butyl) ureido) —6- (3,5
Petition 870160032383, dated 06/29/2016, p. 117/159
115/148 dimethoxyphenyl) pyrido [2,3-d] pyrimidin-2-yl) -N- (4 (diethylamino) butyl) acrylamide is obtained as a pale yellow foam. LCMS (M + 1) = 578.2.
Example 17: COMPOSITE 55 Synthesis [360] [361]
In a dry vessel, sulfuryl chloride (2 equiv.) Is added to a solution of 1- (tert-butyl) -3- (2 - ((4 (diethylamino) butyl) amino) -6- (3,5- dimethoxyphenyl) pyrido [2,3d] pyrimidin-7-yl) urea (1 equiv.) in anhydrous acetonitrile at 0 ° C. After stirring for 2 hours, the reaction mixture is diluted with dichloromethane and washed with saturated aqueous sodium bicarbonate solution. The crude product, 1- (tert-butyl) -3- (6- (2,6dichloro-3,5-dimethoxyphenyl) -2- ((4 (diethylamino) butyl) amino) pyrido [2,3-d] pyrimidin -7-yl) urea, is used in the next step without further purification.
[362] In a dry vessel, acryloyl chloride (2 equiv.) And diisopropylethylamine (4.3 equiv.) Are added to a solution of the product obtained above (1 equiv.) In anhydrous dichloromethane at 0 ° C. After stirring at room temperature for 2 hours, the reaction mixture is concentrated, diluted with DMSO and purified
Petition 870160032383, dated 06/29/2016, p. 118/159
116/148 by reverse phase HPLC (5-95% water / acetonitrile). After drying in a high vacuum, the product N- (7- (3- (tert-butyl) ureido) -6- (2,6dichloro-3,5-dimethoxyphenyl) pyrido [2,3-d] pyrimidin-2-yl ) -N- (4 (diethylamino) butyl) acrylamide is obtained as a yellow foam. LCMS (M + 1) = 646.3.
[363] Procedures similar to the above can be used to prepare other compounds disclosed here.
[364] ⁴ H NMR and LCMS data for Compounds 1 to 55 are summarized below.
Id ofCompound NMR MS COMPOUND1 ⁴ H NMR (400 MHz, DMSO-d6) δ 9.60 (s, 1H), 8.48 (s, 1H), 8.355 (m, 1H), 7.93 (d, J = 8.0 Hz, 1H), 6.97 (br s, 2H), 6.76 (dd, J = 16.0, 8.0 Hz, 1H), 6.58 (br s, 1H), 6.23 (d, J = 16.0 Hz, 1H), 5.655 (d, J = 12.0 Hz, 1H), 3.84 (s, 6H), 3.53 (s, 3H). 350 COMPOUND2358 COMPOUND3381 COMPOUND4382 COMPOUND5384
Petition 870160032383, dated 06/29/2016, p. 119/159
117/148
COMPOUND6 ⁴ H NMR (400 MHz, DMSO-Ú6) δ 9, 60 - 9, 38 (m, 1H), 8.79 (s, 1H), 8.51 (s, 2H), 7.69 (d, J = 8.1 Hz, 1H), 7.19 (t, J = 7.8 Hz, 1H), 7.15 - 7.06 (m, 1H), 6.67 (d, J = 2.3 Hz , 2H), 6, 60 - 6.45 (m, 2H), 6.22 (dd, J = 17.0, 2.1 Hz, 1H), 5.71 (dd, J = 10.2, 2 , 1 Hz, 1H), 3.76 (s, 6H), 2.12 (s, 3H). 415 COMPOUND7 ⁴ H NMR (400 MHz, DMSO ~ d6) δ 9.61 (s, 1H), 8.05 (d, J = 4.0 Hz, 1H), 7.96 (d, J = 8.0 Hz, 1H), 7.82 (dd, J = 8.0, 4.0 Hz, 1H), 7.05 (s, 1H), 6.79 (dd, J = 16.0. 12.0 Hz, 1H ), 6.22 (dd, J = 16.0. 4.0 Hz, 1H), 5.65 (dd, J = 12.0. 4.0 Hz, 1H), 3.98 (s, 6H) , 3.53 (s, 3H). 418 COMPOUND8420 COMPOUND9 ⁴ H NMR (400 MHz, DMSO ~ d6) δ 9.56 (s, 1H), 9.30 (s, 1H), 8.71 (s, 1H), 8.22 - 8.04 (m, 3H ), 8.03 - 7, 87 (m, 2H), 7.64 (m, 2H), 7.52 - 7.38 (m, 2H), 7.29 - 7, 08 (m, 2H), 6.48 (dd, J = 17.0, 10.2 Hz, 1H), 6.21 (dd, J = 17.0, 2.1 Hz, 1H), 5.67 (dd, J = 10, 2, 2.1 Hz, 1H), 2.18 (s, 3H). 442 COMPOUND10 ⁴ H NMR (400 MHz, DMSO-d6) δ 9.57 (s, 1H), 9.30 (br s, 2H), 8.98 (s, 1H), 8.64 (d, J = 2, 7 Hz, 1H), 7.76 (s, 1H), 7.24 (t, J = 7.8 Hz, 1H), 7.14 (d, J = 7.5 Hz, 1H), 6.96 (d, J = 2.2 Hz, 2H), 6.56 (t, J = 2.2 Hz, 1H), 6.51 (dd, J = 17.0, 10.2 Hz, 1H), 6 , 22 (dd, J = 17.0, 2.0 Hz, 1H), 5.68 (dd, J = 10.2, 2.0 Hz, 1H), 3.84 (s, 6H), 2, 18 (s, 3H). 442
Petition 870160032383, dated 06/29/2016, p. 120/159
118/148
COMPOUND11445 COMPOUND12449 COMPOUND13449 COMPOUND14452 COMPOUND15457 COMPOUND16457 COMPOUND17 NMR (400 MHz, DMSO-Ú6) δ 9.66 (s, 1H), 9.27 (s, 1H), 8.86 (s, 1H), 8.03 - 7.96(m, 1H), 7.91 (d, J = 2.0 Hz, 1H), 7.82 (s, 1H), 7.81 - 7.76 (m, 1H), 7.53 (dd, J = 19.0, 6.9 Hz, 1H), 7.41 (d, J = 7.8 Hz, 1H), 7.37 - 7.30 (m, 2H), 6.56 (dd, J = 17.0, 10.2 Hz, 1H), 6.24 (dd, J = 17.0, 1.9 Hz, 1H), 6.20 - 6.14 (m, 1H), 6.06 ( dd, J = 17.2, 2.3 Hz, 1H), 5.71 (dd, J = 10.2, 2.0 Hz, 1H), 5.59 (dd, J = 10.0, 2, 3 Hz, 1H), 2.32 (s, 3H). 457
Petition 870160032383, dated 06/29/2016, p. 121/159
119/148
COMPOUND17A NMR (400 MHz, DMSO-Ú6) δ 9.53 (d, J = 9.6 Hz, 1H), 9.25 (s, 1H), 8.71 (s, 1H), 7.89 (d, J = 2.0 Hz, 1H), 7.78 - 7.61 (m, 2H), 7.53 (s, 1H), 7.42 (dd, J = 9.0, 1.8 Hz, 1H ), 7.31 - 7.18 (m, 2H), 7.13 (d, J = 7.5 Hz, 1H), 6.49 (dd, J = 17.0, 10.2 Hz, 1H) , 6.21 (dd, J = 17.0, 2.1 Hz, 1H), 5.67 (dd, J = 10.2, 2.0 Hz, 1H), 3.90 (s, 3H), 2.19 (s, 3H). 463 COMPOUND18471 COMPOUND19472 COMPOUND20 ² H NMR (400 MHz, DMSO ~ d6) δ 9.34 (s, 1H), 8.92 (s, 1H), 8.47 (d, J = 6.8 Hz, 1H), 7.74 (s, 1H), 7.17 (d, J = 1.9 Hz, 2H), 7.10 (s, 1H), 6.98 (s, 1H), 6.82 (s, 1H), 6.74 (s, 1H), 4.69 - 4.58 (m, 2H), 3.93 (dd, J = 9.7, 6.4 Hz, 2H), 2.72 - 2.64 (m, 1H), 1 , 30 - 1.19 (m, 6H). 474 COMPOUND21480 COMPOUND22 ² H NMR (400 MHz, DMSO ~ d6) δ 9.46 (s, 1H), 9.09 (s, 1H), 8.77 (s, 1H), 7.85 (s, 1H), 7, 57 (d, J = 8.1 Hz, 2H), 7.45 (dd, J = 8.8, 7.4 Hz, 1H), 7.27 - 7.04 (m, 3H), 6.51 (s, 1H), 6.21 (d, J = 17.7 Hz, 1H), 5.68 (d, J = 10.2 Hz, 1H), 3.26 (s, 3H), 2.21 (s, 3H). 481
Petition 870160032383, dated 06/29/2016, p. 122/159
120/148
COMPOUND 483 23NMR (400 MHz, DMSO-Ú6) δ 9.47 (s, 1H), 8.93 (s, 1H), 8.54 (s, 2H), 7.71 (d, J = 8.1 Hz, 1H), 7.19 (t, J = 7.8 Hz, 1H),COMPOUND 7.09 (d, J = 7.4 Hz, 1H), 6.98 (s, 1H), 483 24 6.53 (dd, J = 17.0, 10.2 Hz, 1H), 6.22 (dd, J = 17.0, 2.1 Hz, 1H), 5.70 (dd, J = 10.2, 2.1 Hz, 1H), 3.94 (s, 6H), 2.13 (s, 3H). ² H NMR (400 MHz, DMSO-d ₆ ) δ 9.53 (s, 1H), 9.23 (s, 1H), 8.68 (s, 1H) , 7.82 - 7, 65 (m, 2H), 7.51 (s, 2H), 7.21 (m, 1H), 7, 12COMPOUND (d, J = 6.8 Hz, 1H), 7.01 (s, 1H), 6.49 509 25 (dd, J = 17.0, 10.2 Hz, 1H) , 6.28 - 6, 15 (m, 1H), 5, 68 (dd, J = 10.2 2.0 Hz, 1H), 3.97 (s, 6H), 2.19 (s, 3H). ² H NMR (400 MHz, DMSO ~ d6) δ 9.53 (s, 1H), 9.35 (s, 1H), 9.06 (s, 1H), 8.70 (s, 1H), 8.27 (d, J = 2.6 Hz, 1H), 7.78 (s, 1H),COMPOUND 7.23 (d, J = 7.9 Hz, 1H), 7.15 (s, 1H), 511 26 7.06 (s, 1H), 6.52 (dd, J = 17.0, 10.1 Hz, 1H), 6.22 (dd, J = 17.0, 2.0 Hz, 1H), 5.69 (d, J = 10.6 Hz, 1H), 3.98 (s, 6H), 2.20 (s, 3H). COMPOUND 513 27 COMPOUND 523 28
Petition 870160032383, dated 06/29/2016, p. 123/159
121/148
COMPOUND29 NMR (400 MHz, DMSO-Ú6) δ 9.28 (s, 1H), 9.20 (s, 1H), 8.87 (s, 1H), 7.80 - 7.70(m, 1H), 7.63 (d, J = 7.9 Hz, 1H), 7.54(s, 2H), 7.22 (t, J = 7.8 Hz, 1H), 7.14(d, J = 7.6 Hz, 1H), 7.01 (s, 1H), 5.63(s, 1H), 5.37 (s, 1H), 3.97 (s, 6H), 2.24 (s, 3H), 1.80 (s, 3H). 523 COMPOUND30 ¹ H-NMR (400 MHz, DMSO) δ ppm 9.59 (s, 1H), 9.29 (s, 1H), 7.80 (s, 1H), 7.59 (br. S., 4H) , 7.28 (t, 1H, J = 28 Hz), 7.01 (s, 1H), 6.94 (d, 1H, J = 8 Hz), 6.53-6.47 (m, 1H) , 6.22 (d, 1H, J = 16 Hz), 5.69 (d, 1H, J = 8 Hz), 3.97 (s, 6H), 3.72 (s, 3H). 525 COMPOUND31 ² H NMR (400 MHz, DMSO ~ d6) δ 9.75 (s, 1H), 8.72 (s, 1H), 8.51 (s, 1H), 7.76 (s, 1H), 7.73 - 7, 59 (m, 2H), 7.19 (dtd, J = 23.6, 7.5, 1.6 Hz, 2H), 6.98 (s, 1H), 6.53 (s, 1H), 6 , 48 (dd, J = 17.1, 10.1 Hz, 1H), 6.25 (dd, J = 17.0, 2.0 Hz, 1H), 5.76 5.69 (m, 1H) , 3.96 (s, 6H), 3.47 (s, 3H). 525 COMPOUND32527 COMPOUND33 ² H NMR (400 MHz, DMSO ~ d6) δ 9.52 (s, 1H), 9.20 (s, 1H), 8.79 (s, 1H), 7.75 - 7.68 (m, 1H ), 7.63 (t, J = 7.7 Hz, 1H), 7.48 (s, 2H), 7.10 (t, J = 9.0 Hz, 1H), 6.96 (s, 1H ), 6.41 (dd, J = 17.0, 10.2 Hz, 1H), 6.15 (dd, J = 17.0, 2.1 Hz, 1H), 5.63 (dd, J = 10.2, 2.1 Hz, 1H), 3.92 (s, 6H), 2.03 (m, 3H). 527
Petition 870160032383, dated 06/29/2016, p. 124/159
122/148
COMPOUND34 NMR (400 MHz, DMSO-Ú6) δ 9.53 (d, J = 27.9 Hz, 1H), 9.28 (s, 1H), 8.96 (s, 1H),7.75 (d, J = 29.9 Hz, 1H), 7.59 (d, J =1.7 Hz, 1H), 7.49 (d, J = 10.8 Hz, 1H),7.02 (s, 1H), 6.50 (s, 1H), 6.21 (dd, J =16.9, 2.1 Hz, 1H), 5.75 (s, 1H), 5.68 (dd, J = 10.2, 2.0 Hz, 1H), 3.98 (d, J = 4 , 6 Hz, 6H), 2.19 (s, 3H). 527 COMPOUND35 ² H NMR (400 MHz, DMSO-d ₆ ) δ 9.63 (s, 1H), 9.25 (s, 1H), 8.90 (s, 1H), 8.01 (dd, J = 7, 4, 2.3 Hz, 1H), 7.76 (t, J = 1.3 Hz, 1H), 7.54 (br.s, 2H), 7.41 - 7.28 (m, 2H), 7.01 (s, 1H), 6.56 (dd, J = 17.0, 10.2 Hz, 1H), 6.24 (dd, J = 17.0, 2.0 Hz, 1H), 5 , 71 (dd, J = 10.2, 2.0 Hz, 1H), 3.97 (s, 6H). 529 COMPOUND36 ² H NMR (400 MHz, DMSO ~ d6) δ 11.11 (s, 1H), 10.27 (s, 1H), 9.79 (s, 1H), 8.91 (s, 1H), 7, 93 (d, J = 11.0, 1H), 7.28 (m, 1H), 7.20 (d, J = 8.1 Hz, 1H), 7.11 (m, 2H), 6.97 (s, 1H), 6.70 (dd, J = 17.0, 10.1 Hz, 1H), 6.33 (dd, J = 16.9, 1.8 Hz, 1H), 5.85 ( dd, J = 10.3, 1.8 Hz, 1H), 4.54 (s, 2H), 3.94 (s, 6H). 531 COMPOUND37 ² H NMR (400 MHz, DMSO ~ d6) δ 9.76 (s, 1H), 9.31 (s, 1H), 9.00 (s, 1H), 7.80 (s, 1H), 7, 68 - 7.57 (m, 1H), 7.53 - 7.42 (m, 1H), 7.02 (s, 1H), 6.93 (s, 2H), 6.51 (dd, J = 17.0, 10.2 Hz, 1H), 6.31 - 6.21 (m, 1H), 5.74 (d, J = 10.2 Hz, 1H), 3.97 (s, 6H). 531 COMPOUND38538
Petition 870160032383, dated 06/29/2016, p. 125/159
123/148
COMPOUND39 NMR (400 MHz, DMSO-Ú6) δ 9.47 (s, 1H), 8.43 (d, J = 10.0 Hz, 2H), 7.70 (d, J = 12.6 Hz, 2H) , 7.22 (t, J = 7.8 Hz, 1H),7.14 (d, J = 7.6 Hz, 1H), 6.97 (s, 1H),6.46 (dd, J = 17.0, 10.2 Hz, 1H), 6.18(dd, J = 17.0, 2.1 Hz, 1H), 6.09 (s, 1H),5.65 (dd, J = 10.2, 2.1 Hz, 1H), 3.95 (s,6H), 3.39 (s, 3H), 2.20 (s, 3H). 539 COMPOUND41 ² H NMR (400 MHz, DMSO ~ d6) δ 9.57 (s, 1H), 9.15 (s, 1H), 8.74 (s, 1H), 7.74 (s, 1H), 7, 28 (d, J = 1.7 Hz, 1H), 7.20 (t, J = 7.8 Hz, 1H), 7.11 (d, J = 7.5 Hz, 1H), 7.01 ( s, 2H), 6.48 (dd, J = 17.0, 10.2 Hz, 1H), 6.21 (dd, J = 16.9, 2.0 Hz, 1H), 5.75 5, 61 (m, 1H), 3.97 (s, 6H), 3.83 (s, 3H), 2.18 (s, 3H). 539 COMPOUND43 ² H NMR (400 MHz, DMSO-d ₆ ) δ 9.44 (s, 1H), 9.05 (s, 1H), 8.74 (s, 1H), 7.74 (br.s, 2H) , 7.20 (m, 1H), 7.11 (s, 1H), 6.97 (s, 1H), 6.50 (m, 2H), 6.26 - 6.12 (m, 1H), 5.67 (d, J = 10.2 Hz, 1H), 3.94 (s, 6H), 2.19 (s, 3H), N-Methyl group is buried by peak water. 540 COMPOUND45541 COMPOUND46543 COMPOUND47 ² H NMR (400 MHz, DMSO-d6) δ 9.78 (s, 1H), 9.20 (s, 1H), 8.88 (s, 1H), 7.80 (d, J = 8.3 Hz, 1H), 7.36 - 7.23 (m, 2H), 7.15 6.95 (m, 3H), 6.54 (dd, J = 17.0, 10.2 Hz, 543
Petition 870160032383, dated 06/29/2016, p. 126/159
124/148
1H), 6.26 (dd, J = 17.0, 2.0 Hz, 1H), 5.75 (dd, J = 10.1, 2.1 Hz, 1H), 3.97 (s, 6H ), 3.85 (s, 3H).COMPOUND48 ⁴ H NMR (400 MHz, DMSO-d6) δ 9.48 (s, 1H), 8.35 (s, 1H), 7.99 (s, 1H), 7.66 (s, 1H), 7, 16 (t, J = 7.8 Hz, 1H), 7.10 - 7.06 (m, 1H), 6.99 (s, 1H), 6.53 (dd, J = 17.0, 10, 2 Hz, 1H), 6.22 (dd, J = 16.9, 2.1 Hz, 1H), 5.71 (dd, J = 10.2, 2.0 Hz, 1H), 4.48 ( s, 2H), 3.96 (s, 6H), 3.44 (s, 3H), 2.17 (s, 3H). 544 COMPOUND49 ⁴ H NMR (400 MHz, DMSO-d ₆ ) δ 9.53 (s, 1H), 9.25 (s, 1H), 8.77 (s, 1H), 7.99 (s, 1H), 7 , 75 (s, 1H), 7.52 (br.s, 2H), 7.20 (d, J = 2.5 Hz, 1H), 7.01 (s, 1H), 6.53 (dd, J = 17.0, 10.2 Hz, 1H), 6.22 (dd, J = 17.0, 2.0 Hz, 1H), 5.69 (dd, J = 10.2, 2.0 Hz , 1H), 3.97 (s, 6H). 543 COMPOUND50546 COMPOUND51 ⁴ H NMR (400 MHz, DMSO-d ₆ ) δ 9.50 (s, 1H), 9.22 (s, 1H), 8.76 (s, 1H), 8.31 (d, J = 7, 6, 1H), 7.75 (d, J = 1.4 Hz, 1H), 7.65 7.47 (m, 3H), 7.01 (s, 1H), 6.52 (dd, J = 17.0, 10.2 Hz, 1H), 6.19 (dd, J = 16.9, 2.0 Hz, 1H), 5.66 (dd, J = 10.2, 2.0 Hz, 1H ), 3.97 (s, 6H). 563 COMPOUND52 ⁴ H NMR (400 MHz, DMSO-d6) δ 9.33 (s, 1H), 8.30 (s, 1H), 8.22 (s, 1H), 6.81 (dd, J = 16.0 12.0 Hz, 1H), 6.68 (m, 3H), 6.19 (dd, J = 16.0. 4.0 Hz, 1H), 5.62 (dd, J = 12.0. 4.0 Hz, 1H), 4.12 (t, J = 8.0 Hz, 578
Petition 870160032383, dated 06/29/2016, p. 127/159
125/148
2H), 3.80 (s, 6H), 2.44 (m, 6H), 1.63 (m, 2H), 1.37-1.327 (m, 11H), 0.92 (t, J = 8 , 0 Hz, 6H).COMPOUND54 NMR (400 MHz, DMSO-d6) δ 9.98 (s, 1H),9.08 (s, 1H), 8.30 (s, 1H), 8.21 - 8.07(m, 3H), 7.93 (d, J = 10.7 Hz, 2H), 7.67(m, 4H), 6.50 (dd, J = 16.9, 10.2 Hz, 1H),6, 33 - 6.25 (m, 1H), 5, 83 - 5.76 (m, 1H),3.78 (m, 2H), 3.59 (m, 4H), 3.43 (m, 4H),2.92 (d, J = 11.4 Hz, 2H), 2.30 (s, 3H),2.23 (s, 2H), 2.14 (s, 3H), 1.79 (m, 2H),1.69 - 1.54 (m, 2H). 623 COMPOUND55 NMR (400 MHz, DMSO-d6) δ 9.32 (s, 1H),8.24 (m, 3H), 7.07 (s, 1H), 6.86 (dd, J =16.0. 12.0 Hz, 1H), 6.18 (dd, J = 16.0. 4.0 Hz, 1H), 5.62 (dd, J = 12.0. 4.0 Hz,1H), 4.14 (t, J = 8.0 Hz, 2H), 3.98 (s,6H), 2.43 (m, 6H), 1.63 (m, 2H), 1.40-1.30(m, 11H), 0.90 (t, J = 8.0 Hz, 6H). 64 6
Compound Selectivity [365] The selectivity score is an unbiased measure that allows quantitative comparison between compounds and detailed differentiation and analysis of interaction patterns. A measure of selectivity is calculated using the percentage of control values from a kinase assay panel. Scores from primary surveys (performed in a single concentration) are reported as a percentage of the DMSO control (POC) and are calculated as follows:
Test compound signal - positive control signal x 100
Negative control signal ~ positive control signal
Petition 870160032383, dated 06/29/2016, p. 128/159
126/148 [366] where the negative control is a solvent like DMSO (100% control), and the positive control is a control compound known to bind with high affinity (control 0%).
[367] The selectivity score (S) for each screened compound can be calculated by dividing the number of kinases with a POC below a chosen value, for example, 10, 20, or 35, when screened at a given concentration, for example , 1 μΜ, 3 μΜ, 5 μΜ, or 10 μΜ, by the total number of distinct kinases tested (excluding mutant variants). For example, a selectivity score (S) can be calculated by dividing the number of kinases with a POC less than 10 when displayed in 3 μΜ by the total number of different tested kinases (excluding mutant variants); such a score would be shown as [S (10) at 3 μΜ]. The selectivity of COMPOUND 9 compounds; Compound 9; COMPOUND 11; COMPOUND 15; Compound 16; COMPOUND 20; COMPOUND 21; Compound 23; COMPOUND 24; COMPOUND 25; COMPOUND 26; COMPOUND 27; COMPOUND 30; Compound 32; COMPOUND 35; COMPOUND 60; COMPOUND 38; COMPOUND 39; COMPOUND 41; COMPOUND 45; COMPOUND 48; COMPOUND 50; COMPOUND 52; COMPOUND 54; COMPOUND 55 has been determined; all had selectivity scores [S (10) @ 3 μΜ] of 0.030 or lower.
[368] Compound 9; COMPOUND 11; COMPOUND 15; COMPOUND 16; COMPOUND 20; COMPOUND 21; Compound 23; COMPOUND 24; COMPOUND 25; COMPOUND 26; COMPOUND 32; COMPOUND 35; COMPOUND 60; COMPOUND 38; COMPOUND 39; COMPOUND 45; COMPOUND 48; COMPOUND 50; COMPOSITE 52 all had selectivity scores [S (10) @ 3 μΜ] of 0.010 or lower.
Biochemical activity assessment [369] In order to assess the activity of chemical compounds against the relevant kinase of interest, the Caliper Life Sciences electrophoretic mobility diversion technology platform is used. Fluorescent labeled substrate peptide is incubated in the presence of dosed levels of
Petition 870160032383, dated 06/29/2016, p. 129/159
127/148 compounds, a joint concentration of kinase and ATP, so that a reflective proportion of the peptide is phosphorylated. At the end of the reaction, the mixture of phosphorylated (product) and non-phosphorylated (substrate) peptides is passed through the Caliper LabChip® EZ reader II microfluidic system, under a potential difference applied. The presence of the phosphate group in the product peptide provides a difference in mass and charge between the product and the substrate peptide peptide, resulting in the separation of the substrate products and pools in the sample. As the pools pass the LEDs inside the instrument, these pools are detected and resolved as separate peaks. The relationship between these peaks reflects, therefore, the activity of the object chemical that the concentration as such, under these conditions.
[370] FGFR-1 wild-type in the Km assay: In each well of a 384-well plate, 0.1 ng / ul wild-type FGFR-1 (Carna Biosciences, Inc.) was incubated in a total of 12.5 µl of buffer (100 mM HEPES pH 7.5, 0.015% Brij 35, 10 mM MgCl ₂ , ImM DTT) with 1 µM CSKtide (5-FAM-KKKKEEIYFFFG-NH ₂ ) and 400 µM ATP at 25 ° C for 90 minutes in the presence or absence of a series of dosed concentrations of compound (1% final DMSO concentration). The reaction was stopped by adding 70 µl of stop buffer (100 mM HEPES pH 7.5, 0.015% Brij 35, EDTA 35 mM and 0.2% Coating Reagent 3 (Caliper Lifesciences)). The plate was then read on a Caliper EZ Reader 2 (protocol settings: -1.9 psi, upstream voltage -700, downstream voltage -3000, sip 35s post sample).
[371] FGFR-4 wild type assay at Km: In each well of a 384-well plate, 0.5 ng / ul wild-type FGFR-4 (Carna Biosciences, Inc.) was incubated for a total of 12, 5 µl of buffer (100 mM HEPES pH 7.5, 0.015% Brij 35, 10 mM MgCl ₂ , ImM DTT) with 1 µM CSKtide (5-FAM-KKKKEEIYFFFG-NH ₂ ) and 400 µM ATP at 25 ° C for 90 minutes in the presence or absence of a series of metered concentration of compound (1% final DMSO concentration). The reaction was stopped by adding 70 ui of
Petition 870160032383, dated 06/29/2016, p. 130/159
128/148 stop buffer (100 mM HEPES pH 7.5, 0.015% Brij 35, EDTA 35 mM and 0.2% Coating Reagent 3 (Caliper Lifesciences)). The plate was then read on a Caliper LabChip® EZ reader II (protocol definitions: -1.9 psi, upstream voltage
-700, downstream voltage -3000, sip 35s post-sample).
IDCompound StructureFGFR4ICso FGFR1 IC ₅₀ FGFR1 / FGFR4 ratio COMPOUND1 Ç D Ç COMPOUND2 ... · - '-% ^ ···· χ · ί ·' · i ç D D COMPOUND3 B D THE
Petition 870160032383, dated 06/29/2016, p. 131/159
129/148
COMPOUND4 TJH''0 ç D B COMPOUND5 II ^N ^ ^N 0 B D THE COMPOUND6 0 Vi / 7 -. = N y - A ° / - Ά “™ - 2 f '---- N---O Ç D THE COMPOUND7 1 XX cr ηρ ΧΊ ΓΊ ^Ν <5 _ί; ^ _χ χ ^Ν ο THE D THE
Petition 870160032383, dated 06/29/2016, p. 132/159
130/148
COMPOUND8 1 XX cr ηρ x: i X ^N 0 THE Ç AND COMPOUND9 Ό Ç D D COMPOUND10 1 Οχ / Υ ^ / Οχ ^ XX ζΧ 11 ^hn JL Xj hi t Λ D D AND COMPOUND11 0 ^ = 5 ^ = 01.ZS. .NH^ • rr T-r ^Η Ç D B
Petition 870160032383, dated 06/29/2016, p. 133/159
131/148
COMPOUND12 1II/ b / Ns.í 1N ^ Nο THE B D COMPOUND13 H / = Z ---- G />I M. //IZx / O---- / B D D COMPOUND14 1XXXcr ητ- x; iUN ^ n B Ç F COMPOUND15 XXXxb / Νχí JHN.XJHN ^Λ B D B
Petition 870160032383, dated 06/29/2016, p. 134/159
132/148
COMPOUND16 1 χτ II ^N ^ ^N HN. Y j Hhr à ç D D COMPOUND17 Õ ZI rk2nd B D B COMPOUND17A XX cr XX Uk Yi ^NN HN. -X Yj HIT - Λ B D AND COMPOUND18 ι ° TCj.HN,YjHN ^Λ B D B
Petition 870160032383, dated 06/29/2016, p. 135/159
133/148
COMPOUND19 ' OK H/ B D B COMPOUND20 y-HN/ //O- //H H-- B D AND COMPOUND21 Q-rONH Ij(! /λ ° / ----- NHHN Ç D B COMPOUND22 zz) = ^{H λ Hv} v> ° - B D B COMPOUND23 όόζΐ.The όII Ç D THE COMPOUND24 ----- The Cl B D B
Petition 870160032383, dated 06/29/2016, p. 136/159
134/148
COMPOUND25 CI ^X χΎ A HN HN ^X Cl1Ú THE Ç ANDL CI ^X SHAH COMPOUND0 | Ç D D 25A The llHN JL JlrO___ CI ^{X X} CI COMPOUNDHi l THE Ç THE 26 HN. Γ 11HN ^X 1 JLí ¹ % L Cl '' * 1 J 'Cl COMPOUNDui THE B Ç 27 FHN. r 11HN '*I L %
Petition 870160032383, dated 06/29/2016, p. 137/159
135/148
COMPOUND28 1ΤΪCl * ^> 31ULHN 1XXHN—Λ B D B COMPOUND29 I χχχ Cl ^ ^ * ^CI UL ΎΧ ^hn Xj HhT Ç Ç D COMPOUND30 1 ^ ° XXCl ^ * CIXito Λ THE Ç AND
Petition 870160032383, dated 06/29/2016, p. 138/159
136/148
COMPOUND31 1 TT ίΎ ^χ M'S. hn. Xj HIT 1 THE B B COMPOUND32 TT Cl * ^ Ί3Ι Ml ^hn XX HtsF 1 THE D Ç COMPOUND33 1 χχχ cr τ: ι Uk III N ^N HN .___ J. p Tj HN ^ Λ B D F
Petition 870160032383, dated 06/29/2016, p. 139/159
137/148
COMPOUND34 1 ^cr UL HN _X HN í ¹ '‘ClX) THE Ç D0 _Z O cr ^V CI COMPOUNDUL 1 THE Ç D 35 ClHN. llHN * 'I L % 1 ll ~ Ίcr 11 '-'Cl COMPOUNDTHE II Ç D B 36 FΗΝ _χ | lHN ' V 1 1crοι COMPOUNDUL ll THE Ç Ç 37 FHN. 'Ίτ IIHN ^X L 1]í ¹
Petition 870160032383, dated 06/29/2016, p. 140/159
138/148
COMPOUND38 Λ / Αχ. J ll o / T ^ f z ^N - 'N / 1 r—' ^{NH F} NH Jj / li 7— ^nh ç D AND COMPOUND39 1 YX ° ^N HN .___ Tj HN Λ · THE D AND COMPOUND40 1 ^o '' x _v x ' ^{z :: 5;} ^^ 11 ^ ^NH f Y TIH Λ Ç D THE COMPOUND41 1 XX cr ^ ci XX ⁰ Ifl te A THE Ç THE
Petition 870160032383, dated 06/29/2016, p. 141/159
139/148
COMPOUND42 1 XX / U ° ^X il ^N ^ ^N HN. Xs. Tj HhT Λ THE B F COMPOUND43 XX Γ T ^hn Tj Hhr ^ x ^ Ã THE Ç THE COMPOUND44 1 ° x _s ^ X '' ^^^ X ° ' XX rVv7- .X ^^^, x ^N ° (Y ^N HN. Xj ΗΝΓ A Ç D AND COMPOUND45 1 ° ΧΎ ° ^ Cl ^^ jí ^ ⁰¹ χΧ '^^ χΧ' ^Ν '. í τ ^Νχ Χ ^^ ^Ν HN. Tj Λ THE D AND
Petition 870160032383, dated 06/29/2016, p. 142/159
140/148
COMPOUND46 1 ΎΎ ^í JUN. J.TjΗΓ-ΓΛ THE Ç AND COMPOUND47 χχ ^cr xiiXxXQJLTjHrrΛ THE B B COMPOUND48 ιXX ci * ^ tji p.HN. JLTjΗΓ-ΓΛ THE Ç AND COMPOUND49 xc ^N '^ /' ^N HN. JL XX HLT Ύ1Ι A B D THE
Petition 870160032383, dated 06/29/2016, p. 143/159
141/148
COMPOUND4 9A 1 XX cr ηρ τ: ι Uk ^HN Tj ΗΙ Γ 1 o ^ = s ^ = o B Ç AND COMPOUND50 VJTj Ç D B COMPOUND51 XX ^ UL τΊ f N <s. ___. N 1 HN ^ ^ 0 ^HN vO B D F COMPOUND52 l. N. -N .___ XXX cuCX Xj XXi L ^HN 'X _s ^ ^{í í í:} · ^{0 ls} χ- ^ ⁰ THE B Ç
Petition 870160032383, dated 06/29/2016, p. 144/159
142/148
COMPOUND53 1 Tx Tj Sv A ⁰ THE Ç Ç COMPOUND54 ç%XY0 B D B COMPOUND55 V .N ___ ___ N .___ kxjj u YYi ϊ U HN. .O < ^x c THE B THE
[372] In the table above, for FGFR1 and FGFR4: A means that the IC50 is less than 10 nM; B means that IC50 is greater than or equal to 10 and less than 100 nM; C means that the IC50 is greater than or equal to 100 and less than 1000 nM; D means that the IC50 is greater than 1000 nM.
[373] For the relationship: F means that the ratio of [IC50 to FGFR1] / [ICso to FGFR4] is less than 10; And it means that the ratio is ã 10 and <50; D, means that the ratio is> 50 and <100; C means that the ratio is ã 100 and <200; B means that the ratio is> 200 and <500; A means that the ratio is> 500; The higher the ratio, the more selective the compound is for FGFR4 vs FGFR1.
Cell Potency [374] Dose response in MDA-MB-453 cells, which harbor an FGFR4 activation mutation, was measured as follows. Briefly, MDA-MB-453 cells were seeded at 2.5 x 10 ⁶ cells / well, and fasted overnight. The compounds
Petition 870160032383, dated 06/29/2016, p. 145/159
143/148 were added in various concentrations (3000, 1000, 300, 100, and 30 nM) over 1 hour. The samples were collected and lysed by immunoblot analysis. Erk's phosphorylation was measured and the mean pErk value of three replicates was plotted with three dose-response (inhibition) parameters on an adjustment curve using the GraphPad Prism software, which was used to determine the IC50 values. The data are shown in the table below.
IdCompound of Wattage COMPOUND 18 Ç COMPOUND 20 D COMPOUND 25 B COMPOUND 26 B COMPOUND 27 B COMPOUND 31 THE COMPOUND 33 B COMPOUND 34 B COMPOUND 60 B COMPOUND 61 B COMPOUND 38 Ç COMPOUND 39 THE COMPOUND 41 B COMPOUND 43 THE COMPOUND 45 THE
Petition 870160032383, dated 06/29/2016, p. 146/159
144/148
COMPOUND 46 THE COMPOUND 53 B
[375] At Table, A means that IC50 is < : 1 nM; B means that ICso is h 1 e <10 nM; C means that 0 value IC50 is > 10 and <[376] 100 nM; D means that IC50 úThese data indicate that 100 nM.inhibition in FGFR-4 per
these compounds result in the blocking of oncogenic signaling downstream.
Apoptosis induction with a FGFR4 inhibitor [377] Hep3B cells were seeded at 20K / well in 96-well white plates in 200 µl DMEM / 5% FBS overnight. The next day's compound was added to a final concentration of 0.1% DMSO and incubated for 6 hours. Caspase activity was measured according to the manufacturing instruction (Caspase-Glo3 / 7 Assay (Promega)). Briefly, 100 µl of Caspase-Glo3 / 7 reagent was added to each well and incubated for 1 hour in the dark. Luminescence was measured using Envision. The average caspase activity of two replicates was represented with three dose-response (inhibition) parameters on an adjustment curve using the GraphPad Prism software, which was used to determine the IC50 values. As shown in Fig. 3, treatment in Hep3B cells with COMPOUND 25 for 6 hours leads to the induction of potent apoptosis. BGJ398, a pan-FGFR inhibitor, also results in the induction of apoptosis, albeit at a higher concentration.
Covalence [378] The evidence that COMPOUND 52 covalently binds to FGFR-4 is shown by the mass spectrometry data shown in Fig. 1. In 60 µl of buffer, 300 µM of Compound 1 was incubated with 50 µg ( 75 µM) recombinant GST-labeled wild-type FGFR-4 (Carna Biosciences) for 3 hours at room temperature and subsequently at
Petition 870160032383, dated 06/29/2016, p. 147/159
145/148
4 ° C for 13 hours. The protein-inhibitor complex was then desalted using Pierce (Pierce) Thermo detergent removal columns. The unmodified protein and protein-inhibitor complexes were analyzed by electron spray mass spectrometry to determine their respective molecular weights. Fig. 1a shows the mass of the unmodified protein. As shown, the relevant main peak has a mass of 65,468,371 daltons. Fig. 1b shows the mass of the protein-inhibitor complex. As shown in this, the relevant main peak had a mass of 66043,5123 daltons. The difference between these masses is 575.1252, which is within the accuracy of the Compound 1 mass instrument, 577.34 daltons.
[379] The masses of the FGFR4 and COMPOUND 11 COMPOUND 20, and COMPOUND 54 protein-inhibitor complexes are shown in Fig. 2. CR9 is the peak of FGFR4 protein. As shown by peak CR3, the complex showed a +441 offset when the MW of the compound (COMPOUND 11) was 444.6 da (within the precision of an instrument). In another example, the complex showed a +470 offset from (peak CR2), when the MW of the compound (COMPOUND 20) was 473.4. In yet another example, the complex showed a +631 offset from (peak CRI) when the MW of the compound (COMPOUND 54) was 622.7.
[380] This demonstrates that compounds from a wide variety of structures are all capable of forming covalent complexes with FGFR4.
Binding to Cys552 [381] The crystal structure of COMPOSITE 52 bound to FGFR-4 is shown in Fig. 4. As shown in this, COMPOSITE 52 binds to the cysteine residue 552 of FGFR-4.
[382] The crystal structure of COMPOSITE 25 bound to FGFR-4 is shown in Fig. 5. As shown in this, COMPOSITE 25 also binds to the cysteine residue 552 of FGFR-4.
In vivo efficacy data [383] The effects of COMPOUND 25, BGJ398 (an inhibitor of
Petition 870160032383, dated 06/29/2016, p. 148/159
146/148 pan-FGFR) and sorafenib in inhibiting tumor growth in a subcutaneous xenograft model of liver cancer Hep3B cells with different dosages were studied.
[384] Six nude female mice (Mus musculus), aged 6 to 8 weeks, were used. Tumor cell culture and inoculation: Hep3B cells were cultured with EMEM medium (Invitrogen, USA) supplemented with 10% FBS (Gibco, Australia). The cells were harvested at 90% confluence, and viability was no less than 90%. The mice were implanted subcutaneously (sc) with 200 pL of 10 χ 10 ⁶ Hep3B cells in 50% Matrigel on the right flank, at the beginning of the study.
[385] Animal grouping and dosing schedule: Ten days after cell implantation, when the tumors reached an average volume of 199 mm ³ , 45 mice were selected based on the volume of the tumor and randomly divided into 5 treatment groups (n = 9). The day of randomization was indicated as D _o and treatment was started from then on.
[386] Tumor volume and body weight measurements: tumor size was measured twice a week in two dimensions, using a caliper, and the volume was expressed in mm ³ , using the formula: V = 0.5 axb ² where a and b are the long and short diameters of the tumor, respectively. Body weight was measured at least twice a week.
[387] End of portion in vivo: blood, tumors and livers were collected from three mice in each group treated at 4, 12 and 24 hours after the last dose. The left lobe of the liver was collected for pharmacodynamic studies (PD), and the rest of the liver was stored in formalin for histology. Small tumors were prioritized for use in pharmacokinetic studies. Any remaining tumor was fixed for histological analysis first, and then was quickly frozen for the PD study.
[388] Tumor volumes from nude mice
Petition 870160032383, dated 06/29/2016, p. 149/159
147/148 carriers of Hep3B: Fig. 5 is a line graph representing the growth inhibition of groups treated with COMPOUND 25 (100 mg / kg PO BID), treated with COMPOUND 25 (300 mg / kg PO BID), treated with BGJ398 (20 mg / kg QD PO), and treated with sorafenib (30 mg / kg QD PO) against Hep3B xenograft tumors in nude mice. A statistically significant reduction in tumor volumes was seen in COMPOUND 25 (100 mg / kg PO BID), COMPOUND 25 (300 mg / kg PO, BID) and sorafenib (30 mg / kg QD PO) for efficacy groups when compared with the vehicle group, starting from day 4 after the first administration of the compounds and persisted until the end (Day 19). However, a significant difference in tumor volume between BGJ398 (20 mg / kg QD PO) and vehicle groups was not observed throughout the study. Increasing the dose of COMPOUND 25 from 100 mg / kg to 300 mg / kg increased the efficiency of tumor inhibition. Tumors in both groups treated with COMPOUND 25 (100 mg / kg BID PO) and treated with COMPOUND 25 (300 mg / kg PO BID) regressed, and tumors in the group treated with COMPOUND 25 (300 mg BID / kg PO ) almost disappeared. In this study, the groups treated with COMPOUND 25 (100 mg / kg, PO, BID) and COMPOUND 25 (300 mg / kg PO, BID) showed superiority in inhibiting tumor growth.
[389] Body weight change (%) of nude mice containing Hep3B: Fig. 7 is a line graph that represents the change in body weight (%) throughout the study period. All mice, except mice in the COMPOSITE 25 treated groups, showed significant loss of body weight. The body weight of the mice in the vehicle group decreased by about 10% on day 10 for the tumor load. This result indicated that COMPOSITE 25 was well tolerated in the current dosages and dosing regimen in nude mice, and that COMPOSITE 25 could alleviate body weight loss by inhibiting tumor growth.
[390] Mice treated with COMPOUND 25 (100
Petition 870160032383, dated 06/29/2016, p. 150/159
148/148 mg / kg PO BID), COMPOUND 25 (300 mg / kg PO BID) and sorafenib (30 mg / kg QD PO) showed a significant reduction in tumor volume, compared to the vehicle group, throughout the study. Increasing the dose of COMPOUND 25 from 100 mg / kg to 300 mg / kg increased the efficiency of tumor inhibition. The tumors of mice, both in the groups treated with COMPOUND 25 (100 mg / kg, PO, BID) and treated with COMPOUND 25 (300 mg / kg PO BID) regressed, and tumors in the group treated with COMPOUND 25 (300 mg / kg). kg PO BID) almost disappeared. All mice, except for those in the COMPOUND 25 treated groups, lost a significant amount of body weight. The body weight of the mice in the vehicle group decreased by about 10% on day 10 for the tumor load. These results indicated that COMPOSITE 25 was well tolerated at current dosages and in the administration schedule in nude mice, and that COMPOSITE 25 could alleviate body weight loss by inhibiting tumor growth.
Incorporation by Reference [391] All publications and patents mentioned herein are incorporated by reference in their entirety, as if each individual publication or patent were specifically and individually indicated to be incorporated by reference.
Equivalents [392] Those skilled in the art will recognize, or be able to determine using, no more than routine experimentation, many equivalencies to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

权利要求:
Claims (18)
[1]
1. Compound, characterized by the fact that it has Formula I, or a pharmaceutically acceptable salt thereof:
Warhead

[2]
2/5

[3]
Compound according to claim 1 or 2, characterized by the fact that A is aryl or heteroaryl.
[4]
4. A compound according to claim 3, characterized in that A is selected from phenyl, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, pyrazole, pyridine, pyrazine, pyridazine and pyrimidine.
[5]
Compound according to claim 1 or 2, characterized by the fact that A is heterocyclic.
[6]
6. A compound according to claim 5, characterized by the fact that A is selected from pyrrolidine, piperidine, piperazine and morpholine.
[7]
7. Compound according to claim 1 or 2, characterized by the fact that A is alicyclic.
Petition 870160032383, dated 06/29/2016, p. 153/159
3/5
[8]
A compound according to any one of claims 1 to 7, characterized in that each R is, independently, halo or methoxy.
[9]
Compound according to claim 8, characterized by the fact that two R ² are chlorine and two R ² are methoxy.
[10]
Compound according to any one of claims 1 to 9, characterized in that X is N and Y is CH.
[11]
11. Compound, characterized by the fact that it is selected from the group consisting of:

[12]
12. Pharmaceutical composition, characterized in that it comprises a pharmaceutically acceptable carrier and a compound as defined in any one of claims 1 to 11.
[13]
Pharmaceutical compound or composition according to any one of claims 1 to 12, characterized in that it is for use in the treatment of a condition mediated by FGFR-4.
[14]
Pharmaceutical compound or composition according to any one of claims 1 to 12, characterized in that it is for use in the treatment of a condition defined by FGFR-4 overexpression.
[15]
15. Pharmaceutical compound or composition according to any one of claims 1 to 12, characterized by the fact that it is for use in the treatment of a selected disease of hepatocellular carcinoma, breast cancer,
Petition 870160032383, dated 06/29/2016, p. 155/159
5/5 ovarian cancer, lung cancer, liver cancer, sarcoma and hyperlipidemia.
[16]
16. Use of a compound as defined in any of claims 1 to 11, characterized in that it is in the preparation of a pharmaceutical composition for treating a condition mediated by FGFR-4.
[17]
17. Use of a compound as defined in any one of claims 1 to 11, characterized in that it is in the preparation of a pharmaceutical composition for treating a condition defined by FGFR-4 overexpression.
[18]
18. Use of a compound as defined in any of claims 1 to 11, characterized in that it is in the preparation of a pharmaceutical composition for the treatment of a selected disease of hepatocellular carcinoma, breast cancer, ovarian cancer, lung cancer, liver cancer, sarcoma and hyperlipidemia.

类似技术:

---

公开号 | 公开日 | 专利标题

---

AU2017272281B2|2019-07-04|Inhibitors Of The Fibroblast Growth Factor Receptor

---

US20140187559A1|2014-07-03|Inhibitors of the fibroblast growth factor receptor

---

KR101466412B1|2014-11-28|Pyrrolopyrimidine compounds and their uses

---

JP5188988B2|2013-04-24|Benzazole derivatives, compositions, and methods of use as Aurora kinase inhibitors

---

CN102816162B|2016-04-27|Pyrimido-pyrimidine ketone compounds and medicinal compositions thereof and application

---

AU2014339972A1|2016-04-07|Inhibitors of the fibroblast growth factor receptor

---

BR112021004774A2|2021-08-03|triazole-pyrimidine compounds and their uses

---

AU2016248056B2|2020-07-23|Crystalline FGFR4 inhibitor compound and uses thereof

---

AU2017295628A1|2019-02-21|Heterocyclic compound used as FGFR inhibitor

---

JP2022516882A|2022-03-03|MAT2A aza complex bicyclic inhibitor and its use for the treatment of cancer

---

JP2017510595A|2017-04-13| pyrimido [4,5-e] indolizine

---

Ran et al.2021|Design, synthesis and biological evaluations of a series of Pyrido [1, 2-a] pyrimidinone derivatives as novel selective FGFR inhibitors

---

JP2020531487A|2020-11-05|Azaindolylpyridone and diazaindrillpyridone compounds

---

CA3054343A1|2018-08-30|5-|-2-|nicotinonitrile compounds as ikke, tbk1 and/or sik2 kinases inhibitors

同族专利:

---

公开号 | 公开日

---

RS62233B1|2021-09-30|

---

CA2878412A1|2014-01-16|

---

AU2017272281B2|2019-07-04|

---

PL2872491T3|2021-12-13|

---

CN104540809B|2018-12-11|

---

PT2872491T|2021-08-05|

---

EP2872491B1|2021-05-05|

---

JP2015523383A|2015-08-13|

---

US20150210694A1|2015-07-30|

---

US10196436B2|2019-02-05|

---

SI2872491T1|2021-11-30|

---

EP2872491A2|2015-05-20|

---

US20140088100A1|2014-03-27|

---

US20190359682A1|2019-11-28|

---

NZ703495A|2018-02-23|

---

DK2872491T3|2021-08-09|

---

KR20200117067A|2020-10-13|

---

US9340514B2|2016-05-17|

---

LT2872491T|2021-08-25|

---

US20140378481A1|2014-12-25|

---

IL236611A|2017-02-28|

---

CN109627239A|2019-04-16|

---

MX369472B|2019-11-08|

---

RU2679130C2|2019-02-06|

---

AU2017272281A1|2018-01-04|

---

RU2015104342A|2016-08-27|

---

HUE055502T2|2021-11-29|

---

ZA201500215B|2017-11-29|

---

MX2015000405A|2015-07-14|

---

WO2014011900A3|2014-02-27|

---

RU2019102203A|2019-03-05|

---

CN109627239B|2021-10-12|

---

HRP20211218T1|2021-10-29|

---

US20180362613A1|2018-12-20|

---

HK1206023A1|2015-12-31|

---

KR102163776B1|2020-10-12|

---

US8802697B2|2014-08-12|

---

CN104540809A|2015-04-22|

---

US20170066812A1|2017-03-09|

---

AU2013290074A1|2015-01-29|

---

KR20150029030A|2015-03-17|

---

IL236611D0|2015-02-26|

---

WO2014011900A2|2014-01-16|

---

JP6104377B2|2017-03-29|

---

SG11201500125QA|2015-02-27|

---

US9126951B2|2015-09-08|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US173074A|1876-02-01|Improvement in flour and meal bolts |

---

AT190978T|1994-11-14|2000-04-15|Warner Lambert Co|6-ARYL-PYRIDO PYRIMIDINE AND -NAPHTHYRIDINE FOR INHIBITING CELL REPRODUCTION Caused By PROTEIN-TYROSINE KINASE|

---

IL117923A|1995-05-03|2000-06-01|Warner Lambert Co|Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds|

---

GB9708917D0|1997-05-01|1997-06-25|Pfizer Ltd|Compounds useful in therapy|

---

ID27589A|1998-05-26|2001-04-12|Warner Lambert Comapny|BICYCLIC PYYRIMINE AND DIHYDROPIRYMIDINE BICYCLIC 3,4 AS A RESULTS OF MOBILE PROLIFERATION|

---

US6403799B1|1999-10-21|2002-06-11|Agouron Pharmaceuticals, Inc.|Methods for the preparation of intermediates in the synthesis of HIV-protease inhibitors|

---

MXPA02003950A|1999-10-21|2002-10-23|Hoffmann La Roche|Heteroalkylamino substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase.|

---

AU1462101A|1999-11-22|2001-06-04|Warner-Lambert Company|Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes|

---

AU4540101A|2000-03-01|2001-09-12|Tularik Inc|Hydrazones and analogs as cholesterol lowering agents|

---

AP1333A|2000-08-04|2004-11-28|Warner Lambert Co|2- amino-6-dialkoxyphenyl-pyrido [2,3-d] pyrimidin-7-ones.|

---

WO2002076985A1|2001-03-23|2002-10-03|Smithkline Beecham Corporation|Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases|

---

RS51044B|2002-01-22|2010-10-31|Warner-Lambert Company Llc.|2--pyrido/2,3d/pyrimidin-7-ones|

---

WO2004063195A1|2003-01-03|2004-07-29|Sloan-Kettering Institute For Cancer Research|Pyridopyrimidine kinase inhibitors|

---

US20050124562A1|2003-09-23|2005-06-09|Joseph Guiles|Bis-quinazoline compounds for the treatment of bacterial infections|

---

US20070054916A1|2004-10-01|2007-03-08|Amgen Inc.|Aryl nitrogen-containing bicyclic compounds and methods of use|

---

JP5079500B2|2005-04-28|2012-11-21|協和発酵キリン株式会社|2-Aminoquinazoline derivatives|

---

PL2049502T3|2006-07-28|2012-06-29|Novartis Ag|2,4-substituted quinazolines as lipid kinase inhibitors|

---

MX2009006627A|2006-12-22|2009-08-12|Novartis Ag|Quinazolines for pdk1 inhibition.|

---

CN101679408B|2006-12-22|2016-04-27|Astex治疗学有限公司|As the bicyclic heterocycles of FGFR inhibitor|

---

GB2467670B|2007-10-04|2012-08-01|Intellikine Inc|Chemical entities and therapeutic uses thereof|

---

CA2727455C|2008-06-27|2019-02-12|Avila Therapeutics, Inc.|Heteroaryl compounds and uses thereof|

---

CA2738034A1|2008-09-03|2010-03-11|Licentia Ltd.|Materials and methods for inhibiting cancer cell invasion related to fgfr4|

---

US20100185419A1|2008-09-05|2010-07-22|Avila Therapeutics, Inc.|Algorithm for designing irreversible inhibitors|

---

BRPI0924067A2|2008-12-29|2016-01-26|Fovea Pharmaceuticals|substituted quinazoline compounds|

---

AR084370A1|2009-08-07|2013-05-15|Chugai Pharmaceutical Co Ltd|AMINOPIRAZOL DERIVATIVES|

---

BR112012005962A2|2009-09-16|2017-02-21|Avila Therapeutics Inc|protein kinase conjugates and inhibitors|

---

UY33227A|2010-02-19|2011-09-30|Novartis Ag|PIRROLOPIRIMIDINE COMPOUNDS AS INHIBITORS OF THE CDK4 / 6|

---

GB201007286D0|2010-04-30|2010-06-16|Astex Therapeutics Ltd|New compounds|

---

JP6042871B2|2011-04-21|2016-12-14|アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．|Regulation of hepatitis B virus expression|

---

US9580427B2|2011-05-17|2017-02-28|The Regents Of The University Of California|Kinase inhibitors|

---

FR2985257B1|2011-12-28|2014-02-14|Sanofi Sa|FGFS RECEPTOR AGONISTIC DIMERS , PREPARATION METHOD AND THERAPEUTIC USE THEREOF|

---

EP2657233B1|2012-01-19|2014-08-27|Taiho Pharmaceutical Co., Ltd.|3,5-disubstituted alkynylbenzene compound and salt thereof|

---

GB201209609D0|2012-05-30|2012-07-11|Astex Therapeutics Ltd|New compounds|

---

TWI629266B|2012-12-28|2018-07-11|藍印藥品公司|Inhibitors of the fibroblast growth factor receptor|

---

CN109627239B|2012-07-11|2021-10-12|缆图药品公司|Inhibitors of fibroblast growth factor receptors|

---

US9388185B2|2012-08-10|2016-07-12|Incyte Holdings Corporation|Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors|

---

WO2014044846A1|2012-09-24|2014-03-27|Evotec Ltd.|3--7-isoquinoline derivatives as fgfr inhibitors useful for the treatment of proliferative disorders or dysplasia|

---

HUE040434T2|2013-02-21|2019-03-28|Pfizer|Solid forms of a selective cdk4/6 inhibitor|

---

WO2014160521A1|2013-03-15|2014-10-02|Blueprint Medicines Corporation|Piperazine derivatives and their use as kit modulators|

---

EA036160B1|2013-03-15|2020-10-08|Селджен Кар Ллс|Heteroaryl compounds and uses thereof|

---

AR095464A1|2013-03-15|2015-10-21|Celgene Avilomics Res Inc|HETEROARILO COMPOUNDS AND USES OF THE SAME|

---

US9866307B2|2013-07-14|2018-01-09|Lg Electronics Inc.|Method for transceiving data symbol using antenna correlation in wireless access system which supports massive antenna|

---

US9334263B2|2013-10-17|2016-05-10|Blueprint Medicines Corporation|Compositions useful for treating disorders related to kit|

---

DK3057969T3|2013-10-17|2018-09-24|Blueprint Medicines Corp|COMPOSITIONS USED FOR TREATMENT OF DISEASES RELATED TO ENZYMETE KIT|

---

LT3057943T|2013-10-18|2018-11-12|Eisai R&D Management Co., Ltd.|Pyrimidine fgfr4 inhibitors|

---

MX367723B|2013-10-25|2019-09-03|Novartis Ag|Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors.|

---

AU2014339972B9|2013-10-25|2019-05-30|Blueprint Medicines Corporation|Inhibitors of the fibroblast growth factor receptor|

---

WO2015108992A1|2014-01-15|2015-07-23|Blueprint Medicines Corporation|Heterobicyclic compounds and their use as fgfr4 receptor inhibitors|

---

US9688680B2|2014-08-04|2017-06-27|Blueprint Medicines Corporation|Compositions useful for treating disorders related to kit|

---

WO2016064960A1|2014-10-22|2016-04-28|Incyte Corporation|Bicyclic heterocycles as fgfr4 inhibitors|

---

US10202365B2|2015-02-06|2019-02-12|Blueprint Medicines Corporation|2--pyrimidine derivatives as RET inhibitors|

---

MA41551A|2015-02-20|2017-12-26|Incyte Corp|BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS|

---

ES2895769T3|2015-02-20|2022-02-22|Incyte Corp|Bicyclic heterocycles as FGFR inhibitors|

---

US9580423B2|2015-02-20|2017-02-28|Incyte Corporation|Bicyclic heterocycles as FGFR4 inhibitors|

---

EP3325481B1|2015-07-24|2019-06-12|Blueprint Medicines Corporation|Compounds useful for treating disorders related to kit and pdgfr|

---

MX2018002407A|2015-08-26|2018-11-29|Blueprint Medicines Corp|Compounds and compositions useful for treating disorders related to ntrk.|

---

EP3365335A1|2015-10-23|2018-08-29|Array Biopharma, Inc.|2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3-one compounds as inhibitors of fgfr tyrosine kinases|

---

MA43165A|2015-11-02|2018-09-12|Blueprint Medicines Corp|RET INHIBITORS|

---

EP3377497A1|2015-11-19|2018-09-26|Blueprint Medicines Corporation|Compounds and compositions useful for treating disorders related to ntrk|

---

TW201738228A|2016-03-17|2017-11-01|藍圖醫藥公司|Inhibitors of RET|

---

CN109311889B|2016-04-15|2021-11-16|缆图药品公司|Activin receptor-like kinase inhibitors|

---

US10227329B2|2016-07-22|2019-03-12|Blueprint Medicines Corporation|Compounds useful for treating disorders related to RET|

---

US10035789B2|2016-07-27|2018-07-31|Blueprint Medicines Corporation|Compounds useful for treating disorders related to RET|

---

US20190192522A1|2016-09-08|2019-06-27|Blueprint Medicines Corporation|Inhibitors of the fibroblast growth factor receptor 4 in combination with cyclin-dependent kinase inhibitors|AR077468A1|2009-07-09|2011-08-31|Array Biopharma Inc|PIRAZOLO COMPOUNDSPYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS|

---

WO2012088266A2|2010-12-22|2012-06-28|Incyte Corporation|Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3|

---

MX349869B|2011-07-01|2017-08-17|Ngm Biopharmaceuticals Inc|Compositions, uses and methods for treatment of metabolic disorders and diseases.|

---

JP6301321B2|2012-06-13|2018-03-28|インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ|Substituted tricyclic compounds as FGFR inhibitors|

---

CN109627239B|2012-07-11|2021-10-12|缆图药品公司|Inhibitors of fibroblast growth factor receptors|

---

US9388185B2|2012-08-10|2016-07-12|Incyte Holdings Corporation|Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors|

---

US9290557B2|2012-11-28|2016-03-22|Ngm Biopharmaceuticals, Inc.|Compositions comprising variants and fusions of FGF19 polypeptides|

---

EP2925775B1|2012-11-28|2020-09-16|NGM Biopharmaceuticals, Inc.|Compositions and methods for treatment of metabolic disorders and diseases|

---

US9266892B2|2012-12-19|2016-02-23|Incyte Holdings Corporation|Fused pyrazoles as FGFR inhibitors|

---

US9273107B2|2012-12-27|2016-03-01|Ngm Biopharmaceuticals, Inc.|Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases|

---

KR20150104579A|2012-12-27|2015-09-15|엔지엠 바이오파마슈티컬스, 아이엔씨.|Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases|

---

AR094812A1|2013-02-20|2015-08-26|Eisai R&D Man Co Ltd|DERIVED FROM MONOCYCLIC PYRIDINE AS AN FGFR INHIBITOR|

---

UY35464A|2013-03-15|2014-10-31|Araxes Pharma Llc|KRAS G12C COVALENT INHIBITORS.|

---

AR095464A1|2013-03-15|2015-10-21|Celgene Avilomics Res Inc|HETEROARILO COMPOUNDS AND USES OF THE SAME|

---

CA2907243C|2013-03-15|2021-12-28|Celgene Avilomics Research, Inc.|Substituted dihydropyrimidopyrimidinone compounds and pharmaceutical compositions thereof use fgfr4 inhibitor|

---

WO2014160521A1|2013-03-15|2014-10-02|Blueprint Medicines Corporation|Piperazine derivatives and their use as kit modulators|

---

EA036160B1|2013-03-15|2020-10-08|Селджен Кар Ллс|Heteroaryl compounds and uses thereof|

---

MY181497A|2013-04-19|2020-12-23|Incyte Holdings Corp|Bicyclic heterocycles as fgfr inhibitors|

---

WO2015006492A1|2013-07-09|2015-01-15|Dana-Farber Cancer Institute, Inc.|Kinase inhibitors for the treatment of disease|

---

JO3805B1|2013-10-10|2021-01-31|Araxes Pharma Llc|Inhibitors of kras g12c|

---

DK3057969T3|2013-10-17|2018-09-24|Blueprint Medicines Corp|COMPOSITIONS USED FOR TREATMENT OF DISEASES RELATED TO ENZYMETE KIT|

---

LT3057943T|2013-10-18|2018-11-12|Eisai R&D Management Co., Ltd.|Pyrimidine fgfr4 inhibitors|

---

AU2014339972B9|2013-10-25|2019-05-30|Blueprint Medicines Corporation|Inhibitors of the fibroblast growth factor receptor|

---

MX367723B|2013-10-25|2019-09-03|Novartis Ag|Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors.|

---

CN113769114A|2013-10-28|2021-12-10|恩格姆生物制药公司|Cancer models and related methods|

---

WO2015108992A1|2014-01-15|2015-07-23|Blueprint Medicines Corporation|Heterobicyclic compounds and their use as fgfr4 receptor inhibitors|

---

NZ722624A|2014-01-20|2017-09-29|Cleave Biosciences Inc|Fused pyrimidines as inhibitors of p97 complex|

---

CN106662577B|2014-01-24|2020-07-21|恩格姆生物制药公司|Binding proteins and methods of use thereof|

---

PT3102577T|2014-02-07|2018-10-23|Principia Biopharma Inc|Quinolone derivatives as fibroblast growth factor receptor inhibitors|

---

EP3114124A1|2014-03-03|2017-01-11|Principia Biopharma, Inc.|BENZIMIDAZOLE DERIVATIVES AS RLK and ITK INHIBITORS|

---

US10398758B2|2014-05-28|2019-09-03|Ngm Biopharmaceuticals, Inc.|Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions|

---

CA2951153A1|2014-06-16|2015-12-23|Ngm Biopharmaceuticals, Inc.|Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases|

---

CN105017227B|2014-07-08|2018-03-09|四川百利药业有限责任公司|The aminated compounds of Nquinazoline 4|

---

CA2956270A1|2014-08-18|2016-02-25|Eisai R&D Management Co., Ltd.|Salt of monocyclic pyridine derivative and crystal thereof|

---

JO3556B1|2014-09-18|2020-07-05|Araxes Pharma Llc|Combination therapies for treatment of cancer|

---

JP6585167B2|2014-10-03|2019-10-02|ノバルティス アーゲー|Use of fused bicyclic pyridyl derivatives as FGFR4 inhibitors|

---

US10851105B2|2014-10-22|2020-12-01|Incyte Corporation|Bicyclic heterocycles as FGFR4 inhibitors|

---

BR112017007816A2|2014-10-23|2017-12-19|Ngm Biopharmaceuticals Inc|pharmaceutical compositions comprising peptide variants and methods of using them|

---

WO2016073855A1|2014-11-07|2016-05-12|Ngm Biopharmaceuticals, Inc.|Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders|

---

WO2016115412A1|2015-01-18|2016-07-21|Newave Pharmaceutical Llc|Dual-warhead covalent inhibitors of fgfr-4|

---

US10202365B2|2015-02-06|2019-02-12|Blueprint Medicines Corporation|2--pyrimidine derivatives as RET inhibitors|

---

CN107613769A|2015-02-17|2018-01-19|润新生物公司|Some chemical entities, composition and method|

---

ES2895769T3|2015-02-20|2022-02-22|Incyte Corp|Bicyclic heterocycles as FGFR inhibitors|

---

MA41551A|2015-02-20|2017-12-26|Incyte Corp|BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS|

---

US9580423B2|2015-02-20|2017-02-28|Incyte Corporation|Bicyclic heterocycles as FGFR4 inhibitors|

---

US9802917B2|2015-03-25|2017-10-31|Novartis Ag|Particles of N-amino)pyridin-2-yl)-7-formyl-6-methyl)-3,4-dihydro-1,8-naphthyridine-1-carboxamide|

---

RU2017134379A|2015-03-25|2019-04-03|Новартис Аг|FORMED N-HETEROCYCLIC DERIVATIVES AS FGFR4 INHIBITORS|

---

EP3280708B1|2015-04-10|2021-09-01|Araxes Pharma LLC|Substituted quinazoline compounds and methods of use thereof|

---

KR20180003559A|2015-04-14|2018-01-09|에자이 알앤드디 매니지먼트 가부시키가이샤|Crystalline FGFR4 inhibitor compounds and uses thereof|

---

EP3283462B1|2015-04-15|2020-12-02|Araxes Pharma LLC|Fused-tricyclic inhibitors of kras and methods of use thereof|

---

US10538517B2|2015-05-22|2020-01-21|Principia Biopharma, Inc.|Quinolone derivatives as FGFR inhibitors|

---

CA2987335A1|2015-06-03|2016-12-08|David Goldstein|Tyrosine kinase inhibitors|

---

KR20180041135A|2015-07-16|2018-04-23|어레이 바이오파마 인크.|A pyrazolo [1,5-a] pyridine compound substituted as a RET kinase inhibitor|

---

US10144724B2|2015-07-22|2018-12-04|Araxes Pharma Llc|Substituted quinazoline compounds and methods of use thereof|

---

EP3325481B1|2015-07-24|2019-06-12|Blueprint Medicines Corporation|Compounds useful for treating disorders related to kit and pdgfr|

---

WO2017019957A2|2015-07-29|2017-02-02|Ngm Biopharmaceuticals, Inc.|Binding proteins and methods of use thereof|

---

AU2016304852B2|2015-08-11|2020-12-10|Principia Biopharma, Inc.|Processes for preparing an FGFR inhibitor|

---

MX2018002407A|2015-08-26|2018-11-29|Blueprint Medicines Corp|Compounds and compositions useful for treating disorders related to ntrk.|

---

EP3356353A1|2015-09-28|2018-08-08|Araxes Pharma LLC|Inhibitors of kras g12c mutant proteins|

---

US10975071B2|2015-09-28|2021-04-13|Araxes Pharma Llc|Inhibitors of KRAS G12C mutant proteins|

---

WO2017058792A1|2015-09-28|2017-04-06|Araxes Pharma Llc|Inhibitors of kras g12c mutant proteins|

---

US10875842B2|2015-09-28|2020-12-29|Araxes Pharma Llc|Inhibitors of KRAS G12C mutant proteins|

---

WO2017058805A1|2015-09-28|2017-04-06|Araxes Pharma Llc|Inhibitors of kras g12c mutant proteins|

---

WO2017058902A1|2015-09-28|2017-04-06|Araxes Pharma Llc|Inhibitors of kras g12c mutant proteins|

---

WO2017058768A1|2015-09-28|2017-04-06|Araxes Pharma Llc|Inhibitors of kras g12c mutant proteins|

---

EP3365335A1|2015-10-23|2018-08-29|Array Biopharma, Inc.|2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3-one compounds as inhibitors of fgfr tyrosine kinases|

---

RU2744852C2|2015-10-26|2021-03-16|Локсо Онколоджи, Инк.|Point mutations in trk inhibitor-resistant malignant tumors and related methods|

---

MA43165A|2015-11-02|2018-09-12|Blueprint Medicines Corp|RET INHIBITORS|

---

ES2871036T3|2015-11-09|2021-10-28|Ngm Biopharmaceuticals Inc|Method for treating bile acid-related disorders|

---

MX2018005967A|2015-11-16|2018-08-29|Araxes Pharma Llc|2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof.|

---

EP3377497A1|2015-11-19|2018-09-26|Blueprint Medicines Corporation|Compounds and compositions useful for treating disorders related to ntrk|

---

CN105669566A|2016-03-09|2016-06-15|华东师范大学|Preparation method of pharmaceutical intermediate N-arylquinazolinyl-amine compounds|

---

TW201738228A|2016-03-17|2017-11-01|藍圖醫藥公司|Inhibitors of RET|

---

TN2018000335A1|2016-04-04|2020-01-16|Loxo Oncology Inc|Liquid formulations of -n--2--pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide|

---

WO2017176744A1|2016-04-04|2017-10-12|Loxo Oncology, Inc.|Methods of treating pediatric cancers|

---

US10045991B2|2016-04-04|2018-08-14|Loxo Oncology, Inc.|Methods of treating pediatric cancers|

---

CN109311889B|2016-04-15|2021-11-16|缆图药品公司|Activin receptor-like kinase inhibitors|

---

PL3458456T3|2016-05-18|2021-04-19|Loxo Oncology, Inc.|Preparation of -n--2-pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide|

---

WO2018004258A1|2016-06-28|2018-01-04|한미약품 주식회사|Novel heterocyclic derivative compound and use thereof|

---

KR20180002053A|2016-06-28|2018-01-05|한미약품 주식회사|Novel heterocylcic derivatives and use thereof|

---

US10646488B2|2016-07-13|2020-05-12|Araxes Pharma Llc|Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof|

---

US10227329B2|2016-07-22|2019-03-12|Blueprint Medicines Corporation|Compounds useful for treating disorders related to RET|

---

US10035789B2|2016-07-27|2018-07-31|Blueprint Medicines Corporation|Compounds useful for treating disorders related to RET|

---

WO2018035061A1|2016-08-15|2018-02-22|Neupharma, Inc.|Certain chemical entities, compositions, and methods|

---

WO2018040885A1|2016-09-01|2018-03-08|南京药捷安康生物科技有限公司|Inhibitors of fibroblast growth factor receptor and use thereof|

---

US20190192522A1|2016-09-08|2019-06-27|Blueprint Medicines Corporation|Inhibitors of the fibroblast growth factor receptor 4 in combination with cyclin-dependent kinase inhibitors|

---

WO2018055503A1|2016-09-20|2018-03-29|Novartis Ag|Combination comprising a pd-1 antagonist and an fgfr4 inhibitor|

---

US10280172B2|2016-09-29|2019-05-07|Araxes Pharma Llc|Inhibitors of KRAS G12C mutant proteins|

---

EP3523289A1|2016-10-07|2019-08-14|Araxes Pharma LLC|Heterocyclic compounds as inhibitors of ras and methods of use thereof|

---

CR20190224A|2016-10-10|2019-09-30|Array Biopharma Inc|Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors|

---

TWI704148B|2016-10-10|2020-09-11|美商亞雷生物製藥股份有限公司|Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors|

---

WO2018072707A1|2016-10-18|2018-04-26|保诺科技（北京）有限公司|Aromatic ether derivative, preparation method therefor, and medical applications thereof|

---

MA45802A1|2017-06-26|2019-12-31|Loxo Oncology Inc|Process for the preparation of pyrazolo [1,5-a] pyrimidines and salts thereof|

---

JP2019533701A|2016-11-02|2019-11-21|ノバルティス アーゲー|Combination of FGFR4 inhibitor and bile acid scavenger|

---

AU2017359819B2|2016-11-17|2020-05-28|Guangdong Zhongsheng Pharmaceutical Co., Ltd|FGFR4 inhibitor and preparation method and use thereof|

---

KR101812266B1|2016-11-25|2017-12-27|한국과학기술연구원|4-amino)thieno[3,2-d]pyrimidin-7-carboxamide derivatives as protein kinase inhibitors|

---

CA3042960C|2016-12-19|2021-05-04|Abbisko Therapeutics Co., Ltd.|Fgfr4 inhibitor, preparation method therefor and pharmaceutical use thereof|

---

CN108239069B|2016-12-26|2021-01-05|南京药捷安康生物科技有限公司|Inhibitor for fibroblast growth factor receptor and application thereof|

---

CN108264511B|2017-01-03|2021-04-13|浙江海正药业股份有限公司|Heterocyclic derivative, preparation method thereof and application thereof in medicine|

---

WO2018136661A1|2017-01-18|2018-07-26|Andrews Steven W|SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS|

---

WO2018136663A1|2017-01-18|2018-07-26|Array Biopharma, Inc.|Ret inhibitors|

---

US11059819B2|2017-01-26|2021-07-13|Janssen Biotech, Inc.|Fused hetero-hetero bicyclic compounds and methods of use thereof|

---

EP3573970A1|2017-01-26|2019-12-04|Araxes Pharma LLC|1-quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer|

---

CN108503593B|2017-02-28|2021-04-27|暨南大学|2-aminopyrimidine compounds and application thereof|

---

TN2019000263A1|2017-03-16|2021-01-07|Array Biopharma Inc|Macrocyclic compounds as ros1 kinase inhibitors|

---

WO2018183712A1|2017-03-31|2018-10-04|Blueprint Medicines Corporation|Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr|

---

CN110869357A|2017-05-25|2020-03-06|亚瑞克西斯制药公司|Compounds and methods of use thereof for treating cancer|

---

AU2018271990A1|2017-05-25|2019-12-12|Araxes Pharma Llc|Covalent inhibitors of KRAS|

---

AR111960A1|2017-05-26|2019-09-04|Incyte Corp|CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION|

---

EP3444275A1|2017-08-16|2019-02-20|Exiris S.r.l.|Monoclonal antibody anti-fgfr4|

---

JP2020532581A|2017-09-05|2020-11-12|バイオアーディス， エルエルシー|Aromatic derivatives, their preparation methods, and their medical applications|

---

TW201922252A|2017-10-10|2019-06-16|美商絡速藥業公司|Formulations of 6--4-methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile|

---

TW201922741A|2017-10-10|2019-06-16|美商亞雷生物製藥股份有限公司|Crystalline forms|

---

EP3697786A1|2017-10-18|2020-08-26|Blueprint Medicines Corporation|Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase|

---

CN109721600B|2017-10-30|2021-04-27|上海凌达生物医药有限公司|Nitrogen-containing fused ring compounds and preparation method and application thereof|

---

CA3087354A1|2018-01-18|2019-07-25|Array Biopharma Inc.|Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors|

---

US20200339579A1|2018-01-18|2020-10-29|Array Biopharma Inc.|Substituted pyrazolyl[4,3-c]pyridine compounds as ret kinase inhibitors|

---

US20210040070A1|2018-02-08|2021-02-11|Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd.|Pyrazine-2-ketone compound acting as fgfr inhibitor|

---

JPWO2019189241A1|2018-03-28|2021-03-18|エーザイ・アール・アンド・ディー・マネジメント株式会社|Hepatocellular carcinoma therapeutic agent|

---

CN110386921A|2018-04-23|2019-10-29|南京药捷安康生物科技有限公司|Fibroblast growth factor acceptor inhibitor compound|

---

WO2019213506A1|2018-05-04|2019-11-07|Incyte Corporation|Salts of an fgfr inhibitor|

---

WO2019223766A1|2018-05-25|2019-11-28|上海和誉生物医药科技有限公司|Fgfr inhibitor, preparation method therefor and pharmaceutical application thereof|

---

CN110577524B|2018-06-07|2022-01-28|北京大学深圳研究生院|Kinase selective inhibitor|

---

CN112313207A|2018-06-22|2021-02-02|北京赛特明强医药科技有限公司|Cyano-substituted pyridine and cyano-substituted pyrimidine compounds, and preparation methods and applications thereof|

---

CA3108065A1|2018-07-31|2020-02-06|Loxo Oncology, Inc.|Spray-dried dispersions and formulations of -5-amino-3-methyl)phenyl)-1--1h-pyrazole-4-carboxamide|

---

JP2022500383A|2018-09-10|2022-01-04|アレイ バイオファーマ インコーポレイテッド|Condensed heterocyclic compound as a RET kinase inhibitor|

---

AU2019338992B2|2018-09-14|2022-01-20|Abbisko Therapeutics Co., Ltd.|FGFR inhibitor, preparation method therefor and application thereof|

---

WO2020119606A1|2018-12-10|2020-06-18|Guangdong Newopp Biopharmaceuticals Co., Ltd.|Heterocyclic compounds as inhibitors of fibroblast growth factor receptor|

---

CN113490666A|2018-12-19|2021-10-08|奥瑞生物药品公司|Substituted pyrazolo [1,5-A ] pyridine compounds as inhibitors of FGFR tyrosine kinases|

---

US20220041579A1|2018-12-19|2022-02-10|Array Biopharma Inc.|Substituted quinoxaline compounds as inhibitors of fgfr tyrosine kinases|

---

WO2020177067A1|2019-03-05|2020-09-10|Bioardis Llc|Aromatic derivatives, preparation methods, and medical uses thereof|

---

CN110317176A|2019-07-04|2019-10-11|沈阳药科大学|2- amino-metadiazine compound and application thereof|

---

WO2021023195A1|2019-08-08|2021-02-11|漳州片仔癀药业股份有限公司|Crystal form d of pyrazine-2-ketone compound and preparation method therefor|

---

CN114174272A|2019-08-08|2022-03-11|漳州片仔癀药业股份有限公司|Preparation method of pyrazine-2-ketone compound|

---

WO2021023192A1|2019-08-08|2021-02-11|漳州片仔癀药业股份有限公司|A crystalline form and b crystalline form of pyrazine-2-ketone compound and preparation method thereof|

---

WO2021129561A1|2019-12-23|2021-07-01|北京赛特明强医药科技有限公司|Cyano-substituted pyridine and cyano-substituted pyrimidine compound and preparation method therefor and application thereof|

---

WO2021134004A1|2019-12-27|2021-07-01|Schrodinger, Inc.|Cyclic compounds and methods of using same|

---

US20210214366A1|2020-01-15|2021-07-15|Incyte Corporation|Bicyclic heterocycles as fgfr inhibitors|

法律状态:
2018-01-16| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|

---

2018-03-06| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|

---

2018-03-13| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|

---

2018-03-20| B06I| Publication of requirement cancelled [chapter 6.9 patent gazette]|Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |

---

2018-10-02| B25G| Requested change of headquarter approved|Owner name: BLUEPRINT MEDICINES CORPORATION (US) |

---

2019-04-24| B07E| Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |

---

2019-12-17| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|

---

2021-10-13| B350| Update of information on the portal [chapter 15.35 patent gazette]|

优先权:

---

申请号 | 申请日 | 专利标题

---

US201261670379P| true| 2012-07-11|2012-07-11|

---

US201261746666P| true| 2012-12-28|2012-12-28|

---

PCT/US2013/050106|WO2014011900A2|2012-07-11|2013-07-11|Inhibitors of the fibroblast growth factor receptor|

---